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Abstract 
Owing to their biologically relevant design, physiologically-based pharmacokinetic (PBPK) models 
require quantitative knowledge of organism anatomy and physiology to facilitate appropriate 
parameterization. Within such models, an intrinsic relationship exists between the quality of input 
parameters and the confidence bestowed upon simulated outputs.  Therefore, in order to instil 
confidence in PBPK model predictions of pediatric pharmacokinetics (PK), a fundamental 
understanding of age-specific changes in anatomy and physiology is required. However, due to a lack 
of consensus and general paucity of biological data denoting pediatric gastrointestinal (GI) physiology, 
parameterization of mechanistic oral disposition models in this population is quite challenging. The 
current dissertation expands our understanding of the ontogeny of key physiological aspects regulating 
oral drug disposition and serves to highlight differences between children and adults. In addition, the 
thesis describes essential processes involved in the development of pediatric PBPK models as well as 
demonstrates the use of such models as tools for identification of human physiological values – a utility 
that is of potential interest particularly for children, where several biological knowledge gaps persist.  
To illustrate the key processes involved in the rational development of pediatric PBPK models, 
a structured workflow was proposed and subsequently utilized to develop age-specific PK predictions 
for the benzodiazepine, lorazepam.  Literature-based assessments of the age-dependency of small 
intestinal transit time (SITT), GI solubility, and α-1-acid glycoprotein (AAG) employed different 
methodologies. To discern the influence of age on SITT, random-effects meta-regression models were 
employed. Investigations assessing age-specific changes in GI fluid parameters (i.e. pepsin, bile acids, 
pH, osmolality, etc.) were collected from the literature and served to define the composition of a novel 
set of pediatric biorelevant media representative of the stomach and upper small intestine. Solubility 
assessments were conducted for seven BCS Class II compounds within the developed pediatric media 
and a set of reference adult media. Plasma AAG concentrations were assessed in both healthy subjects 
and those suspected of infection. The analysis evaluated use of linear, power, exponential, log-linear, 
and sigmoid Emax models to describe the ontogeny of AAG. Predictive performance of the most 
suitable ontogeny model was evaluated with regards to its ability to estimate pediatric fraction unbound 
in plasma (fu,p). Predictive performance was measured using average-fold error (AFE) and absolute 
average-fold error (AAFE) as measures of bias and precision, respectively. To demonstrate the use of 
PBPK modeling to facilitate predictions of human physiology, plasma concentration-time data 
depicting oral administration of acyclovir and chlorothiazide in adults were utilized to generate model-
  v 
based estimates of small intestinal water volume (SIWV). Estimates were based on a framework that 
consisted of a whole-body PBPK model integrated with a compartmental absorption and transit (CAT) 
model.  
Use of the proposed workflow permitted for the development of age-specific PBPK models 
that provided relatively accurate estimates of lorazepam PK in children in comparison to a competing 
modeling technique (i.e. Population PK modeling). For SITT, age was not found to be a significant 
modulator. With regards to the age-dependency of GI solubility, for six of the seven BCS class II 
compounds investigated, solubility fell outside an 80-125% range from adult values in at least one of 
the developed pediatric media. The ontogeny of AAG was best approximated using a sigmoid Emax 
model in both healthy and infected subjects. For estimation of pediatric fu,p, the AAG ontogeny equation 
derived from this work (AFE 0.97; AAFE 1.24) provided a superior predictive performance in 
comparison to a previously proposed equation (AFE 0.74; AAFE 1.45). Model-based predictions of 
SIWV (~116 mL) closely approximated experimentally determined in vivo estimates, demonstrating 
the utility PBPK modeling as a rational method for investigating aspects of human physiology. The 
presented work serves to improve the parameterization of PBPK models tasked with simulating oral 
drug disposition in children; however, more research is still required to address additional knowledge 
gaps associated with pediatric GI physiology. 
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Chapter 1: Introduction and Background 
Portions of this chapter are reflective of an original manuscript published by the Ph.D. candidate 
(Anil R Maharaj) in the journal CPT: Pharmacometrics & Systems Pharmacology. All pertinent 
dialogue included in this chapter was written by the Ph.D. candidate. 
Maharaj AR, Edginton AN. Physiologically based pharmacokinetic modeling and simulation in 
pediatric drug development. CPT Pharmacometrics Syst Pharmacol. 2014;3:e150. 
doi:10.1038/psp.2014.45. 
 
1.1 Pediatric Age Groups 
Children represent a heterogeneous group in terms of growth and maturation and are typically 
subdivided based on their stage of development. For example:  
i) Neonate (birth to 1 month) 
ii) Infant (1 month to 2 years) 
iii) Child (2 years to 12 years) 
iv) Adolescent (12 years to 18 years) 
The above terms resemble those employed by the United States Food and Drug Administration (FDA) 
[1] and are qualitatively utilized throughout this thesis with one notable exception. Within chapter 4 
(Assessment of Age-Related Changes in Pediatric Gastrointestinal Solubility), the term ‘infant’ is 
truncated to only include subjects between the ages of 1 month to 1 year. 
 
1.2  Legislation regulating pediatric drug development 
The relative disparity of drug information among children in comparison to adults has long been noted 
by the medical community [2]. The reasons behind this trend are multifactorial but essentially 
correspond to ethical (e.g. obtainment of consent) and logistic issues (e.g. recruitment of patients, 
limitations on the number of biological samples per child) associated with conducting pediatric 
interventional research [3, 4]. With recent data indicating only 46% of drug products with potential 
pediatric implications being adequately labelled for use in children [5], practitioners are often 
compelled to treat children using off-label drug therapies. Off-label medication use among pediatric 
inpatients is particularly high. For example, some institutions have denoted rates as high as 60% of 
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prescriptions [6, 7]. These rates are of particular concern due to a well-established positive association 
between adverse drug events and off-label drug usage [8, 9]. The relative lack of pediatric drug 
information represents a systemic problem and, as such, is not only confined to inpatient institutions. 
Recently, medications available to children on an outpatient basis have raised concerns among 
regulatory authorities.  In 2008, Health Canada issued an advisory indicating that common over the 
counter cough-and-cold medications be relabelled to indicate that such products not be used by children 
below the age of 6 [10]. In the issued advisory, Health Canada recognized that although these 
medications have had a long history of use in children, there was still only limited evidence to support 
their effectiveness. 
 In recognition of the knowledge gap associated with pediatric drug research, the FDA 
introduced the FDA Modernization Act (FDAMA) and the Pediatric Rule in 1997 and 1998, 
respectively.  The FDAMA represented the first piece of legislation which offered financial incentives 
to drug companies in the form of six additional months of patent exclusivity for performing pediatric 
research [11]. Unlike the FDAMA, which was voluntary, the Pediatric Rule mandated pharmaceutical 
companies to conduct pediatric research for applications involving new active ingredients,  dosage 
forms, routes of administration, dosing regimens, or indications [12]. In 2002, the FDAMA was 
extended by the Best Pharmaceuticals for Children Act (BPCA) [13], which added provisions by which 
off-patent drugs could be investigated.  Furthermore, the Pediatric Rule was replaced in 2003 by the 
Pediatric Research Equity Act (PREA) [14]. Both the BPCA and PREA were permanently reauthorized 
in 2012 by the FDA Safety and Innovation Act (FDASIA) [15] and represent the current legislation 
pertaining to pediatric drug research in the United States. Furthermore, the FDASIA expanded the 
PREA to include a provision requiring sponsors to submit a pediatric study plan to the regulatory body 
by the end of Phase 2 trials. Plans should provide a prospective outline of pediatric studies the sponsor 
plans to conduct in support of their application. The directive towards early implementation of pediatric 
investigations is also iterated by the European Medicines Agency, which advises sponsors to submit a 
pediatric investigation plan as early as the completion of healthy subject pharmacokinetic (PK) studies 
(i.e. Phase 1 trials) [16]. 
 Due the abovementioned legislative directives, the past decade has seen an unprecedented 
increase in pediatric focused drug research, advancing the state of medical care amongst children [17]. 
To balance this increased demand for pediatric research with the desire to protect study participants 
from risks associated with clinical investigations, the use of modeling and simulation has been 
supported as a rational means for informing the design of pediatric clinical studies [18]. Modeling and 
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simulation can support several aspect of pediatric trial design including estimation of pediatric specific 
dosages, identification of optimal PK or pharmacodynamic (PD) sampling schemes, and tabulation of 
appropriate sample sizes (i.e. number of participants) [19]. Overall, modeling and simulation permits 
for the development of informative pediatric trials that maximize information gathered while reducing 
the burden imposed on study subjects (e.g. minimizing the number of biological samples per patient, 
reducing the number of pediatric study participants). In recognition of these benefits, the FDA’s 
Advisory Committee for Pharmaceutical Science and Clinical Pharmacology unanimously voted in a 
March 2012 meeting (National Harbor, MD) to support the motion that modeling and simulation be 
considered for all pediatric drug development programs. During the same meeting, the committee also 
assessed whether the routine use of physiologically-based pharmacokinetic (PBPK) modeling, when 
possible, be incorporated into the pediatric drug development process. Although the committee 
expressed concerns regarding limitations and knowledge gaps surrounding pediatric PBPK modeling 
(i.e. ontogeny of transporters), the motion passed with a slim majority by members who felt PBPK 
modeling offered an enhanced ability for predicting and understanding age-related changes in PK 
amongst children.  
 
1.3 Physiologically-based pharmacokinetic models 
This section will provide a brief description of whole-body PBPK modeling and its applicability to 
pediatric drug development. Whole-body PBPK models strive to provide a comprehensive depiction of 
compound PK throughout the entire body. A general schematic depiction of the structure of a whole-
body PBPK  model is illustrated in Figure 1.1 [20].  Dissimilar to empirically derived compartmental 
PK models (Figure 1.2) where compartments represent the sum of kinetically similar tissues, whole-
body PBPK models segregate compartments based on anatomical considerations. Model structure is 
comprised of multiple compartments each representing a defined organ/tissue space. Drug movement 
is facilitated by assigning flow rates to each compartment reminiscent of a circulatory system. Flow is 
unidirectional, permitting movement of drug from the arterial pool, through the tissues, and into the 
venous pool. Typically, systems operate in a loop, permitting venous blood to be recycled back into the 
arterial pool via the lung. Within the model, clearance (metabolism or excretion) can be ascribed to any 
relevant tissue compartment. Commonly, the body’s two main eliminatory organs, the liver and kidney, 
play predominant roles in modulating drug clearance. To computationally account for clearance as well 
as the rate of drug exchange between blood and tissue compartments, models utilize a series of 
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differential equations. Therefore, provided models are programmed appropriately, simulations should 
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Figure 1.2 Schematic depiction of an empirically derived compartmental model (e.g. two 
compartment model) [V1 and V2 denote the volumes of the central and peripheral 
compartments, respectively; k12 and k21 represent the distributional rate constants; and k10 
denotes the elimination rate constant] 
 
The rate of distribution into tissue compartments may be defined as either perfusion-limited or 
permeability-limited. For smaller lipophilic compounds, distribution into compartments is typically a 
function of the rate of blood flow to the tissue (i.e. perfusion-limited). For larger hydrophilic molecules, 
distribution across tissue membranes may be restricted. In these cases, the rate of tissue distribution 
must be described using permeability-limited kinetics [20].  
PBPK models provide an integrative platform for incorporating several levels of information: 
physicochemical, in vitro, preclinical, and clinical. These various data sources serve to inform model 
parameterization. Model parameters can be defined as either system or drug-specific. System-specific 
parameters pertain to the anatomy and physiology of the organism under study. Examples include organ 
volume, composition and blood flow; enzyme/transporter localization and abundance; and plasma 
protein concentrations. Drug-specific parameters pertain to drug physicochemical properties (e.g. 
lipophilicity, molecular weight, pKa, solubility, etc.) and their biological binding affinities (e.g. towards 
plasma proteins, enzymes, and transporters). Based on the inter-relationship between system and drug-
specific parameters, tissue-to-plasma partition coefficients (Kp) and quantitative measures of specific 
clearance pathways (e.g. whole organ intrinsic clearance - CLint) can be derived. Owing to its 
physiologically-based structure and parameterization, PBPK models permit for extrapolation of PK 
estimates between developmentally unique age groups as well as different species. As models are 
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mechanistic, extrapolations can be conducted by modifying system-specific parameters towards the 
organism or age group of interest while maintaining an understanding that drug-specific parameters 
remain constant. This is dissimilar to empirically derived compartmental models where compartments 
typically do not maintain a physiologic basis, limiting their applicability for fostering predictions of PK 
outside the range of data used in model development. The ability of PBPK models to extrapolate 
knowledge between age groups is highly advantageous towards the field of pediatric drug development. 
The platform permits for PK data from adults, which is relatively abundant, to be leveraged to provide 
rational estimates of PK in children. 
PBPK modeling is frequently described as a ‘bottom-up’ approach as its design quantitatively 
incorporates preexisting information regarding anatomic/physiologic parameters and their influence on 
the processes governing PK [21]. By maintaining these relationships within its structure, PBPK models 
provide pediatric researchers with an innovative approach to assess the ramifications of developmental 
changes in anatomy/physiology on compound PK in an a priori manner. Based on the utility of PBPK 
models to garner informative predictions of pediatric PK, interest amongst the pharmaceutical industry 
has increased. This is demonstrated by the proportion of Investigational New Drug and New Drug 
Applications containing pediatric PBPK modeling techniques received by the FDA between 2008 and 
2013 [22].  Of the 84 applications which incorporated PBPK modeling into their submissions, 21% 
were utilized to investigate PK amongst children. 
 
1.4 Structured workflows 
The key steps associated with the development of pediatric PBPK models have been described in two 
recently published workflows [21, 23]. These workflows denote relevant information requirements for 
pediatric PBPK model development as well as a general methodology for their creation. Notably, both 
workflows denote the importance of development and evaluation of an adult PBPK model prior to 
extrapolation towards children. Based on this retrospective methodology, the relative wealth of adult 
PK information can be leveraged in the development of pediatric models.  The use of such workflows 
can potentially impact the pediatric drug development process by ensuring pediatric PBPK models are 
developed in a systematic and rational fashion. This would permit for standardization of regulatory 
submissions and allow for expedited regulatory reviews. 
Chapter 2 of this thesis will demonstrate how such workflows can be utilized to support 
pediatric research and development. The chapter will propose a workflow for facilitating the 
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development of pediatric PBPK models and utilize it to develop age-specific predictions of lorazepam 
PK amongst children. Lorazepam, an intermediate acting benzodiazepine, is administered for a variety 
of ‘off-label’ indications in children including status epilepticus, chemotherapy induced nausea and 
vomiting, anxiety, sedation, and procedural amnesia [24].  Despite extensive use among pediatric 
patients  [25, 26], further information is still needed to adequately define its safety, efficacy, and PK, 
as demonstrated by lorazepam’s inclusion on the National Institutes of Health (NIH) priority list of 
medications requiring urgent pediatric studies in 2003 [27].  The chapter provides the reader with a 
detailed description of each step in the model development process using a functional example. The 
work will demonstrate how multiple levels of information (e.g. in vitro microsomal studies, in vivo 
adult PK data) can contribute towards the development of informative pediatric PBPK models. 
Furthermore, the workflow proposed within the chapter reflects the currently accepted paradigm of how 
PBPK models should be developed to support pediatric drug development research. 
 
1.5 Mechanistic oral absorption modeling 
PBPK models tasked with simulating intravenous (IV) drug administration are associated with higher 
levels of accuracy in comparison to models simulating oral drug delivery.  This notion has been 
previously corroborated by Poulin et al. [28] who compared the predictive accuracy of adult PBPK 
models (IV and oral) at recapitulating plasma concentration-time profiles for a set of 16 compounds. 
Based on an aggregated metric that combined elements of curve shape and non-compartmental 
descriptors (i.e. AUC0-inf and Cmax), the authors found that PBPK models simulating IV administration 
were able to achieve a medium to high degree of accuracy in 69% of the modeled compounds; whereas, 
models simulating oral drug absorption were only able to achieve this level of accuracy in 20% of the 
studied drugs. This pattern of decreased predictive capacities of PBPK models describing oral drug 
administration is not confined to adults. Three recent publications pertaining to the development of 
pediatric PBPK models for voriconazole and sotolol have denoted inaccuracies associated with 
predictions of oral drug disposition, especially in younger subjects such as neonates [29-31]. 
 This discrepancy in predictive performance associated with PBPK models simulating oral drug 
administration can be linked to the complex milieu of physiological and environmental factors that 
interact within the gastrointestinal (GI) tract to facilitate oral absorption. In order to predict the rate and 
extent of oral absorption, a fundamental understanding of several processes including drug dissolution, 
drug degradation, gastric emptying, intestinal transit, drug diffusion/permeation, and first pass 
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metabolism is required. [32]. Within the context of PBPK models, oral absorption is typically 
accommodated via the incorporation of sub-models tasked with providing mechanistic descriptions of 
the abovementioned processes. For example, to facilitate a priori predictions of oral drug absorption, 
most commercially available modeling platforms (i.e. Gastroplus®, PK-Sim®, SimCyp®) have 
integrated a derivation of the compartmental absorption and transit (CAT) model, as originally 
described by Yu et al. [33], into their whole body PBPK model structure.  
The CAT model was originally developed to describe the transit kinetics of the small intestine, 
which is generally regarded as the primary site of oral compound absorption [34].  Based on small 
intestinal transit data derived via scintigraphy from over 400 human subjects, Yu et al. [33] found that 
a multi-compartment model incorporating 7 compartments provided the best fit with observed data. 
Compartments were linked by a unified first-order transit function to describe flow along the small 
intestine. In a subsequent publication, the authors demonstrated the capacity of the CAT model to 
facilitate predictions of oral compound absorption (Figure 1.3) [35]. When combined with data from 
regional intestinal permeability studies in adults, the CAT model provided a good agreement between 
predicted and observed fractions absorbed in humans for ten compounds.  
 
Figure 1.3 Schematic depiction of a CAT model used to facilitate predictions of oral compound 
absorption [ks – first-order gastric emptying rate; kt – first-order intestinal transit rate; and ka 




Contemporary oral absorption models (e.g. ACAT model) have expanded the scope of the 
original CAT model to accommodate additional compartments to describe transit within the stomach 
as well as transit and absorption within the large intestine.  Current models permit for compartments to 
be uniquely parameterized with dissimilar pH values, fluid volumes, transit rates, and surface areas 
based on regional specific (e.g. jejunum vs. ileum) anatomic/physiologic values. Unlike the original 
CAT model, where drug could only persist within the dissolved state, current models permit drug to 
persist in several forms including unreleased, undissolved, dissolved, degraded, metabolized, and 
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absorbed [36]. With the inclusion of empiric as well as mechanistic dissolution functions, models can 
now simulate a variety of drug release profiles.  
Unless contrary evidence suggests otherwise, PBPK models assume oral absorption of 
dissolved drug transpires via passive absorption [20]. Estimates of intestinal permeability can be 
attained using a variety of approaches including in vivo based regional perfusion systems (i.e. Loc-I-
Gut), in vitro based assays (i.e. PAMPA, Caco-2), or in silico based algorithms which derive estimates 
based on compound physico-chemistry [37]. Models can also include phenomena such as luminal 
degradation by including compartment specific degradation rate constants [36]. Lastly, with the 
addition of enterocytic compartments adjacent to the above-illustrated luminal compartments, models 
can incorporate processes such as gut metabolism and active transport (influx/efflux), provided data 
regarding regional distribution of intestinal enzymes and transporters are available. 
Based on their mechanistic design and physiologic relevant parameterization, PBPK models 
establish an intuitive link between the quality of input parameters (e.g. human anatomic/physiologic 
data) and the accuracy of model predictions. Correspondingly, the poor precision of oral PBPK models, 
as described above, speaks to both the complexity and the lack of quantitative information regarding 
GI physiology in humans.  
Prediction of pediatric oral absorption using a PBPK based approach adds an extra layer of 
complexity owing to the need to parameterize models in an age-specific manner. Notably, development 
of such models requires an innate understanding of how GI physiology changes as a function of age 
from birth to adulthood. For example, effective parameterization of a pediatric oral absorption model 
would require information characterizing age-dependent changes in GI pH, luminal fluid composition, 
intestinal fluid volume, gut surface area and length, transit times, and enzyme/transporter localization 
and abundance. Unfortunately, many of these parameters have yet to be fully elucidated within 
pediatrics. In the context of pediatric PBPK modeling, many researchers will simply assume that 
parameters such as gastric emptying time (GET) [30], small intestinal transit time (SITT) [29] and 
intestinal solubility [38] in children are comparable to that of adults. Due to a lack of consensus and 
general paucity of biological data denoting pediatric GI physiology, many of these assumptions have 
yet to be confirmed. As a result, there is a need for high quality research examining developmental 
differences in the processes governing oral absorption. By improving our understanding of pediatric GI 
physiology, such research will permit for effective PBPK model parameterization and subsequent 
improvements in pediatric PK predictions. 
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1.6 Establishing confidence in PBPK model predictions 
Based on a 2010 guidance document pertaining to the characterization and application of PBPK models 
in risk assessment published by the International Programme on Chemical Safety (IPCS) [39], 
establishment of confidence in PBPK model predictions should incorporate three aspects: comparisons 
between simulations and observed data, evaluation of the biological basis of the model, and assessments 
of model uncertainty and sensitivity. Comparisons between model simulations and observed data can 
be instituted using a variety of metrics. For evaluating precision with regards PK measures such as 
AUC0-inf, Cmax and tmax, metrics such as absolute average fold error (AAFE), root mean squared error  
(RMSE),  the mean ratio (obs/pred), and proportion of estimates falling within a specified fold-error 
(i.e. 2-fold, 3-fold etc.) have been utilized [28, 29, 40]. Additionally, assessments of model predictive 
performance for simulating concentration-time values can include qualitative measures such as visual 
predictive checks  (VPC) [40]. In children, the development of PBPK models may serve as the initial 
exploration of pediatric PK. In such cases, in vivo PK data to appraise the accuracy of simulations will 
likely be nonexistent among children. However, a key process in the development of pediatric PBPK 
models, which will be described in more detail in Chapter 2, involves initial development and 
evaluation of an adult model. In this regard, available PK data in adults can be utilized to assess the 
predictive accuracy of simulations generated from the adult PBPK model. This evaluation provides 
information regarding the model’s suitability for performing pediatric extrapolations. Models that 
display good agreement with observed adult data are perceived to have an increased reliability for 
fostering predictions of pediatric PK. In contrast, models that depict deviations from observed data sets 
are perceived to be of low reliability. Such models should not be utilized for pediatric model 
development but instead be reevaluated for the etiology of their poor predictive performance. Based 
this methodology, evaluations using adult PK data can serve to inform the subsequent development of 
pediatric PBPK models. 
 Evaluation of the biological basis of the model assesses fidelity of the model’s structure and 
parameters. Regardless of a model’s ability to recapitulate observed in vivo datasets, PBPK model 
structure and parameterization should remain biologically realistic. For example, adult models that 
incorporate parameter values that are biologically unrealistic (e.g. glomerular filtration rate (GFR) that 
exceeds the upper limit of normal) are of questionable reliability for the subsequent development of 
pediatric PBPK models. Confidence in model predictions is, therefore, contingent on a structure and 
parameterization that are biologically representative of the organism of interest. This concept highlights 
the pivotal need for research in defining the developmental physiology of the GI tract in pediatrics. 
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Without a clear understanding how GI parameters responsible for modulating oral disposition change 
as a function of age, we cannot be assured that pediatric PBPK models are parameterized in 
physiologically relevant manner. 
Lastly, assessments of model uncertainty and sensitivity can also serve to characterize the 
reliability of model predictions. Uncertainty analyses focus on the spread or distribution of simulated 
outputs due to the ambiguity surrounding input parameters and model structure. For sensitivity 
analyses, the emphasis is shifted towards quantitatively describing the influence of model parameters 
on modulating simulated outputs. Uncertainty analyses can be conducted in an iterative manner by 
incorporating the potential range of ambiguous parameter values into simulations. The level of 
uncertainty is then determined based on the ratio of the 95th percentile to the median value for the 
selected output metric (e.g. AUC, Cmax, etc). Quantitative measures of sensitivity can be attained by 
varying individual model parameters by 1% and evaluating the impact on simulated outputs. Based on 
the relationship between uncertainty and sensitivity, inferences regarding model reliability can be 
attained. For example, models possessing parameters with high uncertainty and high sensitivity are 
presumed to have a low reliability. In contrast, models possessing parameters with either low 
uncertainty or low sensitivity are considered to possess a high reliability. Key parameters postulated to 
have sensitivity (i.e. high sensitivity) towards oral compound absorption are highlighted by the 
maximum absorbable dose (MAD) equation [41].  
 
𝑀𝐴𝐷 = 𝑃𝑒𝑓𝑓 𝑥 𝑆𝐴 𝑥 𝑆𝐼𝑇𝑇 𝑥 𝐶𝑠    (Equation 1.1) 
 
Briefly, the equation denotes that the upper limit of oral absorption can be attributed to intestinal 
permeability (Peff), intestinal absorptive surface area (SA),  small intestinal transit time (SITT), and 
intestinal solubility (Cs).  With regards to pediatric oral absorption modeling, such parameters have yet 
to be appropriately defined in an age-specific manner (e.g. high uncertainty). As such, the reliability of 
PBPK models at simulating oral absorption among children may be of questionable reliability. 
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1.7 Literature-based assessments of the ontogeny of biological parameters 
affecting oral compound disposition 
Chapters 3, 4, and 5 of this thesis serves to provide focused assessments of the ontogeny of key 
physiologic parameters responsible for modulating oral drug disposition. The assessments utilize the 
current literature to quantitate age-specific differences in physiology between children and adults.  
 Chapter 3 focusses on the parameter small intestinal transit time (SITT).   The small intestine 
is of particular importance as it represents the region where the majority of nutrient and xenobiotic 
absorption transpires [42]. Correspondingly, knowledge of the time a xenobiotic spends traversing the 
small intestine is essential towards fostering predictions of oral compound absorption.  This is 
particularly true for poorly absorbed compounds, where the extent of absorption is highly mediated by 
the time of contact between the compound and the small intestinal epithelium [43]. 
 Chapter 4 provides a comprehensive assessment of age-specific changes in GI fluid 
composition. The analysis examines changes in luminal bile salt concentrations, pH, osmolality, 
buffering capacity, and concentrations of fat digestion products between children and adults. 
Differences in GI fluid composition can translate into alterations in compound luminal solubility [44] 
- a key parameter influencing oral absorption. As such, quantification of the relationship between age 
and GI fluid composition is inherently required to facilitate appropriate predictions of pediatric oral 
absorption. After providing a literature-based assessment of age-related differences in GI fluid 
composition, the chapter extends these findings by formulating a set of novel pediatric biorelevant 
media. Biorelevant media attempt to simulate the complex physicochemical nature of in vivo GI fluids. 
When used in conjunction with in vitro test (e.g. USP apparatus II -paddle assembly), biorelevant media 
can provide suitable in vitro/in vivo correlations (IVIVC) of oral drug absorption [45, 46]. Developed 
pediatric media were utilized to perform solubility assessments for 7 Biopharmaceutics Classification 
System (BCS) Class II compounds. The BCS (Figure 1.4) categorizes compounds based on two 
properties: aqueous solubility and permeability [47]. Accordingly, compounds can be classified as 
either BCS I (high solubility, high permeability), II (low solubility, high permeability), III (high 
solubility, low permeability), or IV (low solubility, low permeability). For BCS Class II compounds, 
limitations in the extent of oral drug absorption are primarily attributed to inadequate solubility. 
Therefore, changes in the luminal solubility of such compounds may be suggestive of alterations in oral 
drug performance [48]. To assess the impact of developmental changes in fluid composition, solubility 
values determined in age-specific biorelevant media reflective of children and media representative of 
adults were compared. 
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Figure 1.4 The Biopharmaceutics Classification System 
 
 
 Chapter 5 evaluates the ontogeny of a key plasma protein, α-1-acid-glycoprotein (AAG). AAG 
exhibits high affinity towards a variety of basic lipophilic compounds, including several exogenously 
administered xenobiotics [49, 50].  Between children and adults, developmental differences in plasma 
protein concentrations have been documented [51]. As the extent of xenobiotic-protein binding exhibits 
a direct relationship to the concentration of plasma proteins, differences in drug-protein binding 
between children and adults are expected [52]. Within the context of PBPK modeling, the magnitude 
of xenobiotic-protein binding is parameterized using the fraction unbound in plasma (fu,p). This critical 
parameter can exert profound influences towards the processes of clearance and distribution [49], thus 
modulating estimates of systemic xenobiotic exposure. 
 In addition to its effects on systemic PK parameters (e.g. clearance and distribution), 
alterations in fu,p can influence the availability of orally administered compounds by modulating the 
degree of hepatic first-pass. Oral bioavailability is primarily contingent on three processes: intestinal 
absorption, gut metabolism, and hepatic first-pass. The contributions of these processes towards overall 
bioavailability (fraction of administered drug that reaches the systemic circulation) can be succinctly 
described using the following equation: 
 
𝐹 = 𝐹𝑎  𝑥 𝐹𝑔 𝑥 𝐹ℎ       (Equation 1.2) 
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where F, Fa, Fg, and Fh denote the overall bioavailability, fraction of drug absorbed within the intestine, 
fraction of drug escaping intestinal metabolism, and the fraction of drug evading liver metabolism, 
respectively. The effects of liver extraction on F is particularly relevant for high extraction ratio (ER) 
compounds [53]. ER describes the fraction of drug presented to an eliminatory organ (e.g. liver or 
kidney) that is removed during a single pass. High ER drugs refer to those compounds that are 
efficiently removed by an eliminatory organ (ER > 0.7) [54].  The influence of hepatic extraction on F 
can be described using a simple substitution to the equation depicted above: 
 
𝐹 = 𝐹𝑎  𝑥 𝐹𝑔 𝑥 (1 − 𝐸𝑅ℎ)      (Equation 1.3) 
 
where ERh denotes the hepatic ER. Based on this equation, for compounds with high ERh, hepatic first-
pass metabolism will pose a major limitation towards achieving appropriate oral bioavailability. With 
regards to the relevance of developmental changes in fu,p to oral bioavailability, the relationship between 






      (Equation 1.4) 
 
 
where Qh is the hepatic blood flow, Clint is the intrinsic clearance of the liver, and fu,b is the fraction 
unbound in blood (note: exhibits a proportional relationship to the fraction unbound in plasma). In the 
case of low ERh compounds, the Clint*fu,b component of equation 1.4 is minute, allowing the 
denominator to be simplified as just Qh. Therefore, changes in fu,b are likely to be inconsequential to 
the bioavailability of low ERh compounds. However, for high ERh compounds, the magnitude of 
Clint*fu,b is larger and, thus, cannot be simplified within the denominator. As a result, alterations in fu,b 
will inversely effect the oral bioavailability of high ERh drugs. Based on this rationalization, 
developmental differences in AAG concentrations amongst children may potentiate the presence of 
age-specific differences in oral bioavailability. 
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1.8 Utilization of PBPK modeling for optimization of physiological parameters 
Chapter 6 demonstrates an alternative use of PBPK models as a platform for parameter optimization 
rather than its traditional role for generating PK predictions of compound exposure. Within the 
literature, publications depicting adult PBPK models simulating oral drug absorption have employed 
CAT sub-models that vary widely in terms of the amount of fluid allocated to the small intestine (e.g. 
from 250 to 600 mL) [55-58]. Conversely, in vivo estimates of small intestinal water volume (SIWV) 
within adults denote a central tendency between 86-167 mL [59-61]. Since only dissolved drug is 
permitted to permeate the intestinal membrane, defining of the amount of fluid available within the 
small intestine is imperative to facilitate predictions of oral drug disposition.   As previously iterated in 
the section pertaining to the use of structure workflows for the creation of pediatric PBPK models, the 
initial development and evaluation of an adult PBPK model is an essential step for subsequent 
development of informative pediatric models. Aside from ensuring adult models can recapitulate 
observed PK data, evaluations should also include an assessment of the model’s physiologic fidelity 
[39]. Adult models incorporating parameters not consistent with known in vivo measures are considered 
to be of low confidence and are, therefore, limited in terms of performing extrapolations towards 
pediatrics. The methodology employed within Chapter 6 exploits the mechanistic and physiologic basis 
of PBPK models.  Observed plasma concentration-time data following oral drug administration were 
utilized as an input, subsequently allowing the model to approximate the most appropriate SIWV. The 
work seeks to define an optimal value for SIWV within adults. Furthermore, comparison of this 
simulation-based SIWV to physiologically determined values in adults will provide an evaluation the 
biological relevance of the CAT model. The results of this evaluation will serve to establish a level of 
confidence attributed to such models and their applicability to perform extrapolations towards children. 
In addition, the depicted work will clearly define how the small intestinal water is distributed within 
the context of multi-compartmental absorption models (i.e. CAT models) - an aspect that is also of 
interest to the parameterization of pediatric absorption models. 
 
1.9 Overarching Thesis Objective 
To increase the knowledge base associated with aspects of pediatric physiology that influence oral 
compound absorption, allowing for effective PBPK model parameterization and increased confidence 
in model predictions. 
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1.10 Objectives 
a) Propose a structured workflow for scaling PK information from adults to pediatrics using 
PBPK modeling based techniques and provide a functional example of how such a workflow 
can be utilized to support pediatric drug development. 
b) Conduct critical appraisals of the literature to increase the current state of knowledge 
surrounding pediatric physiology pertinent to oral drug disposition 
c) Demonstrate how systemic exposure data following xenobiotic administration can be utilized 
to inform PBPK model parameterization 
 
1.11 Hypotheses 
a) Utilization of structured workflows for the development of pediatric PBPK models provide a 
rational means of leveraging adult PK data to foster predictions of pediatric PK 
b) Critical evaluations of the current literature can be used to improve the parameterization of 
pediatric PBPK models tasked with simulating oral drug disposition 
c) Human systemic exposure data can be utilized to inform PBPK model parameterization in cases 
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Chapter 2: A Workflow Example of PBPK Modeling to Support 
Pediatric Research and Development: Case Study with Lorazepam 
The contents of this chapter are reflective of an original manuscript published by the Ph.D. candidate 
(Anil R Maharaj) in the American Association of Pharmaceutical Scientists (AAPS) Journal. All 
pertinent research analyses was conducted by the Ph.D. candidate. 
Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric 




The Food and Administration Drug (FDA) enacted the Pediatric Research Equity Act (PREA) in 2003, 
requiring pharmaceutical companies to assess pharmacokinetics (PK), safety and efficacy of new drug 
products in pediatric subjects. Recently, several FDA pediatric submissions have incorporated 
physiologically-based pharmacokinetic (PBPK) models, stimulating an interest in their utility among 
regulatory authorities  [23]. In a March 2012 meeting, the majority of the FDA’s Pharmaceutical 
Science and Clinical Pharmacology Advisory Committee voted to support the use of PBPK modeling 
for pediatric drug development; a decision with potential implications towards the manner in which 
pediatric drug information is derived. 
PBPK modelling is characterized by the use of mathematical algorithms to predict the interplay 
between drug specific characteristics, and organism anatomy and physiology. Similar to empirically 
derived compartmental models, the structure of PBPK models includes compartments in order to 
describe the processes of absorption, distribution, metabolism and excretion (ADME). In a PBPK 
model, however, compartments are based on actual organs with inherent volumes and blood flows 
linked through the vasculature. The mechanistic nature of PBPK models permit rational scaling 
between organisms (i.e. rat to human) as well as developmental stages (i.e. adult to child). This is the 
result of defining ADME as a function of anatomy, physiology and biochemistry; components not 
accounted for in traditional compartmental models.  
Use of pediatric PBPK models offer researchers an a priori approach to predict a compound’s 
PK behavior in children, with or without prior PK data in humans, though knowledge of the drug 
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substance’s physicochemical characteristics is essential. The developmental processes involved in the 
creation of pediatric PBPK models has been documented by several researchers and typically include 
defining physiology and anatomy, protein binding, and clearance, all as a function of age [62-64]. 
Amongst the literature, pediatric PBPK models have been utilized in several different capacities: 
suggesting starting doses for children of different age groups, predictions of  environmental 
contaminant exposure,  optimization of clinical drug trial design (sampling schedule, number of 
patients, etc.), and assessment of potential drug-drug interactions [23, 64-66].  
Lorazepam, an intermediate acting benzodiazepine, is administered for a variety of ‘off-label’ 
indications in children including status epilepticus, chemotherapy induced nausea and vomiting, 
anxiety, sedation, and procedural amnesia [24].  Despite extensive use among pediatric patients  [25, 
26], further information is still needed to adequately define its safety, efficacy and PK, as demonstrated 
by lorazepam’s inclusion on the National Institutes of Health (NIH) priority list of medications 
requiring urgent pediatric studies in 2003 [27]. Most published literature regarding lorazepam PK 
parameters (Table 2.1) is primarily focused on an adult patient population. In humans, lorazepam 
exhibits an affinity for albumin with a bound fraction in plasma of approximately 89% [67-69]. Hepatic 
metabolism and renal filtration represent the major and minor pathways of clearance, respectively [70-
72].  
This study will use a systematic workflow to demonstrate how adult drug data is leveraged in 
the development of pediatric PBPK models. Using lorazepam as an example, a rational prediction of 
lorazepam PK will be computed as a function of age and further compared to PK data from a pediatric 











  19 
Table 2.1 Physicochemical, ADME, and Anatomic/Physiologic Data for Initial Parameterization 


















Tissue:plasma (Kp) were estimated using  the methods described by Rodgers and Rowland [80-82] 
Hepatic (plasma) clearance was estimated using a well stirred liver model (equation 2.3) 
a: logarithm of the octanol-water partition coefficient (lipophilicity) 
b: negative logarithm of the acid dissociation constant 
c: plasma fraction unbound 
d: intrinsic clearance of  hepatic isozyme UGT2B7 
e:  renal (plasma) clearance due to glomerular filtration 




2.2.1 Model Building Workflow 
Model building workflow: Following the proposed workflow (figure 2.1), the development of a 
pediatric population PBPK model is presented using lorazepam as an example. The derived model will 







Physicochemical  LogPa  2.39 [73] 
pKab 1.3 (base),  
11.5 (acid) [74]  
ADME fupc 0.11  [67-69] 
CLint(hep-UGT2B7)d 0.439 ml/min/gliver               
[68, 71, 75-77] 
CLGFRe 0.01 ml/min/kg [70-72] 
 
B:Pf 0.642 [78] 
Anatomic/Physiologic Organ Size Generated using simple demographic 
information (Sex: M, Age: 26.6 yrs, Wt: 
68 kg) by  methods described in Willman 
et al 2007 [79]. 
Organ Blood Flow 
Tissue Composition 
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2.2.2 Development of the adult PBPK model 
Model structure and parameterization 
All simulations (adult and pediatric) were completed using PK-Sim® v 4.2 (Bayer Technology 
Services, Leverkusen, Germany), which implements a whole-body PBPK model consisting of 15 
organs. Due to the physicochemical nature of lorazepam (low molecular weight - < 500 g/mol, moderate 
lipophilicity and neutral at physiologic pHs) all organs were considered kinetically equivalent to well-
stirred compartments with the exception of the brain. PK-Sim® utilizes a permeation barrier between 
the plasma and interstitial fluid of the brain to simulate the physiologic equivalent of the blood-brain-
barrier. Specific physicochemical, ADME, and anatomic/physiologic data used for initial 
parameterization of the adult lorazepam model are presented in Table 2.1. Tissue: plasma partition 
coefficients (Kp) were predicted using the in silico tissue composition approach proposed by Rodgers 
and Rowland [80-82]. Using the abovementioned characteristics, an initial adult model was generated.  
 
Optimization of the adult model 
Concentration-time data from four separate adult PK studies [71, 75-77] were dose normalized to 2mg 
and compared to the output of the initial adult PBPK model. Outputs were generated using the average 
observed clearance in conjunction with the mean age and weight of participants in the studies to define 
anatomical and physiological values [79]. A visual check was used to evaluate predictive accuracy 
between simulated (PBPK model) vs. observed concentration-time data and appropriateness of line 
shape.  Subsequently, the model parameters of intrinsic hepatic clearance (CLint(hep-UGT2B7)) as well as 
lipophilicity (logP), a direct predictor of Kp(s), were optimized using the MoBi® Toolbox for 
MATLAB® (Bayer Technology Services GmbH, Leverkusen, Germany/ The Mathworks Inc., Natick, 
MA), an integrative modeling tool that permits parameter analysis. Parameters were iteratively 
optimized to achieve values which minimized the error between observed and model derived 
concentration-time points. 
 
Adult Population Model 
A virtual population of 100 adult individuals was created using PK-Sim®’s Population Module in order 
to simulate the effect of anthropometric and intrinsic clearance variability on the PK behavior of 
lorazepam. The module incorporates the work conducted by Willmann et al. 2007 [79]  to create a 
population of individuals with associated variability consistent with real life observations. 
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Demographic constraints (sex, age, weight) of the simulated population were reflective of the adult 
subjects included among the lorazepam PK studies [71, 75-77]. All subjects received a 2 mg 
intravenous dose, representing a commonly prescribed adult dosage.  Inter-patient variability associated 
with UGT2B7 intrinsic activity, the hepatic enzyme responsible for lorazepam metabolism  [83], was 
estimated from an ex-vivo metabolism study for the probe substrate zidovudine using human liver 
microsomes [84].  As a result, UGT2B7 intrinsic clearance was varied based on a log-normal 
distribution with a geometric standard deviation of 1.34. The average area under the plasma 
concentration-time curve to infinity (AUC0∞), a measure of systemic exposure, was tabulated to 
comparatively assess dosage equivalency between adults and children. Extrapolation to infinity 
occurred by dividing the final concentration (Clast) by the elimination rate constant (λz), where λz was 
calculated based on a linear regression of the final 10% of predicted time points transformed on the 
natural log scale. To evaluate the range of PK variability amongst the virtual population, 5% and 95% 
prediction intervals for concentration-time values were generated and compared to dose normalized 
observed values (assuming linear PK) from each of the four lorazepam PK studies [71, 75-77].  
 
2.2.3 Age-dependent scaling of PBPK model parameters 
Protein binding 
Prediction of pediatric protein binding was estimated using equations presented by McNamara and 
Alcorn [51]. The authors successfully predicted the fraction of protein binding in infants for several 
compounds using fraction unbound in adults and compound specific plasma protein affinity. For 
lorazepam, literature data indicates an affinity for albumin and an average fraction unbound (plasma) 
of 0.11 in adults [67-69].  
 
Clearance 
Total clearance of a compound is calculated as the sum of its individual clearance pathways. For 
lorazepam, the clearance in children was calculated as the sum of scaled hepatic and renal clearances 
using a physiologically-based approach. The process of physiologic hepatic clearance scaling relies on 
the following underlying assumptions [83]:  
 
1. pathways of clearance in children are the same as those observed in adults 
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2. well-stirred model conditions hold (hepatic uptake of the compound is a function of blood flow 
- not permeability across cell membranes.) 
3. enzyme metabolism follows first order kinetics  (concentrations are within linear range – no 
enzyme saturation) 
Hepatic UGT2B7 enzyme activity is on average 5% of the adult value at term, increases to 30% by 
the age of 3 months and reaches adult activity by 1 year of age. To quantify the relationship between 
age and enzyme activity a cubic spline function, as derived by Edginton et al. [83], was utilized. Scaled 
intrinsic clearance in pediatric subjects can be calculated from adult values using the following formula 
[85],  
liver(adult)gUGT2B7int72liver(child)gUGT2B7int




CL is the scaled intrinsic clearance due to UGT2B7 per gram of liver, 
72BUGTOSF  is the ontogeny scaling factor for UGT2B7 specific to the age of the child, and 
liver(adult)gUGT2B7int
CL  is the intrinsic clearance due to UGT2B7 per gram of liver in adults.  Total hepatic 
plasma clearance can be derived from intrinsic clearance using the well-stirred model, 
 
  childliver(child)gUGT2B7intlivertotal(child)int
LWx CLCL   (Equation 2.2) 
 
  (child)liver  total(child)int p(child)u,(child)h 
liver  total(child)intp(child)u,(child)h 
(child)hepatic
P:B/ CL x f   Q
CL x f x Q





CL is the whole liver intrinsic clearance in the child, childLW is the liver weight of 
the child, 
(child)hepaticCL is total hepatic clearance in the child, (child)h Q is liver blood flow in the child, 
p(child)u,f  is the scaled unbound fraction (plasma) in the child, and (child)P:B  is the blood:plasma ratio 
in the child. The B:P ratio is affected by both changes in protein binding and hematocrit and can be 
tabulated using equations derived by Rodgers and Rowland [82], 





H  1 - P:B 
urbcKp (Equation 2.4) 
 
    ]1)-Kp x (f x H[1P:B u rbc,p(child)u,(child))( child (Equation 2.5) 
 
where urbcKp ,  is the unbound partition coefficient of red blood cells (assumed to be constant between 
adults and children),  )(P:B adult is the blood:plasma ratio in adults, (adult)H is the hematocrit in adults, 
p(adult)u,f is the fraction unbound (plasma) in adults, and (child)H   is the hematocrit of the child [86].  
 The effects of maturation and growth on renal function were examined in a seminal paper by 
Hayton [87]. The study proposed a series of equations to estimate renal function parameters, such as 
glomerular filtration rate (GFR) and active secretion, in children as a function of age and weight. To 
scale adult renal clearance values towards pediatric patients the estimated GFR of the child, as 
determined using Hayton’s algorithm, was used in conjunction with the following equation proposed 












CL      (Equation 2.6) 
 
where 
(child)GFRCL  is the child’s clearance due to glomerular filtration, (child)GFR is the estimated GFR 
of the child, 
(adult)GFR is the GFR in adults (assumed to be 110 ml/min), and (adult)GFRCL the clearance 
due to glomerular filtration in adults.  
 
Anatomy/Physiology 
The age dependence of body weight, height, organ weights and blood flows were obtained from 
Edginton et al. [63] and represent those values currently used as default values in PK-Sim®. The above 
parameters were derived based on the mean value for European children ranging from neonates to 18 
years old. 
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2.2.4 Age-dependent PK simulations 
Pharmacokinetic variability among pediatric populations of various age-groups was assessed by 
creating virtual populations of 100 individuals  aged 0, 3, 7, and 14 days; 1, 2, 3, 6 and 9 months; and 
1, 1.5, 2, 3, 4, up to 18 years. All patients received a single 0.05 mg/kg dose of intravenous lorazepam, 
representing a common pediatric dosage. Inter-patient variability associated with hepatic UGT2B7 
intrinsic clearance was assumed to be identical to that of adults. Dosage equivalency between adults 
and children, the dose (mg/kg) required to achieve an AUC0∞ similar to the average value obtained in 
the adult population model, was calculated for each simulated population. In addition, to demonstrate 
the potential utility of this modelling technique, mean tissue concentration-time profiles for targeted 
organs (adipose, muscle, brain) were simulated for a population of 2 year old patients (n = 100) 
following a 0.05 mg/kg intravenous dose. 
 
2.2.5 Assessment of model accuracy 
The predictive accuracy of the derived pediatric lorazepam model at estimating concentration-time 
values  and PK parameters  was evaluated using an observed data set provided by Chamberlain et al. 
[88]. Concentration-time data from  63 pediatric patients, ranging from 5 months to 17 years of age, 
who received intravenous lorazepam either electively or part of routine treatment of status epilepticus 
were included in the sample [88].  Forty of the 63 pediatric subjects received a single intravenous dose 
of lorazepam. Of these subjects, 15 received lorazepam electively. Pediatric PBPK model concentration 
estimates were based on simulations incorporating the age, weight, and height for each child, in addition 
to the dose administered. The predictive accuracy of the pediatric PBPK model for estimating observed 
concentration-time values for each individual patient was assessed by tabulating the average-fold error 
(AFE). 

















Observed PK parameters derived from non-compartmental analysis (NCA) were determined 
for elective patients (n=15) in whom intense serial sampling was performed following intravenous 
lorazepam administration [88]. Lorazepam total body clearance (CL) was calculated as Dose/ 
AUC0∞, where AUC0∞ was determined using the linear-log trapezoidal rule up to the final sample 
time with extrapolation to infinity based on Clast/λz. Non-compartmental extrapolation of AUC0∞ 
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was analogous to the approach used for PBPK model assessment but differed in the algorithm used to 
estimate λz, which was computed based on regression of the natural logarithm of concentration values 
during the post-distributive phase. The volume of distribution (Vss) was calculated as Vss = MRT*CL, 
in which MRT is the mean residence time. MRT was calculated as AUMC0∞/ AUC0∞, where 
AUMC0∞ is the area under the first moment curve from zero to infinity. These parameters were 
similarly calculated from PBPK model simulations. The relative accuracy of predicted CL and Vss 
values, as determined by physiologic scaling, were assessed against observed values (NCA) for each 





error   fold  (Equation 2.8) 
 
As a final evaluation, the PK variability associated with ontogeny and anthropometrics among 
a virtual pediatric patient population after receiving a single 0.05 mg/kg intravenous (bolus) dose of 
lorazepam was compared with individual observed data. Five percent and 95% concentration-time 
prediction intervals were generated for the entire age range (0-18 years) of the virtual pediatric 
population with equal representation from each age. The simulated profile was evaluated using 
individual observed concentration-time data (normalized to 0.05 mg/kg) for 40 of the 63 pediatric 
patients who received a single intravenous dose of lorazepam [88]. 
2.3 Results 
Mean adult hepatic intrinsic clearance and lipophilicity (logP) values were optimized to 0.416 
ml/min/gliver and 2.43, respectively. Figure 2.2A compares the concentration-time profile derived from 
the optimized adult population model to dose-normalized observed data from 4 PK studies [71, 75-77]. 
Observed data in the initial phase of distribution were over predicted by the model; however, 
subsequent data were well described.  The range of PK variability for lorazepam associated with a 
simulated pediatric population (0-18 years) is displayed in figure 2.2B. Approximately 72% of dose-
normalized observed lorazepam concentration-time values from a subset of 40 pediatric patients fell 
within the 90% prediction interval of the simulated population. 
The dosage (mg/kg) required to achieve similar AUC0∞  as those observed in adults after a 2 
mg intravenous dose of lorazepam varied as a function of age (figure 2.3 A,B). Newborns (0 days old) 
required approximately 1/10th of the weight normalized dose given to adults, whereas infants between 
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the ages 1 and 3 years required dosages (mg/kg) that exceeded those of adults.   After 3 years of age, 
the weight normalized dose slowly decreased towards adult requirements. 
Predicted tissue specific concentrations from the pediatric PBPK model were calculated for a 
virtual population of 2 year old patients following a 0.05 mg/kg dose of lorazepam (figure 2.4). 
Estimates indicate that muscle and adipose tissue equilibrate with plasma concentrations at a much 
faster rate compared to the brain.  
The predictive accuracy of concentration-time estimates derived by our pediatric PBPK model 
was assessed using individual patient AFE values for all 63 sample patients (figure 2.5A). Forty-four 
percent, 73%, and 92% of patients had AFE values within 1.25, 1.5, and 2 fold deviation from observed 
values, respectively.   
PBPK estimates of CL and Vss were compared to observed values obtained by NCA from the 
15 elective patients (figure 2.5 B,C).  For CL, 40%, 60%, and 80% of predictions were within 1.25, 1.5 
and 2 fold deviation from observed values, respectively.  Comparatively, predictions of Vss were 
relatively more accurate with 53%, 80%, and 100% of estimates within 1.25, 1.5, and 2 fold error from 
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Figure 2.2 (A) Predicted (solid line corresponds to geometric mean; dashed lines corresponds to 
5thand 95thpercentiles; virtual population n=100) versus observed (symbols [71, 75-77]) plasma 
concentration versus time data following a 2-mg IV lorazepam bolus in adults. Log 
(concentration) versus Log (time) plot is displayed in insert.  (B) Predicted (solid line 
corresponds to geometric mean; dashed lines corresponds to 5th and 95thpercentiles; virtual 
population n=1140) versus observed (symbols [88]) plasma concentration versus time data 
following a 0.05 mg/kg IV lorazepam bolus in children aged 0 to 18 years. Log (concentration) 
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Figure 2.3 Pediatric dose (mg/kg) required to achieve an equivalent AUC0∞ of a 2 mg dose in 




Figure 2.4 Mean tissue concentration-time profiles for selected organs among a virtual 
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Figure 2.5 Predictive accuracy plots - Individual AFE values for PBPK model concentration-
time predictions for the 63 pediatric patients (plot A),  fold error associated PBPK model 
clearance predictions for the 15 elective patients (plot B), and fold error associated PBPK 
model volume of distribution predictions for the 15 elective patients (plot C). (Dotted line 




Integration of PBPK modelling with pediatric drug research has been illustrated by five recent FDA 
submissions [89]. Common applications of modelling in the aforementioned submissions include 
optimizing study design, recommending starting doses for different age groups, and facilitating 
covariate analysis. The workflow presented in Figure 2.1 ensures pediatric PBPK models are developed 
using physiologically rationale approach and incorporates elements from two recently proposed 
workflows. Similar to Figure 2.1, Leong et al  [23] and Edginton [21] both presented workflows which 
included an evaluation of appropriateness of the adult model prior to scaling. Refinement (optimization) 
of the adult model was also included by Leong et al.  Edginton’s use of virtual populations to assess 
  31 
PK variability among simulated adult and pediatric populations was similar to the approach adopted in 
this study.  
The workflow’s evaluation process ensures that the derived adult model adequately reflects in 
vivo PK data. A major underlying assumption involved in physiologic scaling necessitates pathways of 
clearance in children are the same as those observed in adults.  This ensures that physiologic processes 
accounted for in the adult model will be mirrored in the pediatric model. As such, models displaying 
poor predictive accuracy in adults should be re-evaluated for missing drug specific information that 
may explain the discrepancy (i.e. additional transporter affinities, alternative clearance pathways, etc.). 
Scaling to pediatrics should only be considered for adult models found to be in general agreement with 
observed data. In order to better represent in vivo PK, the modeler may opt to refine the adult model 
based on observed data prior to scaling towards pediatrics. Input parameters, such as lipophilicity and 
intrinsic clearance are generally chosen as targets for optimization as a result of uncertainty surrounding 
literature values of lipophilicity and variability of clearance values between PK studies.  
Physiologic scaling also relies on another key assumption in order to extrapolate adult models 
towards pediatrics: enzyme metabolism follows first-order kinetics. Validation of this assumption 
would normally require in vivo dose escalation studies in pediatric patients; data which is simply 
unavailable for most compounds. Consequently, we are reliant on adult PK data to estimate the 
likelihood of enzyme saturation occurring among children. For lorazepam, exposure (AUC0∞) in 
adults has previously been shown to increase proportionately with intravenous dosage increases from 
2 to 4 mg, indicating a lack of saturable metabolism [71].  
The derived adult population PK model (figure 2.2A) exhibited an acceptable fit for the 
majority of observed data with the exception of concentration-time points during the initial phase, post-
administration. This lack of fit may be attributed to an unrealistic assumption made by most PK models: 
initial mixing of blood in the central compartment is instantaneous. As a result, initially simulated 
concentration-time points may appear erroneously high as they fail to account for the lag time 
associated with the introduction of the compound to the systemic circulation and its presence at a 
peripheral sample site [90]. Potential issues related to drug-IV catheter binding may present an 
alternative explanation for the lack of initial data fit.  Reversible binding of drug to the IV catheter 
would result in delayed administration of the entire dose, resulting in a PK profile similar to a short-
term IV infusion as opposed to a bolus dose. Slight over-prediction of initial concentration-time points 
were also observed in the pediatric population PK model (figure 2.2B), a finding which exemplifies the 
congruent relationship between the adult and pediatric model.  
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During the first year of life, increasing UGT2B7 enzyme activity corresponds with increases 
in weight normalized lorazepam clearance.  With dosage rate being directly proportional to clearance, 
it is not surprising that the dosage (mg/kg) required to maintain a similar AUC0∞ as adults after a 2mg 
intravenous dose increases during the first year (figure 2.3B). The average dosage requirement in term 
neonates, where enzyme activity is estimated to be only 5% of adult values, was 0.0037 mg/kg; 
whereas, adults received approximately 0.03 mg/kg. For pediatric subjects between the ages of 1-3 
years, the average weight-normalized clearances exceeded that of adults and, as a result, required 
increased relative dosages to maintain similar exposure rates. These findings have been corroborated 
in the literature by studies examining the age-dependence of lorazepam clearance [68, 83].  Using the 
process of physiologic scaling as outlined in this study, the increased weight-normalized lorazepam 
clearance simulated in young children aged 1-3 years was a function of complete hepatic UGT2B7 
maturation and a higher liver weight: body weight ratio compared to adults.  
Current intravenous dosing recommendations for preoperative administration of lorazepam in 
adults, 0.044 mg/kg (max 2mg/dose) 15-20 minutes before surgery, and in infants and children, 0.05 
mg/kg (range: 0.02-0.09 mg/kg) [24], were compared to dosage requirements derived from our 
simulated pediatric populations. While the suggested pediatric dosing range relates to the majority of 
the simulated children, neonatal dosing (0 days - 1 month) does not appear to follow the same regimen. 
Furthermore, the recommendations provided do not incorporate an age-dependence to dosing. Results 
from our simulations indicate that neonates require substantially lower doses than suggested for infants 
and children (i.e. 0.05 mg/kg). For example newborns (0 days old) require approximately 1/10th (0.0037 
mg/kg) of adult doses; whereas, one month old neonates require approximately 1/4th (0.0077 mg/kg) of 
adult doses. Accordingly, dosing recommendations derived from population PBPK models circumvent 
the use of inexact dosing ranges by assigning a unique dosage to particular age groups.  
The utility of PBPK models at estimating concentrations values within specific organs is 
demonstrated in figure 2.4.  These estimates highlight the potential future of PBPK models to create 
targeted dosing regimens based on a priori estimates of drug distribution within specific compartments 
of interest (i.e. site of action). The plasma concentration simulated by the model is reflective of the 
overall mass-transfer between all organs. As a result, larger organs to which the drug permeates into 
(ie. muscle and adipose) will play a larger role in influencing the overall plasma profile compared to 
smaller organs (brain). By simply evaluating the PBPK model estimates using plasma concentration-
time data we are unable to confirm the reliability of individual organ estimates, especially smaller 
organs which only influence plasma levels minutely. Consequently, in order to increase reliability in 
  33 
specific compartment estimates, experimental data assessing tissue concentration or effect biomarkers 
that can link to target concentrations is inherently needed.     
Using the presented workflow, retrospective assessment of the derived pediatric model may 
only take place once sufficient observed data is available. To evaluate our pediatric lorazepam model, 
concentration-time data from a cohort of 63 pediatric patients was obtained  [88].  For the majority of 
sample patients (approximately 73%), PBPK model concentration estimates were within a 1.5 fold 
prediction error on average.  Additionally, the predicative performance of the pediatric PBPK model at 
estimating CL and Vss was determined among elective patients (n =15) included in Chamberlain et al.’s 
study [88]. For CL, 60% of model estimates were within 1.5 fold deviation from observed values. 
Comparatively, model estimates of Vss were associated with a greater predictive accuracy with 80% of 
estimates lying within 1.5 fold error.  
When attempting to estimate individual subject parameters (i.e. CL and Vss), PBPK models 
normally incorporate superficial biometric data such as age, weight, and height, to derive a complete 
physiologic/anatomic depiction of the subject. All physiologic/anatomic values (i.e. organ weights, % 
enzyme activity) denote values that would be expected from a mean individual of a particular age, 
weight and height.  What this approach does not account for is the intrinsic (inter-patient) variability 
that underpins biological research (i.e. not all 8 year olds, weighing 35kg, and measuring 120cm will 
have the same organ weights). Consequently, the accuracy of individualized PBPK model derived 
parameter estimates will be affected by the magnitude of the inherent inter-subject variability that 
exists. Data driven population PK estimation techniques represent an alternative approach to estimating 
individualized PK parameters. Chamberlain et al. [88] found no covariates which were statistically 
significant to necessitate inclusion into their final PK model. Subsequently, estimates of CL and Vss  
were predicted using 0.14 L/hr/kg0.75 and 1.37 L/kg, respectively. When used to estimate individual PK 
parameters among the elective group (n=15), this method predicted 47%, 67%, and 80% of CL values 
within a 1.25, 1.5, and 2 fold deviation from observed values, respectively.  For Vss, 33%, 87%, and 
100% of estimates fell within 1.25, 1.5, and 2 fold error, respectively. These values are quite similar to 
ones obtained via PBPK modelling. One major difference being that PBPK model estimates were 
generated independent of PK data from children; whereas, Chamberlain et al.’s study derived estimates 
based on data obtained through in vivo experimentation with pediatric subjects. As such, PBPK 
modelling provided a relatively accurate approach for estimating individualized PK parameters 
compared to the estimates generated by Chamberlain et al. Despite the previous finding, a large 
proportion of subjects had CL and Vss estimates associated with greater than 1.25 fold error which 
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indicates, in an absolute sense, individualized predictions generated through PBPK modelling still 
requires further development. 
 With predictions directed towards a mean individual, it not surprising that PBPK modelling 
can be used to estimate average parameter values among specific populations.  For 14 of the 15 pediatric 
subjects among the elective group greater than the age of 5 years, the PBPK model produced mean 
estimates of CL and Vss that exhibited a 14% and -6% relative error, respectively, from the mean 
observed values calculated by NCA.  One patient who was approximately 1 years old was excluded 
from this analysis as the mean clearance was judge to be significantly different than the rest of the 
group, which was comprised of older children. This assertion was based on the increased dosing 
requirements for children between the ages of 1-3 years due to increased weight normalized clearances, 
as depicted in figure 2.3 A,B.   
PBPK models also display a unique ability to estimate the magnitude of variability that 
surrounds PK parameters. Many PBPK modelling applications are capable of generating virtual 
populations in order to estimate PK variability associated with anthropometric differences between 
individuals. These populations can also be manipulated to encompass the range of inter-individual 
variability that exists around each physiological/anatomical value. As such, PBPK population-based 
modelling techniques may be used to provide a priori estimates of variability associated with PK 
parameters such as CL and Vss for a given population.  For example, the coefficient of variation 
associated with observed clearance values, determined by NCA, for 14 of the 15 elective group patients 
greater than 5 years of age was 53%. To generate an a priori estimate of variability using PBPK 
modelling, a uniform virtual population of 1300 children between the ages of 5 and 17 years (100 
children per year) was created with associated variability around organ sizes, tissue blood flows, and 
metabolizing enzyme activity. The coefficient of variation of associated with PBPK model estimates 
of clearance among this population was 43%. Although this estimate under predicts the observed 
variability, it does provide a preliminary estimate of the magnitude of variation that may be observed 
within the population.  Estimates of high degrees of CL and Vss variability among a population for 
drugs with narrow therapeutic indexes may indicate the need for individualized dosing regimens; 
whereas, drugs with wider therapeutic indexes may be administered using fixed dosing levels (ie. 60 
mg for 1-2 year olds, 80 mg for 2-5 year olds, etc.). 
Although evaluation of the derived PBPK model represents a crucial step in the workflow 
process, a clear metric has yet to be proposed to aid researchers in classifying a particular model as 
“good” vs. “bad”. As such, acceptable tolerances of predictive performance of the pediatric model 
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should be established on a drug by drug basis based on current information available in adults: PK-PD 
relationship, safety profile, and therapeutic index.       
The derived pediatric population PBPK model was able to account for approximately 72% of 
the variability associated with concentration-time points observed in a subset of 40 pediatric patients. 
The inability of the model to fully account for the variability observed is likely a result of the uniform 
nature of age groups included in the simulated population. One thousand one hundred and forty 
pediatric patients, between the ages of 0 days to 18 years, were simulated with 60 patients being selected 
per year. As a result, PK variability associated with the simulated population was skewed towards the 
large majority of patients whose clearance values were similar to that of adults (i.e., patients greater 
than 3 years of age). Patients with relatively lower and higher clearance values, neonates and children 
aged 1-3 years, respectively, comprised a small portion of the simulated population and, therefore, only 
minimally contributed to the PK variability amongst the total population. Consequently, the total range 
of simulated variability may have been understated with use of a uniformly aged population. 
 
2.5 Conclusion 
Since lorazepam’s inclusion on NIH’s priority list in 2003, two clinical pediatric studies have been 
completed under the sponsorship of National Institute of Child Health and Human Development 
(NICHD) with one additional study in the recruitment phase. With future advancements in model 
development there is the potential for PBPK models to shift from being used as a compliment to clinical 
PK studies to a partial replacement. For example, PBPK models may be used to decrease the amount 
of clinical trials required in children by functioning as the primary exploratory investigation of drug 
PK.  This could potentially eliminate the need for exploratory PK studies in children and permit clinical 
investigations to function on a confirmatory basis. With the recent FDA recommendation, interest in 
the use and development of pediatric PBPK models will inevitably increase. The current study 
demonstrates the fundamental processes required for development of a pediatric PBPK model 
incorporating existing adult drug data. Using this approach, the model was able to predict lorazepam 
PK in children as a function of age. With the rise in use of PBPK modelling software in the field of 
pediatric drug development, the use of procedural workflows, similar to the one presented, will ensure 
consistency in model outputs and potentially permit for expedited reviews of such research by 
regulatory bodies.  
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Chapter 3: Examining Small Intestinal Transit Time as a Function of 
Age – Is There Evidence to Support Age-Dependent Differences 
Among Children? 
 
The contents of this chapter are reflective of an original manuscript published by the Ph.D. candidate 
(Anil R Maharaj) in the journal Drug Metabolism & Disposition. All pertinent research analyses was 
conducted by the Ph.D. candidate. 
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3.1 Introduction 
Estimation of bioavailability following oral compound administration is an inherently complex 
procedure, requiring a fundamental understanding of the interplay between compound and formulation 
properties and the dynamic nature of the alimentary canal. Within the gastrointestinal (GI) tract a 
multitude of physiological parameters can exert an influence on both the rate and extent of compound 
absorption including gastric emptying time (GET), small intestinal transit time (SITT), regional 
differences in pH and permeability, relative abundances of intestinal transporters and enzymes, and GI 
fluid volumes. As developmental changes in any of the aforementioned parameters may impart 
differences in oral absorption between children and adults, there is an inherent need to identify which 
parameters change as a function of age and by how much.  The small intestine is of particular 
importance as it represents the region where the majority of nutrient and xenobiotic absorption 
transpires [42]. This is due to the presence of several morphological features on the luminal surface 
such a folds (valves of Kerckring), villi, and microvilli which serve to significantly expand the 
absorptive surface area [91]. Correspondingly, knowledge of the time a xenobiotic spends traversing 
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the small intestine is essential towards fostering predictions of oral compound absorption.  This is 
particularly true for poorly absorbed compounds, where the extent of absorption is highly mediated by 
the time of contact between the compound and the small intestinal epithelium [43].  
Conceptually, the widely utilized maximum absorbable dose (MAD) equation as proposed by 
Johnson and Swindell [92] offers a simplistic overview of how small intestinal transit time (i.e. SITT) 
can influence the extent of compound absorption. The equation (3.1) utilizes the absorption rate 
constant (ka), compound specific saturation solubility (Cs), small intestinal water volume (SIWV), and 
SITT to garner estimates of the MAD following oral compound administration. 
 
𝑀𝐴𝐷 = 𝑘𝑎 ∗ 𝐶𝑠 ∗ 𝑆𝐼𝑊𝑉 ∗ 𝑆𝐼𝑇𝑇  (Equation 3.1) 
 
Based on equation 3.1, shorter SITT (i.e.  ↓SITT) would translate to lower compound 
availability following oral administration; whereas, longer SITT (i.e. ↑SITT) would result in the 
opposite. Owing to the influence of intestinal transit on oral drug absorption, there exists an inherent 
need to identify specific subpopulations exhibiting differences in SITT [93]. 
In humans, estimates of SITT have been determined using a variety of techniques including 
lactulose H2 (hydrogen) breath tests, scintigraphy and wireless pH/pressure monitoring devices [94-
96]. Scintigraphy, however, is generally regarded as the ‘gold standard’ for SITT assessment. Amongst 
adults, SITT is generally assumed to be independent of feeding state, age, gender, weight, and 
compound formulation (i.e. tablet vs. solution) [33]. In an analysis of over 400 adult small intestinal 
transit times compiled over multiple investigations utilizing scintigraphy, Yu et al. [33] estimated the 
average (±SD)  SITT to be 199 min ± 78 min. However, as data pertaining to children were not formally 
assessed by the analysis, the applicability of these values towards pediatric subjects, who are 
developmentally immature, remains questionable. 
Based on previously published literature reviews, which are non-quantitative in nature, it has 
been postulated that older children may possess shorter (i.e. faster) intestinal transit times compared to 
adults [97, 98]. This assertion originates, in part, from clinical investigations in asthmatic children 
administered sustained-release (SR) theophylline.  Children frequently demonstrated large inter-
individual differences in the percent fluctuation between maximum and minimum steady-state 
theophylline plasma concentrations (i.e. [Cpeak-Ctrough/Ctrough] x 100) [99, 100]. As such, they generally 
require more frequent dosage administration times in order to maintain appropriate therapeutic 
concentrations [101]. In addition to higher weight normalized clearances compared to adults [102], the 
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etiology of this variability among children has also been attributed to inconsistent theophylline SR 
absorption due to variability in parameters such as intestinal transit time [103].  
Since intestinal transit has the capacity to influence the extent of absorption (i.e. bioavailability) 
of certain xenobiotics [104], an understanding of the differences in SITT between children and adults 
is critical to deriving age appropriate dosage regimens. This article will serve to examine the 
relationship between age and mean SITT based on available literature and provide a current assessment 
of small intestinal transit in children and adults. In addition, the pharmacokinetic (PK) influence of 




3.2.1 Literature-based assessment of SITT as function of age 
Primary literature sources documenting SITT from children to adults were acquired from the PubMed 
database (last accessed June 2015). In addition, secondary [105, 106] and tertiary [107] literature 
sources were utilized as focal points from which further primary investigations were obtained. Data 
were limited to subjects free of pathologies that may influence intestinal motility. As such, subjects 
with GI disorders such diarrhea, constipation, ileus and Crohn's disease were excluded. The analysis 
included data pertaining to various formulations (solutions, single unit capsules, multi-unit pellets) as 
well as different feeding states (i.e. fasting and fed). 
Methods employed to measure SITT were wide ranging and included H2 breath tests, 
scintigraphy, wireless pH/pressure capsules, lactose-[13C]ureide breath tests, fluoroscopy (X-ray), and 
magnetic tracking systems. Upon initial evaluation of the data, two separate investigations reported by 
Fallingborg et al. in which fluoroscopy (X-ray) was utilized purported the two longest SITT compared 
to other investigations (7.5h and 8h) [108, 109]. Transit times recorded by this method traced the GI 
movement of an orally administered capsule through the use of bony landmarks and gaseous outlines. 
Consequently, subtle movements such as displacement of the dosage form from the ileum to the caecum 
may not have been easily discerned. In addition, as the use of fluoroscopy was exclusively confined to 
these two investigations from the same research group, supplementary studies conducted by separate 
investigators were unable to assess the validity of these findings. As a result, data pertaining to the two 
aforementioned studies were removed from the analysis.    
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Lactulose H2 breath tests report intestinal transit in terms of orocecal transit time (OCTT) rather 
than an exact measurement of SITT. Furthermore, among adults, lactulose has been demonstrated to 
dramatically accelerate normal small intestinal transit while reducing associated inter-subject 
variability [96]. As the focus of this analysis was to define the effects of age on SITT under normal 
conditions, inclusion of studies where intestinal transit was altered would appear counterintuitive. 
Unfortunately, a large majority of pediatric investigations exclusively employed lactulose H2 breath 
testing. Exclusion of such data would notably decrease the power of the analysis towards recognizing 
developmental differences in intestinal transit among the youngest cohort of patients. As a result, the 
analysis did not exclude studies in which intestinal transit was measured via lactulose H2 breath tests; 
however, data from these investigations were segregated and analyzed separately.  
To discern the influence of age on SITT based on separate investigations acquired from the 
literature, the analysis utilized meta-regression [110]. Briefly, meta-regression is a technique by which 
weighted data from separate investigations can be combined to provide an assessment of the influence 
of specific covariates on a given outcome or effect. Unlike the more familiar regression analyses 
typically employed within primary investigations, which examines relationships at the level of 
individual subjects, meta-regression examines the relationship between study-level covariates (i.e. age) 
and aggregated measures of effect (i.e. mean intestinal transit time) among separate investigations. In 
this context, mean intestinal transit time parallels the concept of a dependent variable used in 
conventional linear regression. 
For each study, the aggregated measure of effect was recorded as the mean SITT, or mean 
OCTT for studies employing breath tests. Variances associated with each measure of intestinal transit 
were calculated based on the following formula: 
 





     (Equation 3.2) 
 
where SDi  is the study-specific standard deviation associated with intestinal transit and  ni is the number 
of subjects examined within the specific study. Since the analysis compiles SITT (or OCTT) data as 
measured among separate subject groups by different investigators, heterogeneity of intestinal transit 
between studies was expected. Therefore, a random-effects model with between-study variability was 
adopted. Using this method, weights associated with each intestinal transit measure were tabulated as 
the reciprocal of the sum of within-study variance (i.e. Variancei) and between-study variance (τ2). 
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Between-study variance was approximated using a restricted maximum likelihood (REML) estimation 
technique [111]. 
Since meta-regression requires study specific effect measures (e.g. SITT) to be summarized in 
the form of mean and standard deviation, supplementary estimation techniques were employed for 
studies that summarized data using alternative statistics. For studies where SITT (or OCTT) were 
represented by the median, maximum and minimum, estimates of mean and standard deviation were 
computed as described by Hozo et al. [112]. For studies where SITT were summarized using the 
interquartile range (i.e. 25th percentile, median, and 75th percentile), the estimation techniques denoted 
by Wan et al. were employed [113]. In several investigations multiple SITT determinations were 
conducted on the same participants under various conditions (i.e. fasted vs. fed or transit of tablet vs. 
transit of solution). In such cases, data provided by each treatment arm were considered to be highly 
correlated (i.e. Pearson’s correlation coefficient (r) ≈ 1). Inclusion of correlated data into the analysis 
as though it represents separate independent entities would inappropriately bias parameter estimates. 
To circumvent this issue, the analysis aggregated data to provide a single estimate of SITT (or OCTT) 
represented by the mean and pooled standard deviation (equation 3.3) between separate treatment 






2  +  𝑠2
2 + (2𝑟 ∙ 𝑠1 ∙ 𝑠2 )         (Equation 3.3) 
 
Equation 3.3 depicts the formula for the pooled standard deviation (SDi) where 𝑠1  is the 
standard deviation associated with the first treatment arm, 𝑠2  is the standard deviation associated with 
the second treatment arm, and 𝑟 is the correlation coefficient between measures of intestinal transit 
from each treatment arm (assumed to be 1 for this analysis). 
Examination of the influence of age on mean intestinal transit time was conducted using two 
separate analyses. The first analysis was restricted to studies that employed lactulose H2 breast tests, 
where intestinal transit was postulated to be accelerated due to the effects of lactulose. A random-effect 
meta-regression was conducted using age as the sole modulator.  For the remaining studies that 
employed scintigraphy, wireless pH/pressure capsules, lactose-[13C]ureide breath tests, H2 breath tests 
(without lactulose) and magnetic tracking systems, data was also analyzed using a random-effect meta-
regression model, but with both age and measurement method as modulators. As scintigraphy 
represents the anecdotal ‘gold standard’ method, the variable ‘measurement method’ was coded as 
either 0 or 1: 0 pertaining to studies utilizing scintigraphy and 1 pertaining to studies employing other 
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measurement techniques. Age was quantified by the mean age as depicted from each investigation. If 
mean values were not specified but alternative summary statistics were available, the mean age was 
estimated in a similar manner as depicted for intestinal transit times. For some adult investigations, 
only the range (i.e. minimum and maximum) of ages of the study participants were described. In these 
studies age was denoted by the middle of the age range.  In two adult investigations [114, 115] no ages 
were specified. For these studies a mean of 45 years was utilized, which represents the approximate 
middle of the adult age range from our collected cohort of studies. Both linear and curve-linear 
relationships between age and intestinal transit were investigated based on the following models: 
 
𝐿𝑖𝑛𝑒𝑎𝑟:        
𝑆𝐼𝑇𝑇 =  𝐵0 + (𝑀𝑒𝑎𝑠𝑢𝑟𝑚𝑒𝑛𝑡 𝑀𝑒𝑡ℎ𝑜𝑑 ∗ 𝐵1) + (𝐴𝑔𝑒 ∗ 𝐵2)             (Equation 3.4) 
 
 
2𝑛𝑑 𝑂𝑟𝑑𝑒𝑟 𝑃𝑜𝑙𝑦𝑛𝑜𝑚𝑖𝑎𝑙:        
𝑆𝐼𝑇𝑇 =  𝐵0 +  (𝑀𝑒𝑎𝑠𝑢𝑟𝑚𝑒𝑛𝑡 𝑀𝑒𝑡ℎ𝑜𝑑 ∗ 𝐵1) + (𝐴𝑔𝑒 ∗ 𝐵2) +  (𝐴𝑔𝑒
2 ∗ 𝐵3)   (Equation 3.5) 
 
 
3𝑟𝑑 𝑂𝑟𝑑𝑒𝑟 𝑃𝑜𝑙𝑦𝑛𝑜𝑚𝑖𝑎𝑙:        
𝑆𝐼𝑇𝑇 =  𝐵0 + (𝑀𝑒𝑎𝑠𝑢𝑟𝑚𝑒𝑛𝑡 𝑀𝑒𝑡ℎ𝑜𝑑 ∗ 𝐵1) + (𝐴𝑔𝑒 ∗ 𝐵2) +  (𝐴𝑔𝑒
2 ∗ 𝐵3) +  (𝐴𝑔𝑒
3 ∗ 𝐵4)     
(Equation 3.6) 
 
where the estimated regression coefficients for the model intercept, the binary variable ‘measurement 
method’, and the continuous variables age, age2, and age3 are denoted by 𝐵0, 𝐵1,𝐵2, 𝐵3, and 𝐵4, 
respectively. 
To reduce collinearity and mitigate computational errors associated with polynomial regression 
models, the explanatory variable, age, was centered (i.e. x i-x̅) within each analysis [116]. Tables are 
subsequently presented using centered data; however, figures are presented using actual age (i.e. 
uncentered) to ease interpretation. In addition to the models depicted above, models that included 
interaction terms between age and measurement method were also explored for studies where intestinal 
transit was measured by scintigraphy and other auxiliary techniques.  All analyses were conducted 
using the metafor package [117]  in conjunction with R statistical software (v3.1.2).  Modulating 
variables (age and measurement method) were deemed significant contributors to the model if 
associated parameter estimates attained p-values of ≤ 0.05. For studies where results were presented 
graphically, data was quantified using GetData Graph Digitizer (v2.26). 
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3.2.2 Model-based assessment of the influence of intestinal transit on theophylline 
pharmacokinetics in children 
To assess the impact of alterations in intestinal transit on the PK of theophylline among children, a 
physiologically-based pharmacokinetic (PBPK) modeling approach was utilized. Simulations were 
parameterized based on a previously conducted in vivo PK study conducted by Pedersen and Steffensen 
[118]. Briefly, the study investigated the absorption of a SR once-daily theophylline preparation in 
children ranging from 8 to 14 years. Plasma concentration values were ascertained from 14 children on 
days 6 and 7 following multi-dose administration. 
Simulations were conducted using PK-Sim® v5.2 (Bayer Technology Services, Leverkusen, 
Germany). Development of pediatric specific PBPK models followed a well-accepted modeling 
paradigm [23] whereby adult models are first developed and evaluated prior to scaling models towards 
a younger population. The adult model was parameterized utilizing drug-specific properties obtained 
from the literature (e.g. molecular weight, logP, pKa, solubility). System-specific parameters (e.g. 
organ weights and blood flows) were provided within the software platform. Tissue: plasma partition 
coefficients (Kp) were estimated using in silico tissue composition-based algorithms published by 
Rodgers and Rowland [80-82].  Albumin was denoted as the principle binding protein of theophylline 
in plasma with an average fraction unbound of approximately 0.58 in healthy adults [119, 120]. Human 
intestinal permeability was estimated for theophylline by scaling from in vitro Caco-2 data [121]. 
Correspondingly, simulations utilized an intestinal permeability of 4.4x10-4 cm/s, a value that is 
qualitatively associated with high permeability compounds [122].  
In adults, theophylline clearance is a combination of hepatic metabolism (CYP1A2 and 
CYP2E1) and glomerular filtration [83, 123]. Utilizing the PBPK model framework, literature-based 
PK studies depicting concentration-time profiles following administration of theophylline either 
intravenously [124, 125] or orally [126] as an immediate release formulation (assuming fraction 
absorbed = 1) were utilized to obtain specific estimates of hepatic and renal clearance in healthy adults. 
This method of parameter obtainment has been previously described in literature [127]. In addition, 
using a similar modality, tissue: plasma partition coefficients were refined using a single global scalar 
value to ensure simulated results from the adult PBPK model adequately represented observed PK data. 
Following development and refinement of the adult model, pediatric model development 
commenced. A population of n = 50 was generated [79] in order the match the demographics (age, 
weight, %females) of children examined by Pedersen and Steffensen [118]. Simulations utilized an oral 
dose of 15.5 mg/kg/q24h, representing the average dose administered during the study. Plasma sample 
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time points within the simulation were congruent to those depicted by the study. In vivo release 
characteristics of the SR theophylline preparation was simulated based on fraction absorbed vs. time 
data obtained from PK evaluations following single-dose administration to a similar subset of children 
investigated within the same study. Using this approach, it was inherently assumed that theophylline 
release from the formulation was the principle rate-limiting factor for absorption. To explore the 
influence of intestinal transit on theophylline PK, pediatric models were parameterized  using separate 
intestinal transit rates: [1] SITT and large intestinal transit time (LITT) were held at the reference adult 
values, [2] SITT was decreased by 25% compared to adult values (i.e. faster) while LITT was held at 
the reference, [3] SITT was decreased by 50% compared to adult values (i.e. faster) while LITT was 
held at the reference, [4] both SITT and LITT were decreased by 25% compared to adult values (i.e. 
faster), and [5] both SITT and LITT were decreased by 50% compared to adult values (i.e. faster). 
Simulated estimates of Cmax, Cmin, and percent fluctuation between peak and trough plasma 
concentrations [(Cmax - Cmin)/Cmin] after 1 week of dosing were compared to observed data presented by 
Pedersen and Steffensen [118]. 
 
3.3 Results 
Estimates of SITT and OCTT were compiled over 40 separate investigations obtained from the 
literature (Figure 3.1) [94-96, 114, 115, 128-162] and pertained to subject groups ranging in average 
age between 20 days to 67 years. OCTT was measured via lactulose H2 breath testing in 14 subject 
groups [96, 128-137] while estimates of intestinal transit time were ascertained via scintigraphy in 28 
groups [94, 96, 115, 138-156]  and other measurement techniques  in 10 subject groups [95, 114, 134, 
135, 157-162]. Correspondingly, 52 subject groups were included within the analysis.  The analysis 
included 11 investigations [138, 140, 142-145, 148, 150, 152-154] where estimates of intestinal transit 
were pooled between test conditions (e.g. fasted vs. fed). For each of these investigations, mean 
intestinal transit times were not found to be significantly different between treatment arms as either 
denoted by the authors’ or independently confirmed using a paired student’s t test (p-value > 0.05 – 
two tailed test). One investigation by Clarke et al. [141] examined GI transit kinetics of pellets of 
varying sizes (0.5 and 4.75 mm) and densities (1.5 and 2.6 g/cm3) in a single group of adult subjects 
using scintigraphy. A statisically significant difference in SITT was denoted between pellets of different 
sizes (p ≤ 0.05). Conseqently, data concerning this study was analyzed as two separate subject groups 
pertaining to each pellet size rather than combining data across both formulations.  
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As an initial assessment, differences between the separate measurement methods was examined 
with a preliminary meta-regression run with the entire data set using measurement technique (i.e. 
lactulose H2 breath test vs. other vs. scintigraphy) as the sole modulator of mean intestinal transit time 
(Figure 3.2). Compared to investigations employing the ‘gold standard’ measurement technique 
scintigraphy, studies utilizing lactulose H2 breath tests displayed mean intestinal transit times that were 
approximately 133 mins faster (i.e. smaller). This result is consistent with previous literature denoting 
lactulose’s ability to accelerate intestinal transit [96].  Moreover, intestinal transit time estimates 
determined using other measurement methods (i.e. wireless pH/pressure capsules, lactose-[13C]ureide 
breath test, H2 breath tests [without lactulose] and magnetic tracking systems) were on average 60 mins 
slower (i.e. greater) when compared to investigations utilizing scintigraphy. 
Data pertaining to intestinal transit studies employing lactulose H2 breath tests [96, 128-137] 
are displayed as a function of age in Figure 3.3. Fitted estimates based on a linear meta-regression 
model are superimposed and depict a negative correlation between age and OCTT. However, the 
estimated parameter associated with age did not attain statistical significance, indicating a lack of 
evidence to support the notion that age influences OCTT (Table 3.1).  Second and 3rd order polynomial 
models (Appendix A Figure 1) exhibited slightly more complex relationships between age and OCTT, 
but similar to the linear model, age was not considered a significant modulator (Appendix A Tables 1 
and 2). 
For studies utilizing scintigraphy in addition to other measurement techniques [94-96, 114, 
115, 134, 135, 138-162], data are displayed in Figure 3.4. Separate regression lines based on a linear 
meta-regression model have been superimposed according to the measurement technique employed 
(higher order polynomial models are displayed in Appendix A Figure 2). Parameter estimates pertaining 
to the linear model are displayed in Table 3.2 while those pertaining to the 2nd and 3rd order polynomial 
models are denoted within Appendix A Tables 3 and 4, respectively. For all tested models (linear, 2nd 
order polynomial, 3rd order polynomial), the coefficient associated with measurement method was 
found to be a significant modulator of mean small intestinal transit. However, similar to the previous 
assessment, age was not found to be significantly associated with mean intestinal transit time. For 
models which included interaction terms between age and measurement method, parameter estimates 
associated either age or the interaction term(s) were not significant modulators of mean SITT within 
the linear and 2nd order polynomial models (Appendix A Tables 7 & 8 and Figures 4 & 5). For the 3rd 
order polynomial model, the interaction term associated with ‘Age3*Measurement method’ did attain 
statistical significance (p-value = 0.0391) (Appendix A Table 9 and Figure 6). However, this result was 
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not thought to convey a meaningful relationship between age, measurement technique and SITT as the 
adjusted R2 (R2adj), which normalizes for the effects of the additional interacting parameters, was similar 
between 3rd order polynomial models with and without interaction terms (R2adj 0.266 vs. 0.259, 
respectively). In addition, highly parameterized models, such as the abovementioned interaction 
models, increase the risk of type I errors (false positives) [163] and, as such, covariates which display 
significance within this context should be interpreted with caution. 
Simulations of theophylline SR in children (8-14 years) utilizing adult intestinal transit values 
provided a mean Cmax along with an associated estimate of variability, as denoted by the coefficient of 
variation (CV%), that were similar to those observed by Pedersen and Steffensen [118] (Table 3.3). 
However, simulations over-predicted the mean Cmin by approximately 1.2 mcg/mL, whereas percent 
fluctuation between Cmax and Cmin was under-predicted by approximately 20% when compared to 
observed data. Changes to SITT in isolation (i.e. without changes to LITT) did not appear to affect 
simulated outcomes as Cmax, Cmin, and the percent fluctuation were essentially identical to those 
simulations where SITT was held at adult values. Cmax, Cmin, and percent fluctuation were also 
unchanged in simulations where total intestinal transit time was decreased (i.e. both SITT and LITT) 
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Figure 3.1 Mean intestinal transit time (SITT or OCTT) estimates pertaining to each study 
group included within the analysis. Data is reflective of transit values from normal subjects, 
free of GI disease. 
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Figure 3.2 SITT or OCTT segmented according to measurement method for all investigations 
[94-96, 114, 115, 128-162] (i.e all age groups) documenting intestinal transit in normal subjects 
free of GI disease (open circles). The diameter of each circle is proportional to the 
1/(Variancei)1/2. Mean values, as estimated according to a meta-regression model employing 
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 Table 3.1 Lactulose H2 Breath Tests – Linear Meta-Regression Model 
Summary 
Statistics 
k a=14 QM (df=1) b= 0.5296 (p =0.4668) I2 c= 92.53% R2 d = 0.00% 
 
 Estimate Standard 
Error 






     
Intercept (B0) 73.8142 4.5321   <0.0001   64.9315   82.6969   
Age (B1) -0.3663 0.5034    0.4668 -1.3529 0.6203 
 
Random Effects 
     
Between study 
variance (τ2) 
239.7203 116.7795 - - - 
Tau (τ) 15.4829 - - - - 
      
      
a k = number of subject groups  
b QM = heterogeneity statistic (Cochran’s Q) – tests whether any coefficient (not including the 
intercept) is significantly different than 0 
c I2 = % of total variability due to heterogeneity 
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Figure 3.3 OCTT as a function of age for investigations employing lactulose H2 breath testing 
[96, 128-137] in normal subjects free of GI disease (open circles). The diameter of each circle is 
proportional to the 1/(Variancei)1/2. Estimates of OCTT based on a meta-regression model with 
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 Table 3.2 Scintigraphy and Other Techniques – Linear Meta-Regression Model 
Summary 
Statistics 
ka=38 QM (df=2)b= 19.1664 (p < 0.0001) I2 c= 84.57% R2 d= 39.63% 
 
 Estimate Standard 
Error 






     
Intercept (B0) 206.9675    7.8990   <0.0001   191.4857   222.4493   
Measurement 
Method (B1) 
61.5907   14.0951    <0.0001    33.9648    89.2166   
Age (B2) 0.4183 0.4689    0.3723    -0.5006 1.3373 
 
Random Effects 
     
Between study 
variance (τ2) 
1165.4337 370.2652 - - - 
Tau (τ) 34.1384 - - - - 
      
 
a k = number of subject groups  
b QM = heterogeneity statistic (Cochran’s Q) – tests whether any coefficient (not including the 
intercept) is significantly different than 0 
c I2 = % of total variability due to heterogeneity 
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Figure 3.4 SITT or OCTT as a function of age for investigations employing scintigraphy [94, 96, 
115, 138-156] (black circles) and other measurement techniques [95, 114, 134, 135, 157-162] 
(open circles) in normal subjects free of GI disease. The diameter of each circle is proportional 
to the 1/(Variancei)1/2. Estimates of mean intestinal transit time based on a meta-regression 
model with age as a linear regressor have been separately superimposed for studies utilizing 
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Table 3.3 Simulated vs. Observed Theophylline Absorption PK at 1 Week Following Daily 
Administration of a Sustained Release Formulation in Older Children (8-14 yrs) 
 Source Mean Cmax [mcg/mL] 
            (CV%a) 
Mean Cmin [mcg/mL]  
            (CV%) 
Mean Percent Fluctuation (%)b 
                    (CV%) 



































12.53g 8.48 52.39 
(27.15%) (37.68%) (25.60%) 
SITT (↓ 25%)e 12.53 8.48 52.38 
LITT (adult) (27.16%) (37.68%) (25.63%) 
SITT (↓ 50%) 12.53 8.48 52.38 
LITT (adult) (27.15%) (37.68%) (25.63%) 
SITT (↓ 25%) 12.53 8.48 52.40 
LITT (↓ 25%) f (27.14%) (37.68%) (25.65%) 
SITT (↓ 50%) 11.15 7.81 46.91 
 LITT (↓ 50%) (29.01%) (38.66%) (24.49%) 
 
a - coefficient of variation 
b -  percent fluctuation between peak and trough plasma concentration values over a given dosing 
interval (i.e. [peak – trough]/trough). 
c – Data reported by Pedersen and Steffensen on Day 6 following oral maintenance (q24h) therapy 
with a sustained release theophylline formulation (Noctelin – Riker Labs Inc.) [n = 14]. 
d - Data reported for 10 of 14 children investigated by Pedersen and Steffensen on Day 7 following 
oral maintenance (q24h) therapy with a sustained release theophylline formulation (Noctelin – Riker 
Labs Inc.) [n = 10 – same study group as depicted above; data for 4 children was unavailable] 
e - 25% reduction in small intestinal transit time (SITT) from adult values. SITT for normal adults 
was parameterized as 2.1h - the default PK-Sim® v5.2 value. This represent the time span between 
gastric emptying of 63% of a nonabsorbable marker and localization of 90% of the marker within the 
caecum. 
f - 25% reduction in large intestinal transit time (LITT) from adult values. LITT for normal adults 
was parameterized as 44.2h - the default PK-Sim® v5.2 value. This represent the time span between 
90% of a nonabsorbable marker reaching the caecum and localization of 70% of the marker within 
the feces. 
g- PBPK models were not parameterized to include intradose variability. (i.e. once steady-state was 
achieved, concentration-time values were congruent between dosing intervals). As such, simulated 
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Table 3.4 Capsule Endoscopy Studies – Linear Meta-Regression Model 
Summary 
Statistics 
k a=16 QM (df=1) b= 7.6931 (p =0.0055) I2 c= 93.76% R2 d= 41.58% 
 
 Estimate Standard 
Error 






     
Intercept (B0) 270.3442   8.8046   <0.0001   253.0875   287.6009   
Age (B1) -1.0695 0.3856   0.0055 -1.8252 -0.3137 
 
Random Effects 
     
Between study 
variance (τ2) 
908.1523 432.9293 - - - 
Tau (τ) 30.1356 - - - - 
      
 
a k = number of subject groups  
bQM = heterogeneity statistic (Cochran’s Q) – tests whether any coefficient (not including the 
intercept) is significantly different than 0 
c I2 = % of total variability due to heterogeneity 
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Figure 3.5 SITT as a function of age for investigations employing capsule endoscopy (open 
circles). The diameter of each circle is proportional to the 1/(Variancei)1/2. Estimates of SITT 
based on a meta-regression model with age as a linear regressor have been superimposed for 
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3.4 Discussion 
Owing to the importance of the small intestine towards the absorption of nutrients and xenobiotics, 
knowledge of its transit kinetics is of key interest to pharmaceutical researchers. Though estimates of 
small intestinal transit have been conducted by several investigators, typically subjects are confined to 
a specific demographic cohorts (e.g. children, adult, elderly). The presented work sought to summarize 
the literature pertaining to small intestinal transit in order to assess for differences between children 
and adults. The analysis included data from several studies employing a variety of measurement 
techniques (i.e. lactulose H2 breath tests, scintigraphy, wireless pH/pressure capsules, etc.). To evaluate 
the influence of age on SITT across the diverse array of collected investigations, meta-regression was 
utilized. Based on this analysis of the current literature, age was not found to significantly influence 
SITT.  
Within the analysis, studies were specifically confined to subjects free of GI pathology to 
mitigate the potential effects of disease or altered health statuses on intestinal transit. This criterion 
ensured the analysis provided an assessment of the influence of age on mean SITT within the context 
of normal human development. To provide an example of the potential bias that can be introduced into 
such an analysis if patients were not stratified accordingly, a separate evaluation of SITT was conducted 
using data derived from capsule endoscopy investigations. Capsule endoscopy is a diagnostic procedure 
that permits for imaging of the small bowel while minimizing the degree of invasiveness and patient 
discomfort typically associated with traditional endoscopic procedures. Subjects are required to 
swallow a wireless video transmitting capsule that transverses the GI tract through the actions of 
intestinal peristalsis. Images are transmitted to a portable recording device and capsule location is 
determined using the obtained images [164]. Literature data pertaining to capsule endoscopy is 
primarily focused towards disease diagnosis with information regarding GI transit commonly reported 
as a secondary outcome. Such studies typically include patients with known or suspected GI disease 
for indications such as obscure GI bleeding, undiagnosed abdominal pain, suspected Crohn’s disease, 
ulcerative colitis, celiac disease, and small bowel tumors [165]. Based on 11 capsule endoscopy studies 
[165-175], which provided information on 16 unique subject groups with mean ages ranging from 2.9 
to 64 years, a meta-regression was performed using a similar methodology as described above. The 
analysis depicted a negative correlation between age and mean SITT using a linear model (Figure 3.5). 
In contrast with the previous analyses which focused on healthy/normal subjects, this analysis denoted 
age to be a significant modulator of mean SITT (Table 3.4). In addition, 2nd and 3rd order polynomial 
regression models also found parameters associated with either age, age2, or age3 provided significant 
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contributions towards reducing the heterogeneity associated with SITT (Appendix A Tables 5 and 6 & 
Figure 3) .  The etiology of this association is unclear, but may be linked to differences in disease 
prevalence between children and adults. 
The results of the analyses in healthy/normal subjects which indicate no significant effect of 
age towards SITT contrasts with previously held assertions that older children exhibit faster intestinal 
transit times than adults [97, 98]. This notion has been linked to previous pharmacokinetic 
investigations of SR theophylline in asthmatic children who typically display large degrees of inter-
individual variability in terms of systemic concentrations [99, 100]. However, large degrees of inter-
subject variability in absorption have also been denoted in adults administered SR formulations of 
theophylline [176].  Within our analysis, theophylline absorption among older children was examined 
using a model-based approach. From this assessment it was found that alterations of SITT lacked 
influence on the oral absorption of SR theophylline. Of note, discernable changes in theophylline 
absorption were only observed when total intestinal transit time (i.e. SITT and LITT) was greatly 
altered (i.e. ↓ 50%). Consequently, the results of these simulations downplay decreased SITT as a 
primary factor contributing to pharmacokinetic variability of SR theophylline in older children.  
Although not formally addressed in this investigation, simulations in younger pediatric cohorts 
provided a similar outcome to those depicted for older children (i.e. changes in SITT failed to influence 
the PK of SR theophylline). The reasons behind this observation are two-fold. First, mechanistic 
pediatric oral absorption models are rather underdeveloped due to limited information surrounding age-
specific differences in intestinal permeability, luminal fluid volumes and composition, and abundance 
of intestinal transporters. As a result, pediatric oral absorption models are commonly parameterized in 
a similar manner to those of adults. Secondly, theophylline is considered a BCS Class I compound (high 
solubility, high permeability) with adequate levels of absorption attainable throughout the entire GI 
tract (i.e. small bowel and colon) [177]. When formulated as an SR preparation, the limiting factor 
modulating theophylline absorption can be attributed to its rate of release. Consequently, simulations 
failed to depict any changes in oral absorption of SR theophylline except in extreme cases where total 
intestinal transit time is shorter than formulation release time (i.e. total intestinal transit time ↓ 50%). 
In studies where the effects of separate formulations (solution vs. tablet) or different feeding 
conditions (fasted vs. fed) were explored in the same study participants, the analysis assumed SITT 
estimates were highly correlated (i.e. r ≈1). This permitted for SITT to be summarized between 
treatment arms using the overall mean and pooled standard deviation. Similarity of intestinal transit 
kinetics between separate dosage forms and different feeding conditions was assumed based on data 
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presented by Davis et al [146]. The study examined 201 SITT estimates as measured by scintigraphy 
among normal adult subjects for single unit dosages, pellets, and solutions under various feeding 
conditions. The results conveyed no statistical difference in the transit behavior between formulations 
and a lack of effect of feeding status.  
 The current investigation segregated data measured by lactulose H2 breath testing due to the 
propensity of lactulose to accelerate intestinal transit. In addition, lactulose H2 breath tests typically 
report reduced degrees of inter-subject variability in transit times compared to studies where lactulose 
was not administered [96]. These findings prevented the amalgamation of intestinal transit data 
obtained from scintigraphy and other auxiliary techniques with lactulose H2 breath tests into a single 
analysis, as reductions in intestinal transit time variability due to lactulose may have unfairly weighted 
the meta-regression analysis towards these investigations. Dissimilar to scintigraphy, which provides 
isolated measures of small bowel transit, lactulose H2 breath tests provides composite estimates of oral 
to cecal transit. Thus, in order to assess the effects of age on SITT using such studies, both esophageal 
and gastric transit must be considered. For liquids, esophageal transit transpires in the realm of seconds 
and is not considered to vary with age [178]. However, gastric emptying varies between fasted and fed 
states and can be influenced by factors such as feed composition and osmolality [107]. In a recent 
assessment of gastric transit data from neonates to adults, it was found that gastric emptying was not 
significantly influenced by age [179]. In addition, the time at which increased levels of H2 are first 
detected in expired air, denoted as the OCTT, correlates with the foremost portion of lactulose reaching 
the caecum rather than a specific quantity (i.e. 10% of lactulose entering the caecum) [107]. 
Consequently, for breath testing, differences in gastric emptying times (i.e. fasted vs. fed states) should 
not exert a substantial influence on OCTT. Based on this assessment, OCTT as measured by lactulose 
H2 breath testing should provide a suitable surrogate for SITT, albeit in an accelerated state.  
The analysis included data pertaining to 52 normal/healthy subject groups, 16 of which were 
representative of children less than 18 years old. The frequency of pediatric subject groups stratified 
according specific to developmental age ranges were as follows: 1 neonate (0-30 days), 1 infant (1 
month -2 years), 3 young children (2 – 5 years), 10 children (6-12 years), and 1 adolescent (12-18 
years). Accordingly, it can be seen that data pertaining to the youngest cohorts of children, especially 
those less than 2 years of age, are disproportionately underrepresented within the analysis. This pattern 
is concerning as the youngest subjects (i.e. neonates) are considered to be the most functionally 
immature and, therefore, the most likely to display developmental differences in comparison to adults. 
Consequently, the findings presented by this analysis are contingent on currently available literature 
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and, as such, are malleable to change if additional investigations, especially in neonates and infants, are 
prospectively conducted. 
In one investigation, SITT within a single subject group was found to be statistically different 
(p-value ≤ 0.05) between administration of pellets of varying size (0.5 vs. 4.75 mm pellets) [141]. 
Rather than combine the measurements into to single outcome, the data was analyzed as separate 
groups. Although this clearly introduces the small degree of bias into our analysis, the presented results 
are similar to that if the investigation was simply excluded from the analysis altogether.  A major 
limitation associated with meta-regression or any other technique where data is summarized over trials 
as opposed to individual subjects is aggregation bias (i.e. ecological fallacy). This bias describes the 
loss of information that occurs when data is averaged across trials, resulting in an inability to detect 
correlations that would be present if individual study subjects were assessed [180]. Unfortunately, the 
majority of literature investigations summarize data over all study subjects as opposed to denoting 
individualized measures of age and SITT. Consequently, despite the potential for aggregation bias, 
meta-regression was still deemed the most appropriate analysis technique. 
 
3.5 Conclusion 
The essential role of the small intestine towards facilitating absorption of nutrients and xenobiotics 
highlights the inherent need to appropriately define its transit kinetics. Within the literature, SITT has 
been reported using a variety of measurement methods by several research groups. Previous 
investigations have summarized SITT reflective of adult subjects, but the relevance of these values 
towards children remained questionable. The present study employed meta-regression in order to 
summarize the effect of age on SITT. Based on this analysis, there is no evidence to suggest that mean 
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Chapter 4: Assessment of Age-Related Changes in Pediatric 
Gastrointestinal Solubility 
The contents of this chapter are reflective of an original manuscript published by the Ph.D. candidate 
(Anil R Maharaj) in the journal Pharmaceutical Research. All pertinent research analyses was 
conducted by the Ph.D. candidate. 
Maharaj AR, Edginton AN, Fotaki N. Assessment of Age-Related Changes in Pediatric 




The use of in vitro tests to forecast oral drug performance can serve to identify compounds displaying 
inadequate or unfavorable absorption profiles during early stages of drug development. To facilitate 
such in vitro – in vivo correlations (IVIVC), test media utilized should reflect the complex 
physiochemical nature of human gastrointestinal (GI) fluids.  Accordingly, several formulas of 
biorelevant media have been developed based on the intraluminal conditions of the GI tract in adults 
[181-183]. For immediate release dosage forms, where drug release is expected to occur within the 
upper region of the GI tract, biorelevant media depicting the stomach and proximal small intestine are 
typically formulated.   
Compared to compendial media, use of biorelevant media within in vitro dissolution 
experiments has been demonstrated to provide IVIVC that better predict oral drug absorption in adults 
[45, 46]. Despite these favorable results, the use of biorelevant media for establishing IVIVC within 
pediatric populations is contentious. This is because contemporary biorelevant media [181, 182] are 
formulated based on gastrointestinal conditions of an adult human. Consequently, their applicability 
towards pediatric populations, who are developmentally distinct in terms of gastrointestinal 
anatomy/physiology, remains questionable. Of most interest are children belonging to the youngest age 
groups (i.e. neonates and infants) who display the greatest developmental differences in comparison to 
adults [184, 185]. 
In recognition of the potential impact that developmental differences in GI anatomy/physiology 
can exert on oral drug absorption, a Pediatric Biopharmaceutics Classification System (P-BCS) 
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Working Group was assembled to assess whether a similar classification system as utilized in adults 
could be developed for children [186]. The Biopharmaceutics Classification System (BCS) categorizes 
drugs based on two properties, aqueous solubility and permeability [47]. Accordingly, compounds can 
be classified as either BCS I (high solubility, high permeability), II (low solubility, high permeability), 
III (high solubility, low permeability), or IV (low solubility, low permeability). The classification 
system supports several aspects of oral drug development in adults, including assessment of generic 
biowaiver applicability, lead compound selection, and formulation development [186]. Based on their 
findings in a 2012 publication, the P-BCS Working Group concluded that in order to have merit, 
substantial knowledge gaps with regards to pediatric GI physiology, intestinal permeability, and 
ontogeny of drug metabolizing enzymes/transporters needs to be addressed prior to establishing of a 
pediatric-focused BCS [186]. To enhance its applicability towards pediatric populations, it is clear that 
development of a P-BCS would require considerable modification of the current system. Of interest is 
how developmental changes in GI fluid composition affects compound solubility in relation to adults. 
In addition to age-related changes, the composition of GI luminal fluids undergoes positional 
changes from the stomach to the colon. Changes in composition including bile salt concentration, pH, 
osmolality, buffer capacity, and presence of fat digestion products, can impart changes in compound 
specific solubility [44]. Therefore, to discern whether relevant differences in luminal solubility exist 
between pediatrics and adults, quantification of the relationship between age and GI fluid composition 
is inherently required.  
This study serves to assess the impacts of growth and maturation on gastrointestinal solubility. 
Pediatric biorelevant media representative of the stomach and proximal small intestine were developed 
based on an assessment of the available literature. Developed pediatric media were utilized to perform 
solubility assessments for seven BCS Class II compounds. To assess the impact of developmental 
changes in fluid composition, solubility values were compared between the different age-specific media 




Acetic acid (>99.7%), acetonitrile, dapsone, fenofibrate, indomethacin, hydrochloric acid 36.5-38%, 
methanol, pepsin (from porcine), phenytoin acid and sodium oleate were obtained from Sigma-Aldrich 
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Company Ltd., Dorset, England. Griseofulvin, maleic acid, sodium acetate, sodium chloride, sodium 
hydroxide, orthophosphoric acid and spironolactone were acquired from Fisher Scientific UK Ltd., 
Loughborough, England. Ammonium acetate (FSA Laboratory Supplies, Loughborough, UK), 
carbamazepine (Fagron UK Ltd, Newcastle upon Tyne, England), sodium taurocholate (Prodotti 
Chimici Alimentari S.P.A., Basaluzzo, Italy), egg lecithin - Lipoid EPCS (Lipoid GmbH, 
Ludwigshafen, Germany) and glyceryl monooleate - Rylo Mg 19 (Danisco, Brabrand, Denmark) were 
obtained from the sources specified. Ultra-high-temperature treated whole cow’s milk standardized to 
less than 4% fat was acquired from Sainsbury’s, London, England. Two infant formulas manufactured 
by Cow & Gate, Trowbridge, England were utilized in the study: First Infant Milk (cow’s milk-based 
formula) and Infasoy (soya-based formula). Water was ultra-pure (Milli-Q) laboratory grade. Dialysis 
tubing (12-14000 Da MWCO) was acquired from Medicell Membranes Ltd., London, England.  
Equipment utilized in the current investigation included a Buchi R114 Rotavapor (Flawil, Switzerland), 
a Beckman Coulter J2-MC centrifuge (High Wycombe, England), a Mettler Toledo SevenCompact 
S210 pH meter (Schwerzenbach, Switzerland), an Advanced Instruments Inc. micro-osmometer Model 
3300 (Norwood, MA) and an Agilent Technologies 1200 series HPLC system (Santa Clara, CA): binary 
pump (G1212A), autosampler (G1329A), thermostatted column compartment (G1316A), and diode 
array detector (G1315D). 
 
4.2.2 Media development 
Biorelevant media as characterized by Jantratid et al. [182]  were selected as the focal points from 
which subsequent age-specific media were developed. The authors described four separate media 
reflective of the physiology of the stomach and proximal small intestine in adults in fasting and fed 
states: Fasted-State Simulated Gastric Fluid (FaSSGF), Fed-State Simulated Gastric Fluid (FeSSGF), 
Fasted-State Simulated Intestinal Fluid v2 (FaSSIF.v2), and Fed-State Simulated Intestinal Fluid v2 
(FeSSIF.v2) (Table 4.1).  Based on relative differences between adult and pediatric GI physiology, 
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*adult media compositions as described in Jantratid et al. [182] 
 
Component FaSSGF FeSSGF FaSSIF.v2 FeSSIF.v2 
Sodium Taurocholate  80 (uM) - 3 (mM) 10 (mM) 
Lecithin 20 (uM) - 0.2 (mM) 2 (mM) 
Pepsin (mg/mL) 0.1 - - - 
Sodium Chloride 
(mM) 
34.2 237.02 68.62 125.5 
Acetic Acid (mM) - 17.12 - - 
Sodium Acetate (mM) - 29.75 - - 
Maleic Acid (mM) - - 19.12 55.02 
Sodium Hydroxide 
(mM) 
- - 34.8 81.65 
Glyceryl Monooleate 
(mM) 
- - - 5 
Sodium Oleate (mM) - - - 0.8 
Milk:Buffer - 1:1  - 
HCl/NaOH qs pH 1.6 pH 5 pH 6.5 pH 5.8 
     
pH 1.6 5 6.5 5.8 
Osmolarity 
(mOsm/kg) 
120.7 400 180 390 
Buffering Capacity 
(mEq/L/ ∆pH) 
- 25 10 25 
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Investigations assessing developmental changes in gastrointestinal fluid composition were 
collected from the literature. For studies where information was displayed graphically, data was 
quantified using GetData Graph Digitizer (v2.26). Dependent on the specific media being formulated 
(i.e. FaSSGF), information pertaining to different physiological parameters were required: 
 
(a) FaSSGF – pepsin concentrations, pH, osmolality, and bile salt/lecithin concentrations 
(b) FeSSGF – feed type (i.e. cow’s milk-based vs. soy-based formula), pH, osmolality, and 
buffering capacity  
(c) FaSSIF – pH, bile salt/lecithin concentrations, osmolality, and buffering capacity 
(d) FeSSIF – pH, osmolality, bile salt/lecithin concentrations, fat digestion products, and buffering 
capacity 
Parameter values were compiled and, where suitable, graphically displayed as a function of age as 
an initial evaluation. If changes in GI fluid parameters between pediatric age groups and adults were 
noted, differences were computed based on a simplistic measure, the arithmetic mean. As the propensity 
of developmental effects were expected to be most prominent within the earliest stages of life, media 
reflective of the following age groups were formulated: neonates (0 – 28 days) and infants (1 – 12 
months). When data pertaining to specific parameters were unavailable in children, either a default 
value representative of adult media or an inference based on current physiological knowledge was 
adopted. 
Based on this analysis, biorelevant media reflective of pediatric physiology were defined. Media 
preparation was conducted using the methods depicted in Jantratid et al [182]. Measures of osmolality 
and pH were instituted to ensure prepared media conformed to desired values. Osmolality was 
measured using freezing point depression (Micro-osmometer - Advanced Instruments Inc.).  
Discrepancies between measured and desired osmolality were corrected by adjusting media sodium 
chloride concentrations as described in the literature [182]. Media pH was titrated using 1M HCl or 1M 
NaOH, if necessary. Buffering capacity of pediatric formula (cow’s milk-based and soy-based) was 
determined based on the methodology presented by Hentges et al [187]. Values presented represent the 
amount of acid or base (i.e. mEq) required to induce of pH change of 1 unit per litre of formula [188]. 
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4.2.3 Solubility assessment 
4.2.3.1 Compound selection 
Solubility assessments were conducted using BCS class II compounds. Compounds were further 
restricted to include only those with documented usages, including investigational uses, in both children 
and adults. Based on the above criteria, seven compounds were selected including carbamazepine, 
dapsone, fenofibrate, griseofulvin, indomethacin, phenytoin and spironolactone. Compound 
physicochemical properties are displayed in Table 4.2. 
 





*physicochemical data obtained from DrugBank [189] 
 
4.2.3.2 Solubility experiments 
Compound specific solubility assessments were conducted in each of the developed pediatric media as 
well as in the reference adult media to assess for age-related differences. Experiments were conducted 
within a shaking water bath set to 37OC and 200 strokes/min.  
Compound specific solubility values in aqueous-based media (FaSSGF, FaSSIF and FeSSIF) 
were determined based on the following procedure. A mass of solid (powdered) compound to saturate 
10 mL of biorelevant media was added to borosilicate glass tubes. Next, 10 mL of freshly prepared age-
specific media (pediatric or adult) was added. Tubes were covered with parafilm and placed in the 
shaking water bath. Solubility assessments for all compounds, with the exception of fenofibrate, were 
conducted following a 24 hour dwell period. For fenofibrate, previous investigations have employed 
Compound Molecular Weight 
(g/mol) 
LogP pKa (acid/base) 
Dapsone 248 0.97 2.4 (base) 
Griseofulvin 353 2.18 - 
Carbamazepine 236 2.45 -  
Phenytoin 252 2.47 9.5 (acid) 
Spironolactone 417 2.78 -  
Indomethacin 358 4.27 3.8 (acid) 
Fenofibrate 361 5.3 -  
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longer dwell periods (i.e. 48-72 hours) in order to achieve equilibrium solubility [190, 191]. 
Correspondingly, a dwell period of 72 hours was utilized in this investigation. Saturated media samples 
were filtered through 0.45 μm regenerated cellulose filters and diluted with fresh media prior to 
assessment. HPLC-UV was utilized to quantify solubility. Analytical HPLC procedures were based on 
modifications of methods depicted in the literature and are denoted in Table 4.3. Solubility assessments 
were conducted in triplicate for each test media (pediatric and adult). Calibration curves were 
constructed using five standard concentrations. Standards were formulated as mobile phase dilutions 
of a concentrated stock solution consisting of compound dissolved in an organic solvent (i.e. methanol). 
All dilutions were conducted using volumetric glassware.   
Due to the addition of either milk or infant formula, fed-state gastric media exists as a complex 
multiphase system [192]. Proteins within the media deter direct filtration of samples through 0.45 μm 
filters. As a result, the investigation utilized equilibrium dialysis to assess compound solubility within 
all fed-state gastric media, which negated the need for sample filtration to remove excess drug. To 
ensure restrictions in the rate of membrane permeation did not delimit solubility determinations, 
samples were permitted to dwell for an additional 24 hours compared to aqueous-based media. A mass 
of solid compound required to saturate 25 mL of media was added to separate 50 mL plastic centrifuge 
tubes. Twenty mL of freshly prepared media was then added. Next, a dialysis membrane (MWCO 12-
14000 Da) containing 5 mL of fresh media was placed in each tube. Tubes were capped and placed in 
a shaking water bath. Solubility assessments were conducted after a 48 hour dwell period with the 
exception of fenofibrate, which was assessed after 96 hours. For assessment, tubes were taken from the 
water bath, the dialysis membrane was removed, and its contents were extracted. One mL of media 
from the within the membrane was combined with 2 mL of methanol and vortexed for 5 seconds. The 
mixture was centrifuged at 8000 rpm and 4oC for 15 minutes. The resulting supernatant was filtered 
through 0.45 μm regenerated cellulose filters (Cronus) and diluted in mobile phase prior to analysis. 
Solubility values were quantified using HPLC-UV under the conditions specified in Table 4.3. 
Calibrations curves with five standard concentrations were constructed for each test media. Standards 
were created by dilution of a stock solution, as described above, with fresh media using volumetric 
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Table 4.3 HPLC-UV analytic conditions 












1 Carbamazepine MeOH/ Water 
(60:40) 
1 20 50 285 6.6 [193] 





1 20 10 295 5.6 [194] 





1 25 80 286 6.5 [195] 
2 Griseofulvin MeOH/ Water 
(65:35) 
1 20 20 292 4.5 [196] 
2 Indomethacin MeOH/ Water 
with 1.67% 
orthophosphor
ic acid (70:30) 
1 23 100 270 9.9 [197] 
2 Phenytoin* Water/ AcN 
(50:50) 
0.5 20 10 210 5.6 [198] 
2 Spironolactone MeOH/ Water 
(70:30) 
1 20 40 237 5.7 [199] 
 
Column 1: Hypersil (Thermo) BDS -C18 250 x 4.6mm - 5 μm 
Column 2: Zorbax SB-C18 150 x 4.6mm – 3.5μm 
a - Q = flow rate;  b - λ = UV wavelength; c - Rt = retention time 
* - HPLC conditions altered for solubility assessments with FeSSGF media due to interference with 
media components. Mobile phase (Water/AcN – 60:40), Q (1ml/min) and Rt=4.8 mins. 
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One-way analysis of variance (ANOVA) with a post-hoc Tukey’s test was applied to identify 
statistically significant differences in solubility between various age-specific media (i.e. neonate-
infant-adult). All statistical analyses were conducted using R statistical software (v 3.1.2).  The 
investigation utilized a significance level of p≤0.05. Average solubility differences between 
developed pediatric media and the corresponding reference adult media were expressed as a ratio % 
(𝜇pediatric /𝜇adult x 100). Values greater than 100% indicate compound solubility within the pediatric 
media exceeded the solubility observed in adults, whereas values less than 100% conveyed the 
opposite. To denote relevant discrepancies in solubility, reference points corresponding to ratios of 
80% and 125% were used. These values parallel the 80-125% bioequivalence criterion as specified by 
the US-Food and Drug Administration (US-FDA) [200]. Within the analysis, statistically significant 
mean ratios falling outside the pre-specified boundary range were estimated to be at an increased risk 
for exhibiting alterations in oral drug performance between children and adults. In contrast, when 
mean ratios were within the 80-125%, boundary, age-specific solubility differences were not expected 
to alter oral drug performance.  
The influence of bile salts (NaTc) on modulating compound solubility within the developed 
biorelevant media was approximated using the equations presented by Mithani et al. [201], 
 
𝑙𝑜𝑔𝑆𝑅 = 2.09 + (0.64 ∙ 𝑙𝑜𝑔𝑃) (Equation 4.1) 
𝑆𝐶𝑏𝑠 = 𝑆𝑅 ∙ 𝑆𝐶𝑎𝑞 (Equation 4.2) 
𝐶𝑠𝑥 = 𝐶𝑠𝑜 + (𝑆𝐶𝑏𝑠 ∙ 𝑀𝑊 ∙  [𝑁𝑎𝑇𝑐] )      (Equation 4.3) 
 
where SR is the solubilization ratio, logP is the logarithm of the octanol-water partition coefficient, 
SCbs is the bile salt solubilization capacity, SCaq is the solubilization capacity of water, Csx is the 
estimated compound solubility (mcg/mL) in the presence bile salts, Cso is the aqueous solubility 
(mcg/mL), MW is the compound specific molecular weight and [NaTc] is the media concentration 
(mM) of sodium taurocholate (bile salt). The equations, which describe the quantitative relationship 
between bile acids and compound solubility within aqueous based systems, incorporated bile salt 
concentrations for each age-specific media formulated with NaTc (FaSSGF, FaSSIF and FeSSIF). For 
neutral compounds (griseofulvin, spironolactone, carbamazepine and fenofibrate), experimentally 
determined aqueous solubility values served as inputs. For ionizable compounds (phenytoin-acid, 
indomethacin-acid, and dapsone-base), pH specific aqueous solubility values, as estimated by the 
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Henderson-Hassalbach equation, were utilized. The ratio of compound solubility, relative to adults, was 
estimated for each of the developed pediatric media (i.e. pediatricpred/adultpred x 100). A comparison 
between these predictions, which solely account for the effect of bile acids, and measured values, which 






𝜇 𝑝𝑒𝑑𝑖𝑎𝑡𝑟𝑖𝑐 𝑠𝑜𝑙𝑢𝑏𝑖𝑙𝑖𝑡𝑦(𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑) 
𝜇 𝑎𝑑𝑢𝑙𝑡 𝑠𝑜𝑙𝑢𝑏𝑖𝑙𝑖𝑡𝑦(𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑)






𝑗=1   
(Equation 4.4) 
Here, the RMSE provides a quantitative assessment of the influence of media bile salts on modulating 
compound solubility. For example, high agreement between predicted and measured solubility ratios, 




Literature data utilized to define age-specific GI parameters were primarily sequestered from studies 
examining healthy/normal children in order to mitigate the confounding effects of altered health 
statuses. For example, several investigations examining fasting gastric pH in children focused on pre-
operative subjects with no known GI disease undergoing elective surgery. However, due the scarcity 
of pediatric data, some investigations examining critically ill subjects (i.e. NICU, PICU, or ICU 
patients) as well as preterm neonates were included in the analysis.  Such studies were additionally 
scrutinized to ensure their appropriateness towards defining GI parameters reflective of normal 
children. Investigations of gastric pH including critically ill subjects were restricted to studies where 
acid reducing agents (i.e. H2 antagonists) were withheld [202-204]. Two pediatric studies assessing 
fasting gastric pepsin levels included subjects deemed as critically ill [205, 206].  As pepsin 
concentrations were presented as a percentage of adult values, data from these studies were compared 
to reference data [207] derived from critically ill adult subjects to normalize for any potential effects of 
illness. Similar to term neonates, preterm neonates by a gestational age of 34 weeks are expected to 
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possess the ability to suckle and swallow to facilitate oral nutrition [208]. Consequently, to minimize 
the effects of immaturity within the analysis, studies were delimited to those where the average 
postmenstrual age (gestational age + postnatal age) of subjects was approximately ≥ 34 weeks. 
 
4.3.1 Pediatric Fasted-State Simulated Gastric Fluid (P-FaSSGF) 
Studies depicting gastric pepsin concentrations in pediatric subjects are presented as a percentage of 
adult values in Figure 4.1A.  Reported concentrations were measured in a fasting state with or without 
histalog stimulation. Values derived from histalog stimulation tests were compared to adult subjects 
referenced within the same study [209]. For other studies, reference adult values were ascertained from 
separate investigations by the same research group or investigations utilizing a similar assay technique. 
A segmented analysis towards neonatal subjects was only conducted in a single study [209]. The 
investigation showed gastric pepsin concentrations approached infantile (1m-12m) levels after the first 
week of postnatal life. For example, neonates between 1-8 days postnatal age exhibited mean pepsin 
concentrations of ~15% of adult values while older neonates (10-32 days) and infants (67-110 days) 
both expressed similar mean concentrations of ~41% of adult values. Neonatal FaSSGF was developed 
based on the youngest cohort of subjects (i.e. those within the 1st week of life) to depict a state where 
the effects of development are most pronounced. Infant FaSSGF was formulated using pepsin 
concentrations summarized over several investigations. Concentrations of 15% and 25% of adult 
reference values (FaSSGF) were utilized for neonatal and infant FaSSGF, respectively.
 Investigations depicting fasting gastric pH values in pediatric subjects are summarized in 
Figure 4.1B. Adult values represented by the mean from separate investigations, as summarized by Di 
Maio and Carrier [210], are displayed for reference. After the first day of life, fasting gastric pH rapidly 
normalizes towards adult values. Correspondingly, pediatric media (neonate and infant) representative 
of the fasted gastric state maintained the same pH as denoted by the reference adult media (i.e. FaSSGF 
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Figure 4.1 (A) Fasting gastric pepsin concentrations amongst pediatrics [205, 206, 209, 211] is 
expressed as a percentage of adult values [207, 209, 212]. Investigations where pepsin 
concentrations were quantified over a specific age range without denoting the group’s mean age 
were graphically depicted as the middle of the age range. Average (mean) values pertaining to 
neonates (0-28days) and infants (1m-12m) are illustrated for reference (red – x’s). (B) Fasting 
gastric pH amongst pediatrics (black circles) is depicted as the central tendency, either mean or 
median, from separate investigations [202-204, 213-232]. Studies where gastric pH values was 
quantified over specific age range without denoting the group’s mean age were graphically 
depicted using the middle of the age range. Adult data is depicted by mean pH values from 
separate studies, as summarized by Di Maio and Carrier [210]. Dashed reference lines 
correspond to the maximum and minimum mean pH values observed within the presented 
adult studies. 
 
A single pediatric study was identified that investigated fasting gastric osmolality in 40 
postoperative infants with a mean age of approximately 8 months [232]. The investigation depicted an 
average osmolality of 253 mOsm/L, which is more than twice the value of adult FaSSGF (120 
mOsm/L). However, these finding may not be entirely reflective of healthy infants. In postoperative 
subjects, administered medications and patient induced stress during surgery can effect gastric 
secretions and, thus, osmolality. Consequently, owing to the lack of appropriate data to establish a 
relationship between age and fasting gastric osmolality, the pre-established value from adults was 
employed to develop pediatric media. 
  71 
Literature-based assessments of gastric bile acids and phospholipids (i.e. lecithin) in the fasting 
state were not available for pediatric subjects. As the gastric mucosa does not contain the capacity to 
produce or excrete bile, the presence of gastric bile acids are primarily the result of duodenogastric 
reflux, a normal physiological phenomenon documented in adults [233, 234]. Therefore, it was 
postulated that intestinal bile levels would influence the magnitude of bile acids present within gastric 
fluids. With frequent feeding schedules, neonates and infants are often maintained within the fed-state 
during waking hours. As such, bile acid (i.e. NaTc) values within pediatric FaSSGF were derived using 
fed-state intestinal bile levels. The following formula was used to quantify NaTc concentrations in 
pediatric FaSSGF, 
𝑝𝐹𝑎𝑆𝑆𝐺𝐹[𝑁𝑎𝑇𝑐] (𝑢𝑀) =  
𝑝𝐹𝑒𝑆𝑆𝐼𝐹[𝑁𝑎𝑇𝑐]
𝐹𝑒𝑆𝑆𝐼𝐹[𝑁𝑎𝑇𝑐]
∙ 𝐹𝑎𝑆𝑆𝐺𝐹[𝑁𝑎𝑇𝑐]    (Equation 4.5) 
 
where pFaSSGF[NaTc] is the bile acid (NaTc) concentration in pediatric FaSSGF, pFeSSIF[NaTc] is the 
NaTc concentration in pediatric FeSSIF, FeSSIF[NaTc] is the NaTc concentration in the reference adult 
FeSSIF media (10 mM), and FaSSGF[NaTc] is the NaTc concentration in reference adult FaSSGF 
media (80 uM). Bile acid values within pediatric FeSSIF media are presented in a forthcoming 
section.  For lecithin, pediatric FaSSGF was formulated to maintain the same ratio of 
[NaTc]/[lecithin] as depicted by adult FaSSGF. Compositions of the developed neonatal and infant 
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Table 4.4 Pediatric Fasted-State Simulated Gastric Fluids (P-FaSSGF) 
Component Pn-FaSSGFa Pi-FaSSGFb 
Sodium Taurocholate (uM) 20 60 
Lecithin (uM) 5 15 
Pepsin (mg/mL) 0.015 0.025 
 Sodium Chloride (mM) 34.2 34.2  
HCl qs pH 1.6 pH 1.6 
pH 1.6 1.6 
Osmolarity (mOsm/kg) 120.7 120.7  
Buffering Capacity (mEq/L/ ∆pH) - - 
 
a - Pn-FaSSGF – pediatric fasted-state gastric media representative of neonates (0-28 days) 
 
b - Pi-FaSSGF – pediatric fasted-state gastric media representative of infants (1-12 months) 
  
4.3.2 Pediatric Fed-State Simulated Gastric Fluid (P-FeSSGF) 
The composition of FeSSGF is largely influenced by added meal components. In adult FeSSGF, cow’s 
milk is typically incorporated as it contains similar ratios of carbohydrate/protein/fat as a typical 
breakfast meal and avoids logistic difficulties associated with the use of homogenized solid meals [235, 
236]. To institute the most physiologically relevant depiction of gastric contents in children, pediatric 
media were formulated using two types of commonly marketed infant formula: Cow & Gate First Infant 
Milk (cow’s milk-based formula) and Infasoy (soya-based formula).  Development of separate pediatric 
FeSSGF media comprised of different formulas permitted for forthcoming solubility assessments to 
investigate the influence of pediatric diet on biorelevant solubility. 
Gastric pH within the fed-state is dependent of several factors including feed composition and 
time of measurement [237, 238]. Since many pediatric investigations administer various feeds (i.e. 
breast milk, infant formula, or D5W) and measure postprandial pH at selective time intervals, defining 
age-specific pH values was quite challenging. Adult FeSSGF represents a snapshot of the ‘middle’ 
phase of gastric digestion between 75 and 165 minutes post-meal ingestion [182]. The pH of adult 
FeSSGF was derived from Kalantzi et al.’s study, where a liquid meal consisting of 500mL Ensure 
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plus® was administered to 20 healthy subjects [238]. The study denoted a pH of 5 as the approximate 
average over the abovementioned time period. However, in a separate investigation by Dressman et al. 
[239], where gastric pH was monitored  following ingestion of a standard solid meal (1000 Kcal),  
postprandial pH values differed from the results attained by Kalantzi et al. Following administration of 
a solid meal, gastric pH decreased towards fasting values at a faster rate compared to subjects 
administered a liquid meal. For example, median pH values persisted above 3 for approximately 60 
minutes vs. > 180 minutes following solid meal vs. liquid meal ingestion, respectively [238, 239]. As 
solid foods are anecdotally the most common form of meals consumed by adults, comparison of 
postprandial pH changes between children, administered a typical meal (i.e. formula), and adults, 
administered a solid meal, were used to define pH for the developed pediatric FeSSGF. Sondheimer et 
al. investigated the influence of postnatal age (PNA) on gastric pH in healthy preterm neonates [240]. 
In-situ pH monitoring was conducted following administration of infant formula in two groups of 
neonates aged 2-6 days and 7-15 days PNA.  Comparing pH values at approximately 120 minutes post-
meal (i.e, mid-point of the 75-165 minute time frame) between the cohort of older preterm neonates 
and adults, as reported by Dressman et al., pH was found to be higher (0.7-1.8 units) among neonates. 
As a result, neonatal FeSSGF was formulated to adopt a slightly higher pH (pH = 5.7) as compared to 
the reference adult FeSSGF (pH = 5). 
Osmolality of pediatric FeSSGF was defined by two investigations. The first, conducted by 
Billeaud et al. [241], characterized gastric osmolality among 15 low birth weight neonates with a mean 
PNA and gestational age (GA) of 8 days and 35.4 weeks, respectively. Eight test feeds, each differing 
in osmolality, were administered. The study noted a positive linear relationship between feed and 
gastric osmolality over the 3 hour study period. In a separate investigation by Thatrimontrichai and 
Janjindamai [242], three separate expressed breast milk feeds, which ranged in osmolality due to the 
addition of mineral/vitamin supplements, were tested in 26 neonate/infant subjects with a median PNA 
and GA of 30 days and 30 weeks, respectively. Within the study, meals with higher osmolalities were 
found to be associated with comparatively higher gastric osmolalities over the 1 hour test period. A 
linear regression model depicting the degree of association between feed osmolality and 60 minute 
postprandial gastric osmolality was developed based on the results of Billeaud et al.’s [241] 
investigation (Figure 4.2). Although a 60 minute sampling point was not obtained during the original 
study, the value was estimated as the average between the 45 and 90 minute sampling intervals. The 
validity of the derived regression equation was tested by comparing gastric osmolality predictions to 
the data presented within Thatrimontrichai and Janjindamai’s study [242]. The results of this 
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comparison are depicted in Table 4.5. Estimates from the regression equation were within 8% of 
measured values. As such, the equation was deemed appropriate for defining osmolality in neonatal 
FeSSGF. Although a sampling point of 60 minutes was clearly outside the time frame used to define 
adult FeSSGF (75-165 minutes), children, especially those within the youngest age groups, are typically 
fed on a more consistent basis during waking hours (i.e. every 2-3 hours). Correspondingly, defining 
gastric osmolality in children based on one hour postprandial values may provide an age appropriate 
representation of the ‘middle’ phase of gastric digestion, which adult FeSSGF is formulated to mimic. 
 
 
Figure 4.2 Neonatal gastric osmolality 60 minutes post-meal expressed as a function of feed 
osmolality. Data (black circles) represent average gastric osmolality values recorded amongst 
neonatal subjects as described by Billeaud et al [241].  A linear regression model (red line) was 
fit to the data. 
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Table 4.5 Predictive performance of the osmolality regression equation 




Osmolality - 60 min 
postprandial (Median - 
mOsm/kg)a 
Predicted Gastric 
Osmolality – 60 min 
postprandial 
(mOsm/kg)b 
% Prediction Error 
((Pred– Obs) / Obs) x 100 
344 354 327 -7.6 % 
426 383 368 -3.9 % 
315 315 313 -0.6 % 
 
a - Values derived from Thatrimontrichai and Janjindamai [242]  
b - Predictions based on regression model, as derived from Billeaud et al. [241] 
 
 
Since basal gastric volumes in infants are minute [226], the composition of gastric fluids 
postprandially can likely be attributed to the properties of the ingested meal. As such, the buffering 
capacity of pediatric FeSSGF was determined based on the buffering capacity of infant formula 
incorporated into the media. Since two separate neonatal media, one based on cow’s milk formula and 
the other based on soy formula, were developed, buffering capacity determinations for each respective 
formula were required. Determinations were conducted at pH 5.7, the desired pH of neonatal FeSSGF. 
The buffering capacity (mean ± SD) of cow’s milk formula at pH 5.7 was 14.03 ± 0.164. Soy-formula 
at pH 5.7 displayed similar a buffering capacity (14.94 ± 0.318 mEq/L/∆pH). For simplicity, neonatal 
FeSSGF based on cow’s milk formula and soy formula were prepared to target a buffering capacity of 
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Table 4.6 Pediatric Fed-State Simulated Gastric Fluids (P-FeSSGF) 
Component Pnc-FeSSGFa Pns-FeSSGFb 
 Sodium Chloride (mM) 100.35 94.79 
Acetic Acid (mM) 7.25 7.25 
Sodium Acetate (mM) 64.65 64.65 
Milk:buffer 1:1 1:1 




Osmolarity (mOsm/kg) 340 240 
Buffering Capacity 
(mEq/L/ ∆pH) 
15  15 
 
a - Pnc-FeSSGF – pediatric fed-state gastric media representative of neonates (0-28 days) fed cow’s 
milk-based formula 
b - Pns-FeSSGF – pediatric fed-state gastric media representative of neonates (0-28 days) fed soy-
based formula  
 
Appropriate information to define infantile fed-state gastric fluids (i.e. 1-12m) was not attained 
from the literature. As a result, an infant FeSSGF media was not developed. However, as the 
composition of FeSSGF is primarily attributed the contents of the added meal component, assessments 
conducted in neonatal media which incorporate infant formula should provide a general indication of 
expected solubility changes in infants consuming similar feeds. In addition, comparisons between 
neonatal media that are similar in all respects with the exception of the type of meal component added 
(i.e. cow’s milk-based formula vs. soy-based formula) provide an assessment of the impact of feed 
composition on biorelevant solubility. 
4.3.3 Pediatric Fasted-State Simulated Intestinal Fluid (P-FaSSIF) 
Intestinal pH values depicted in the literature are summarized as a function of postnatal age in Figure 
4.3A. The majority of pediatric data were attained from the distal duodenum though a few studies that 
sampled from the proximal jejunum were also included. Adult pH is depicted as mean values from 
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separate investigations, as summarized by Fuchs and Dressman [243].  Studies investigating intestinal 
pH in children, especially in the youngest age groups, were not widely published in the literature. In 
addition, data obtained from adults encompassed a large degree of variability. Consequently, no distinct 
relationship between age and fasted-state intestinal pH was observed. Pediatric media were 
subsequently formulated using the same pH as denoted for the adult reference media (i.e. FaSSIF – pH 
= 6.5).  
Fasting bile salt concentrations from the proximal small intestine are depicted as a function of 
age in Figure 4.3B. A large degree of variability was apparent in both children and adults as denoted 
by the spread of data. Discernable differences between pediatric age groups (i.e. neonates, infants) and 
adults were not visually evident. Furthermore, the linear association between the logarithm of age and 
bile acid concentrations was negligible (R2=0.05) among pediatrics. Due the substantial degree of 
variability between pediatric studies, P-FaSSIF was developed to assess two potential scenarios. In one 
media, bile salt concentrations were formulated to be 150% of adult values. In the second media, 
concentrations were formulated to be 50% lower than adults. A pediatric media where bile salt 
concentrations were similar to adult values did not necessitate development of a new media as this 
scenario was already depicted by the adult reference. Developed media represent hypothetical 
depictions of bile acid concentrations within a biologically plausible range. Correspondingly, the 
magnitude of compound specific solubility differences denoted in such media provides an indication 
of whether additional pediatric investigations are required to define bile acids within the fasted-state 
intestine. 
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Figure 4.3 (A) Pediatric fasting intestinal pH (black circles) is depicted as the central tendency, 
either mean or median, from separate investigations [109, 204-206, 244-246]. Studies where pH 
was summarized over a specific age range without denoting the group’s mean age were 
graphically depicted using the middle of the age range. The majority of data was derived from 
distal duodenum, though studies which included sampling sites from the proximal jejunum 
were also included. Adult duodenal bile acid concentrations (red circles) are depicted as mean 
values from separate studies, as summarized by Fuchs and Dressman [243]. (B) Fasting 
duodenal bile salt concentrations amongst pediatrics (black circles) are depicted as the central 
tendency, either mean or median, from separate investigations [247-257]. Studies where bile 
acids were summarized over a specific age range without denoting the group’s mean age were 
graphically depicted using the middle of the age range. Adult duodenal bile acid concentrations 
(red circles) are depicted as mean values from separate studies, as summarized by Fuchs and 
Dressman [243].  
No pediatric data pertaining to phospholipids (i.e. lecithin), buffering capacity, and osmolality 
of intestinal fluids in the fasted-state were ascertained.  Pediatric media were therefore formulated to 
maintain the same [NaTc]/[lecithin] ratio as depicted in the adult reference media (FaSSIF). Buffering 
capacity and osmolality were also defined using adult values. Compositions of the proposed P-FaSSIF 
media are presented in Table 4.7. 
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Table 4.7 Pediatric Fasted-State Simulated Intestinal Fluids (P-FaSSIF) 




Lecithin (mM) 0.1 0.3 
Maleic acid (mM) 19.12 19.12 
Sodium hydroxide (mM) 34.8 34.8 
Sodium Chloride (mM) 68.62  68.62  
   
pH 6.5 6.5 
Osmolarity (mOsm/kg) 180 180 
Buffering Capacity 
(mEql/L/ ∆pH)  
10 10 
 
a - P-FaSSIF-50% – pediatric fasted-state intestinal media formulated with bile salt concentrations 
50% (i.e. 1.5mM) of adult levels 
b - P-FaSSIF-150% – pediatric fasted-state intestinal media formulated with bile salt concentrations 
150% (i.e. 4.5 mM) of adult levels 
 
4.3.4 Pediatric Fed-State Simulated Intestinal Fluid (P-FeSSIF) 
Fed-state duodenal pH values from separate pediatric and adult investigations are presented in Figure 
4.4A.  Of the few studies presented amongst pediatrics, pH values appear to overlap with those 
depicted from adults. Owing to the disparate nature of available data, pH differences between each 
age group (neonate, infants, and adult) could not be fully elucidated. Pediatric FeSSIF media were 
therefore formulated using the same pH as the adult reference (i.e. pH = 5.8). 
Assessments of postprandial intestinal osmolality amongst pediatrics were also scarcely 
published within the literature. A single study conducted by Billeaud et al. [241], which was also 
utilized to define pediatric FeSSGF osmolality, was identified. Duodenal osmolality was assessed in 
15 low birth weight neonates following administration of a variety of feeds, each varying in osmolality. 
A positive linear association between feed and duodenal osmolality was found. A regression model was 
constructed using a congruent approach as previously discussed for defining FeSSGF osmolality 
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(Figure 4.4B). Although a suitable coefficient of determination (R2 = 0.92) between feed osmolality 
and 60 minute postprandial duodenal osmolality was attained, a second study from which the model 
could be evaluated within pediatrics was unavailable. As an alternative assessment, the model was 
utilized to estimate to duodenal osmolality in two adult studies. Mean duodenal osmolality values of 
approximately 405 and 392 mOsm/kg were observed 1 hour following administration of liquid meals 
containing 610 and 670 mOsm/kg in separate investigations conducted by Kalantzi et al. [238] and 
Clarysse et al. [258], respectively. The proposed regression model provided duodenal osmolality 
estimates of 430 (6% over-prediction) and 454 (16% over-prediction) mOsm/kg for each respective 
adult investigation. Although derived from a cohort of neonatal subjects, the model exhibited an 
adequate predictive capacity in adults. By extension, its use for estimating intestinal osmolality amongst 
pediatrics (neonates and infants) was considered to be appropriate. The osmolality of neonatal FeSSIF 
was formulated to reflect two separate feed types, breast milk, with a reported osmolality of ~300 
mOsm/kg [241, 259], and cow’s milk-based formula with a measured osmolality of 368 mOsm/kg 
(Cow & Gate First Infant Milk). For FeSSIF reflective of older children (i.e. infants) where weaning is 
commonly instituted, only a single feed type was investigated, cow’s milk formula. Using the 
aforementioned regression equation, osmolality of the developed pediatric FeSSIF was defined as 300 
and 330 mOsm/kg post-administration of breast milk and cow’s milk-based formula, respectively. 
Fed-state duodenal bile salt concentrations among pediatrics and adults are summarized in 
Figure 4.4C. A positive linear association between the logarithm of age and duodenal bile acid 
concentrations was denoted among children (R2 = 0.54). Bile acid concentrations among adults 
displayed variability, but for the most part studies depicted a mean value of approximately 10 mM, 
corresponding to the concentration of the reference adult media (FeSSIF v2). Mean bile acid 
concentrations among neonates (0-28 days) and infants (1-12m) were approximately 25% (i.e. 2.5 mM) 
and 75% (i.e. 7.5 mM) of adult values, respectively. Pediatric FeSSIF were subsequently formulated 
using these bile acid concentrations. 
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Figure 4.4 (A) Fed-state duodenal pH from separate pediatric investigations (black circles) is 
depicted by the central tendency, either mean or median [244, 260-262]. Studies where pH was 
summarized over a specific age range without denoting the group’s mean age were graphically 
depicted using the middle of the age range. Adult pH values (red circles) are presented as the 
central tendency (mean or median) from separate investigations [238, 239, 244, 258, 263]. (B) 
Neonatal duodenal osmolality 60 minutes post-meal expressed as a function of feed osmolality. 
Data (black circles) represent average duodenal osmolality values recorded amongst neonatal 
subjects as described by Billeaud et al [241]. A linear regression model (red line) was fit to the 
data. (C) Fed-state duodenal bile salt concentrations amongst pediatrics (black circles) is 
depicted as the mean from separate investigations [250, 252, 254, 256, 261, 264, 265]. Studies 
where data was summarized over a specific age range without denoting the group’s mean age 
were graphically depicted using the middle of the age range. Adult duodenal bile acid 
concentrations (0.5-1hr postprandially) (red circles) are depicted as the mean value from the 
various publications [210, 238, 258, 266, 267]. 
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Pediatric studies characterizing concentrations of fat digestion products in the intestinal lumen 
have not been reported in the literature. However, since the quantity of such products is dependent on 
the interrelationship between fat digestion and absorption, an examination of these processes was 
instituted in order to derive age-dependent estimates. In newborns, concentrations of pancreatic 
colipase-dependent triglyceride lipase, the enzyme primarily responsible for lipid metabolism in adults, 
is decreased [268]. Despite this, the presence of auxiliary enzymes such as human gastric lipase, 
pancreatic lipase-related protein 2 and bile salt-stimulated lipase, are postulated to provide an efficient 
means of lipid digestion for newborns [268].  In terms of absorption, breast-fed neonates exhibit fat 
absorption coefficients reminiscent to that of adults despite lower duodenal bile acid concentrations 
[253]. It was therefore inferred that the developmental capacity of both fat digestion and absorption 
were comparable to adults amongst this pediatric cohort. FeSSIF media reflective of breast-fed neonates 
were correspondingly formulated using the same concentrations lipid digestion products (glyceryl 
monooleate and sodium oleate) as defined for the adult reference media (i.e. FeSSIF). 
However, among formula-fed neonates, fat absorption coefficients are notably lower compared 
to their breast-fed counterparts as well as adults [253, 256].  Unlike breast-fed neonates, intestinal bile 
concentrations in formula-fed neonates were found to exhibit a positive linear correlation with percent 
fat absorption [253, 256]. To decipher whether a deficiency in lipid absorption or lipid digestion was 
the primary factor limiting internalization of fats in formula-fed neonates, pathophysiological 
information pertaining to necrotizing entercolitis (NEC) was used. NEC is a debilitating inflammatory 
GI condition occurring typically in preterm neonates but also uncommonly in term neonates. In both 
groups, the incidence of NEC is substantially higher in formula-fed subjects as compared to those 
receiving enteral feeds with breast milk [269, 270]. Though the mechanism of pathogenesis of NEC is 
not completely understood, one theory as described by the work published by Penn et al. [271] 
identified the presence of elevated concentrations of free fatty acid (FFA) as the culpable factor. The 
study found lipase digestion of formula, but not human milk, exhibited a cytotoxic effect in three 
different cell types. Furthermore, digested formula displayed significantly greater levels of FFA 
compared to lipase digested human milk. Based on this finding in conjunction the prevalence of NEC 
amongst the youngest cohort of neonates, it was inferred that the process of lipid digestion was not 
developmentally impaired in formula-fed neonates. Hence, the decreased capacity for fat internalization 
was attributed to an inadequate lipid absorptive capacity in such subjects. Correspondingly, formula-
fed neonates would be expected to exhibit higher luminal concentrations of lipid digestion products. 
Using 75% as the average coefficient of fat absorption in formula-fed neonates [253, 256, 268], the 
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concentration of lipid digestion products (glyceryl monooleate and sodium oleate) was estimated to be 
1.33x (i.e. 1/0.75) greater in the intestinal lumen of neonates that are formula-fed compared those that 
are breast-milk fed.  P-FeSSIF media pertaining to formula-fed neonates was developed based on the 
above assertion. In infants, where luminal bile acid concentrations are higher, fat absorption is not 
expected to exhibit developmental impairment. Pediatric FeSSIF reflective of formula fed infants was 
therefore formulated using the same concentrations of fat digestion products as depicted for the adult 
reference media. 
No pediatric studies investigating buffering capacity and concentrations of phospholipids (i.e 
lecithin) within the fed-state intestinal lumen were obtained. Buffering capacity of the developed 
pediatric media were consequently formulated using a value of 25 mEq/L/ ∆pH, the adult reference 
value.  Using a similar approach as employed for P-FaSSGF and P-FaSSIF, lecithin concentrations 
were fixed to provide the same ratio of [NaTc]/[lecithin] as expressed by the reference adult media 
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Table 4.8 Pediatric Fed-State Simulated Intestinal Fluids (P-FeSSIF) 
Component Pnb-FeSSIFa Pnc-FeSSIFb Pi-FeSSIFc 
Sodium Taurocholate 
(mM) 
2.5 2.5 7.5 
Lecithin (mM) 0.5 0.5 1.5 
Glyceryl monooleate 
(mM) 
5 6.65 5 
Sodium oleate (mM) 0.8 1.06 0.8 
Maleic acid (mM) 55.02 55.02 55.02 
Sodium hydroxide (mM) 81.65 81.65 81.65 
 Sodium Chloride (mM) 95 111.73 107.35 
    
pH 5.8 5.8 5.8 
Osmolarity (mOsm/kg) 300  330  330  
Buffering Capacity 
(mEq/L/ ∆pH)  
25 25 25 
 
a - Pnb-FeSSIF – pediatric fed-state intestinal media representative of neonates (0-28 days) fed breast 
milk 
b - Pnc-FeSSIF – pediatric fed-state intestinal media representative of neonates (0-28 days) fed cow’s 
milk-based formula 
c - Pi-FeSSIF – pediatric fed-state intestinal media representative of infants (1-12 months)  fed cow’s 
milk-based formula 
 
4.3.5 Solubility assessments 
Solubility determinations for six of the seven compounds (carbamazepine, dapsone, griseofulvin, 
indomethacin, phenytoin and spironolactione) were conducted in age-specific media representative of 
all four gastrointestinal states: FaSSGF, FeSSGF, FaSSIF and FeSSIF (Figure 4.5). For fenofibrate, use 
of the predefined equilibrium dialysis method did not serve as a suitable technique for solubility 
determinations in fed-state gastric media. Penetration of fenofibrate through the dialysis membrane was 
inefficient during the selected study interval (96 hours) and, as a result, solubility could not be 
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quantified. Figure 4.6 depicts solubility determinations of fenofibrate in age-specific media reflective 
of the remaining three gastrointestinal states: FaSSGF, FaSSIF and FeSSIF.  
For pediatric media representative of the fasted gastric state (i.e. P-FaSSGF), three compounds 
(carbamazepine, indomethacin and fenofibrate) exhibited mean solubility values below the 80 to 125% 
reference range, relative to adults. However for indomethacin, this difference was not statistically 
significant. Relative solubility changes depicted between neonatal and infant FaSSGF were consistent 
in terms of direction and magnitude for six of seven compounds. Only one compound, carbamazepine, 
displayed a statistically significant difference in solubility between neonatal and infant FaSSGF.  
Solubility assessments in neonatal fed-state gastric media (i.e. P-FeSSGF), developed using 
cow’s milk-based or soy-based formula, were compared to solubilities attained in adult FeSSGF 
formulated with cow’s milk. Five compounds (carbamazepine, dapsone, griseofulvin, phenytoin and 
indomethacin) exhibited changes in solubility that fell outside the aforementioned reference range in at 
least one of the developed neonatal media.  A trend towards lower solubility values in neonatal media 
was found for four of the compounds (carbamazepine, dapsone, griseofulvin and phenytoin). For 
indomethacin, a weak acid (pKa = 4.5), an increase in solubility compared to adult media was observed 
that was attributed, in part, to the higher pH of neonatal FeSSGF. Statistically significant differences 
in solubility between neonatal media formulated using either cow’s milk-based or soy-based formula 
was observed in 4/6 compounds. For carbamazepine, solubility values in media comprised with cow’s 
milk formula was greater than that of media comprised with soy formula. For dapsone, phenytoin and 
indomethacin the opposite was observed. In contrast, for spironolactone and griseofulvin, no 
statistically significant difference in compound solubility was noted between the respective neonatal 
media. 
Since a consensus regarding differences in bile salt concentrations between children and adults 
within the fasted-state intestine was not achieved, compound solubility was investigated based on two 
theoretical media that incorporated bile salt concentrations of 150% (4.5 mM) and 50% (1.5 mM) of 
those in adults. For the majority of compounds (6/7), solubility determinations in both media fell within 
an 80% to 125% range when compared to adult values. However, for fenofibrate (logP = 5.3), solubility 
in P-FaSSIF-50% media was 56% of the value observed in the adult reference. 
Solubility determinations conducted in pediatric media reflective of the fed-state intestine (i.e. 
P-FeSSIF) were compared to values attained in adult FeSSIF. For three of seven compounds 
(fenofibrate, griseofulvin and phenytoin), mean solubilities of less than 80% of adult values were 
observed in at least one of the formulated P-FeSSIF.  These relevant solubility alterations were 
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exclusively found in neonatal media. In comparison, mean solubility values in infant FeSSIF fell within 
80-125% of adult values for all compounds investigated. A general trend towards statistically 
significant lower solubilities in neonatal media compared to infant FeSSIF was observed in five of 
seven compounds. Statistically significant solubility differences between neonatal media formulated to 
depict intestinal fluids following administration of cow’s milk-based formula (Pnc-FeSSIF) or breast 
milk (Pnb-FeSSSIF) were denoted for three compounds (griseofulvin, spironolactone, and phenytoin). 
A higher solubility was observed for griseofulvin in Pnc-FeSSIF though in both neonatal media, values 
were below the 80-125% reference range. Solubility was also greater in Pnc-FeSSIF for spironolactone 
but, in this case, solubility values in both media fell within the 80-125% reference range. In contrast, 
for phenytoin, a higher solubility was observed in Pnb-FeSSIF. Solubility in Pnb-FeSSIF fell within 
80-125% of adult values, but for media depicting formula-fed neonates (Pnc-FeSSIF), the mean 
solubility was well below the 80% reference point. 
  Changes in compound solubility between pediatric and adult media induced by alterations in 
bile salt concentrations were estimated according to the equations proposed by Mithani et al [201]. 
These values are displayed in Figures 4.5 and 4.6 (red dots) for media formulated with NaTc (i.e. 
FaSSGF, FaSSIF, and FeSSIF). Table 4.9 displays RMSE values between predicted and measured 
solubility ratios for the developed pediatric media in order of increasing compound lipophilicity. For 
the two least lipophilic compounds investigated (dapsone and griseofulvin), predictions made using 
Mithani el al.’s equations were within a RMSE of 10%. In these cases, the equations provide an 
acceptable approximation of the direction and magnitude of solubility changes observed in pediatric 
media. As compound lipophilicity increased, a departure between predicted and measured solubility 
ratios was observed as indicated by larger RMSE values. For such compounds, the predicted magnitude 
of solubility changes due to alterations in media NaTc content were typically overstated when compared 
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Figure 4.5 Measured solubility in age-specific biorelevant media expressed as the mean 
solubility ratio (bars) between each respective pediatric and adult media (i.e. Pi-FaSSGF / 
FaSSGFAdult).  Predicted solubility ratios due to differences in media bile acid content were 
calculated for P-FaSSGF, P-FaSSIF, and P-FeSSIF according Mithani et al.’s equations (red 
line, dots) [201]. Dashed lines (---) characterizing the bioequivalence criterion (80-125%) are 
displayed for reference. Media are denoted as follows: Pi-FaSSGF (Infant FaSSGF), Pn-
FaSSGF (Neonate FaSSGF), Pnc-FeSSGF (Neonate FeSSGF comprised of cow’s milk-based 
formula), Pns-FeSSGF (Neonate FeSSGF comprised of soy-based formula), P-FaSSIF-150% 
(Pediatric FaSSIF comprised with 4.5 mM NaTc), P-FaSSIF-50% (Pediatric FaSSIF comprised 
with 1.5 mM NaTc), Pi-FeSSIF (Infant FeSSIF), Pnb-FeSSIF (Neonatal breast-fed FeSSIF), and 
Pnc-FeSSIF (Neonatal formula-fed FeSSIF). Statistically significant solubility differences 
(p≤0.05) compared to (a) adult media, (i) infant media, (n) neonatal media, and (b) P-FaSSIF-
150% were depicted using the symbols indicated.  
(see next page) 
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Figure 4.6 Measured solubility in age-specific biorelevant media expressed as the mean 
solubility ratio (bars) between each respective pediatric and adult media (i.e. Pi-FaSSGF / 
FaSSGFAdult).  Predicted solubility ratios due to differences in media bile acid content were 
calculated for P-FaSSGF, P-FaSSIF, and P-FeSSIF according Mithani et al.’s equations (red 
line, dots) [201]. Dashed lines (---) characterizing the bioequivalence criterion (80-125%) are 
displayed for reference.  For a description of media abbreviations and symbols (a,b,n,i), see the 
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Table 4.9 Predictive performance of Mithani et al.’s [201] equations at characterizing 
compound specific solubility changes in pediatric media 
 
Compound RMSEa 
Dapsone (logP = 0.97) 8.5% 
Griseofulvin (logP = 2.18) 3.7% 
Carbamazepine (logP = 2.45) 16.9% 
Phenytoin (logP = 2.47) 10.9% 
Spironolactone (logP = 2.78) 17.4% 
Indomethacin (logP = 4.27) 39.1% 
Fenofibrate (logP = 5.3) 28.5% 
 
a - Root mean square error (RMSE) was tabulated based on Eq 4.4. Only pediatric media formulated 
with bile salts (i.e. P-FaSSGF, P-FaSSIF, and P-FeSSIF) were included in the assessment. 
 
4.4 Discussion  
Based on an assessment of the current literature, biorelevant media simulating the unique intricacies of 
the upper gastrointestinal tract (stomach and proximal small intestine) in pediatrics were developed and 
utilized to estimate compound specific solubility. Preferably, solubility comparisons between pediatrics 
and adults should be conducted using ex-vivo luminal fluid samples, but due to the numerous logistical 
and ethical constraints associated with obtaining of such samples in pediatrics, the use of biorelevant 
media was deemed as a suitable approach. In adults the appropriateness of biorelevant media has been 
established by investigations depicting strong positive correlations in compound solubility between 
simulated and human intestinal fluids [272, 273].  
Pediatric fed-state gastric media (P-FeSSGF) was formulated using either cow’s milk-based or 
soy-based formula to assess the impact of feed type on compound solubility. The use of human breast 
milk within the investigation was precluded due to logistic issues associated sample obtainment and 
uniformity. In terms of uniformity, the composition human breast milk is well known to exhibit both 
intra- and inter-subject variability in composition [274]. Infant formulas, however, are subject to quality 
control inspections to ensure batch-to-batch uniformity, ensuring biorelevant media are prepared in a 
reproducible fashion. Marketed infant formulas are designed to mimic the composition of human breast 
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milk with regards to the proportions of energy provided from protein, fats, and carbohydrates [275].  In 
human breast milk, proteins are predominantly comprised of two forms, whey and casein, in a ratio of 
60:40, respectively. In contrast, the whey-to-casein ratio of cow’s milk is 18:82 [275]. To address this 
discrepancy, many formulas, including Cow & Gate First Infant Milk (cow’s milk based), have 
introduced additional amounts of whey protein in order to mimic ratios observed in human milk [275]. 
The influence of casein on compound solubility has previously been depicted for the anticoagulant 
dicumarol, where increases in casein concentration corresponded to higher dicumarol solubility values 
[276]. Despite supplementation with vitamins and minerals, infant formula cannot fully reproduce the 
biological complexity of human breast milk which contains antibodies, enzymes, and growth factors 
[275]. However, cow’s milk formula does provide a suitable approximation in terms of macronutrient 
composition and protein type that is free from the inherent variability associated with breast milk. As 
such, solubility studies conducted in neonatal FeSSGF comprised with cow’s milk formula may 
encompass applicability towards breast fed neonates. 
 Concentrations of media components were formulated to represent the average tendency over 
a specific age range. To summarize age-specific data from the literature, the investigation utilized non-
weighted arithmetic means. Though simplistic in nature, use of the arithmetic mean was preferred over 
other more robust computational or statistical analyses based on several considerations. First, there is 
the relative disparity of literature investigations devoted to defining the composition of luminal fluids 
in pediatrics compared to adults. For many media components only a handful of studies were available 
to quantify differences between subsequent age groups. Of studies obtained, high degrees of variability 
were typically noted. This is likely attributed to the dynamic nature of the developmental process, where 
the composition of luminal fluids continually change as children mature. Due to this disparity of 
available data and its inherent variability, employment of statistical tests to identify significant 
differences in component concentrations between adjacent age groups were not applicable. Similarly, 
the use of regression analyses were typically unable to establish meaningful correlations between 
parameter values and age. A second consideration for the preferential use of non-weighted arithmetic 
means was due to the precarious nature of qualifying investigations. A large majority of pediatric 
studies were completed over three decades ago, where differences in reporting standards and 
quantitative techniques were wide-ranging. Employment of a non-weighted approach was instituted to 
simplify the analysis though, understandably, the method lacks the informative capacity of approaches 
that consider study quality, as frequently adopted by systematic reviews [277]. Finally, studies varied 
in terms of data presentation, making implementation of weighted averages difficult. Reporting of 
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variability associated with luminal fluids components was inconsistent between investigations. For 
example, separate studies utilized a variety of measures including standard deviation, range, or 
interquartile range. Additionally, the number of subjects allocated to specific age ranges were not 
identified by some investigators [205]. Due to this lack of consistency between studies, employment of 
a weighted mean was precluded in favor of a non-weighted approach. As the arithmetic mean does not 
provide an indication of parameter variability, the analysis is unable to depict expected variations within 
the population. However, as biorelevant media is developed to represent luminal fluids in an average 
individual, descriptions of parameter variability were unnecessary. 
 Due to the disparate nature of available pediatric data, the quantitative value of many media 
components were based on biological inferences or adoption of adult values. For example pediatric 
investigations pertaining to luminal concentrations of pepsin, phospholipids, fat digestion products, and 
osmolality were either scarcely reported or lacking within the literature. The proposed age-specific 
media attempted to approximate the in vivo composition of pediatric luminal fluids based on a current 
state of knowledge. As future investigations are obtained, such formulations should undoubtedly be 
modified to provide greater degrees of biological relevance. 
 In addition to its primary goal of facilitating suitable IVIVC, biorelevant media should 
demonstrate a practical degree of stability.  Apart from noticeable changes in visual appearance, media 
stability can be formally evaluated by assessing for alterations in physicochemical parameters under 
ambient and test conditions. In Jantratid et al.’s original publication [182], which described the 
reference adult media utilized by this investigation, stability was evaluated through measurements of 
media pH, buffering capacity and osmolality. For adult FeSSGF and FeSSIF-v2, consistency in 
physicochemical parameters were observed under ambient conditions over a 72 hour study period. In 
addition, with the exception of minor changes in osmolality, the abovementioned media demonstrated 
stability under test conditions of 37oC over the same time period. Changes in media physicochemical 
properties (i.e. poor stability) during solubility assessments may lead to corresponding changes in 
compound specific saturation solubility. In the current investigation, solubility assessments in fed-state 
simulated gastric media comprised of cow’s milk (FeSSGF) and infant formula (neonatal FeSSGF) 
were conducted at 37oC after 48 hours for most compounds. Though stability studies were not 
conducted within the developed pediatric FeSSGF, it was inferred that stability would be similar to that 
of adult FeSSGF. However, if large scale implementation of the depicted pediatric media is desired, 
future research evaluating media stability will certainly be required.   
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For the majority of study compounds, solubility assessments proceeded without issue. However 
for fenofibrate, the most lipophilic compound evaluated (logP = 5.3), logistic issues materialized with 
solubility determinations in biorelevant media reflective of the fed gastric state. For FeSSGF media, 
the study employed equilibrium dialysis to assess compound solubility. Though this technique proved 
effective for most compounds, it was unsuitable for fenofibrate.  Following a 96 hour dwell period, 
fenofibrate concentrations within the membrane were below the limit of quantification. This result may 
indicate inadequate permeation of the dialysis membrane by fenofibrate in milk or formula-based 
samples. A congruent example is demonstrated by the in vivo pharmacokinetics of fenofibrate. In 
humans, fenofibrate exhibits extensive protein binding (~99%) and, as such, filtration by hemodialysis 
is not considered effective [278, 279]. Based on this assessment, use of equilibrium dialysis was not 
considered feasible for determination of fenofibrate solubility in fed state gastric media. These values 
were correspondingly excluded from the analysis. 
Solubility assessments were confined to BCS Class II compounds, where limitations in 
absorption are primarily attributed to inadequate drug solubility. For such compounds, differences in 
luminal solubility may signify alterations in oral drug performance [48]. To maintain a degree of 
biological relevance, the analysis was further limited to compounds where documented or 
investigational uses in both children and adults have been depicted. To identify relevant changes in 
age-specific solubility, the study utilized the same threshold as depicted by the US-FDA for attainment 
of in vivo bioequivalence (i.e. 80-125%) [200].  It should be noted however that solubility is only one 
parameter which can exert an effect on oral compound absorption. Other parameters including gastric 
emptying time, small intestinal transit time, intestinal permeability, gut metabolism, luminal 
degradation and presence of intestinal transporters may also impart an influence in vivo. In order to 
fully elucidate the impacts of growth and development on oral compound absorption, a more 
comprehensive analyses such as physiologically-based pharmacokinetic (PBPK) modeling would be 
required to integrate age-dependencies in all the aforementioned parameters. The presented analysis 
which focusses on biorelevant solubility as a surrogate for oral compound performance was therefore 
an overt simplification. However, this approach was justified based on the cohort of compounds 
assessed, which was confined to solubility-limited (BCS Class II) drugs.  
Compared to adult media, solubility in pediatric fasted-state gastric media (i.e. P-FaSSGF) was 
both statistically different (p≤0.05) and outside the purported bioequivalence criterion for two 
compounds, fenofibrate and carbamazepine. For fenofibrate, mean solubility values in adult FaSSGF 
and pure water were comparable at 0.281 and 0.206 mcg/mL, respectively. In contrast, solubility within 
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adult fasted-state intestinal media (i.e. FaSSIF) was considerably greater (2.42 mcg/mL). The 
discrepancy in solubility values between FaSSGF and FaSSIF provides an indication of the relative 
influence of each state on modulating oral absorption. In this case, due to its poor solubility in 
comparison to intestinal fluids, fasted state gastric fluids are unlikely to play an influential role on 
modulating the extent of fenofibrate absorption. Solubility alterations observed in P-FaSSGF were 
therefore not postulated to impact the oral performance of fenofibrate in children.  Differences in 
solubility between neonatal and infant FaSSGF reached a statistically significant threshold for only one 
compound, carbamazepine. However for both media, the mean solubility fell outside the 
bioequivalence threshold when compared to adult values. Based on this analysis, an argument may be 
formed as to the need for separate pediatric media since solubilities in neonate and infant FaSSGF 
appear to be similar in most cases. The current investigation focused on solubility, a compound specific 
property. However, in terms of establishing IVIVC for solid dosage forms, biorelevant media is 
typically employed within dissolution tests to assess formulation properties [280]. In addition to 
modulating solubility, media components that are age-specific may also exert an influence on the rate 
of compound release and subsequent dissolution from a formulation. For example, the addition of 
pepsin into biorelevant media has been demonstrated to decrease surface tension [183]. For specific 
formulations, such changes can exert of an effect on the rate of compound dissolution [281]. Also, the 
presence of pepsin within dissolution media can facilitate effective compound release from cross-linked 
gelatin capsules [282]. Therefore, although comparable solubilities were observed for neonatal and 
infant FaSSGF media, use of separate age-specific media may be justified for use in dissolution testing. 
Solubility assessments in age-specific FeSSGF media were conducted for six compounds.  For 
the majority of compounds (5/6), the mean solubility in neonatal media, comprised of either cow’s 
milk-based or soy-based formula, fell outside the 80-125% bioequivalence criterion in relation to adult 
media comprised of milk. In addition, statistically significant differences in compound solubility 
between pediatric media comprised with cow’s milk-based and soy-based formula were observed in 
four compounds. These results infer that differences in feed composition between children as well as 
between children and adults can impart relevant changes in gastric solubility and, potentially, affect 
oral compound performance. 
Of the limited pediatric investigations examining luminal fluids within the fasted-state 
proximal intestine, bile salt concentrations were found to exhibit a high degree of variability without 
any apparent age dependency. To explore the impact of such variations, two FaSSIF media were 
developed with bile salt concentrations of 50% (1.5 mM) and 150% (4.5 mM) of adult values. For the 
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majority of compounds (6/7), mean solubility values within the two proposed P-FaSSIF media fell 
within an 80-125% range from adult values. However for the most lipophilic compound, fenofibrate 
(logP = 5.3), solubility in P-FaSSIF media containing 1.5 mM NaTc was 56% of adult values. If such 
a media is reflective of in vivo luminal fluids in children, the observed change in solubility may signify 
an alteration in fenofibrate oral performance compared to adults. Prospectively, hydrophobic 
compounds are expected to play an increasingly important role in therapeutics as use of drug discovery 
techniques such a high-throughput screening typically produces candidate compounds of higher 
lipophilicity [283]. To provide an accurate depiction of luminal solubility for such compounds, a 
consensus regarding intestinal bile salt concentrations in pediatrics is needed. This demonstrates a need 
for more high quality studies characterizing gastrointestinal physiology in pediatrics. 
Solubility assessments conducted in fed-state intestinal media representative of infants were 
within 80-125% of adult values for all 7 compounds tested. Such a result was unsurprising as infant 
and adult media were compositionally similar, aside from small deviations in bile salt content, lecithin, 
and osmolality. Two neonatal media were formulated to reflect differences in intestinal fluid 
composition following administration of breast milk or cow’s milk-based formula. Mean compound 
solubility values in neonatal media fell outside the 80-125% criterion from adult values for 3 of the 7 
compounds examined. Statistically significant differences in solubility between media reflective of 
breast-fed and formula-fed neonates was observed for 3 compounds. The relative magnitude of these 
differences appeared to be compound specific. For example, spironolactone solubility in intestinal 
media reflective of breast and formula fed neonates were 83% vs. 91% of adult values, respectively. In 
contrast, for phenytoin a larger discrepancy between solubility ratios was observed (92% vs. 61% of 
adult values, respectively). These findings demonstrate the potential impact of different feed types on 
intestinal compound solubility.  
The study also included an evaluation the relative importance of bile salts in modulating 
compound solubility within the developed pediatric media. Predictive equations presented by Mithani 
et al. [201] were used to estimate the impact of alterations in bile salt content on compound solubility. 
Measured solubility values, which are influenced by all media components, were compared to estimated 
values, which only account for differences in media bile salts, using RMSE. The analysis demonstrated 
a decreased predictive capacity of the aforementioned equations (ie. larger RMSE values) as compound 
lipophilicity (logP) increased. This indicates that as compound lipophilicity increases, other media 
components, aside from bile salts, exert a more pronounced role in modulating compound solubility. 
For example, the capacity of media components such as buffer (sodium phosphate), fat digestion 
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products (sodium oleate) and salt (sodium chloride) to modify compound solubility has previously been 
demonstrated within the literature [44].  
4.5 Conclusion 
The current investigation strove to appropriately depict the in vivo composition of pediatric luminal 
fluids based on the current literature and represents an initial foray into the development of pediatric 
biorelevant media.  To increase the biological applicability of future iterations of such media, it is 
clear prospective studies focused on defining the composition of the pediatric lumen under varying 
conditions is required. For 6 of the 7 BCS Class II compounds investigated, solubility fell outside an 
80-125% range from adult values in at least one of the developed pediatric media. This result 
demonstrates the impact of age-related alterations in GI fluid composition on compound solubility. 
Solubility represents an integral component of the BCS, a framework which is extensively utilized by 
both industry and regulatory bodies to guide drug development in adults. The utility of a similar 
classification system in pediatrics is in part contingent on our understanding of how developmental 
differences between children and adults translates to alterations in definable properties such as 
compound solubility. The investigation sought to address this concern and, in turn, provides a 
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Chapter 5: Improving Pediatric Protein Binding Estimates: An 
Evaluation of α1-acid glycoprotein (AAG) Maturation in Healthy and 
Sick Populations 
The contents of this chapter are reflective of an original manuscript submitted by the Ph.D. candidate 
(Anil R Maharaj) to the journal Clinical Pharmacokinetics in Nov 2016. All pertinent research analyses 
was conducted by the Ph.D. candidate. 
 
5.1 Introduction 
Plasma protein binding is a key physiological process capable of imparting influence on both 
pharmacokinetic (PK) and pharmacodynamic (PD) properties of xenobiotics. As such, measures of 
plasma protein binding are typically considered an intrinsic component for scaling PK data from 
preclinical species or in vitro systems towards humans [284]. Between children and adults, 
developmental differences in the concentration of plasma proteins have been documented [51]. As the 
extent of xenobiotic-protein binding exhibits a direct relationship to the concentration of plasma 
proteins, differences in protein binding between children and adults are expected [52]. 
Correspondingly, quantitative descriptions of the ontogeny of plasma proteins represent a central 
component of scaling PK between different maturational stages (i.e. intraspecies scaling) [66]. 
Human serum albumin (HSA) and α-1-acid glycoprotein (AAG) are the two major proteins 
present in serum with binding capacities towards a wide variety xenobiotics [285].  Whereas HSA is 
typically associated with binding acidic exogenous compounds, AAG displays a high affinity towards 
basic lipophilic compounds [49, 50]. AAG is comprised of a highly glycosylated single polypeptide 
chain [285] with a molecular weight ranging between 41-43 kDa [286]. Binding of xenobiotics is 
facilitated by the presence of a single ligand-binding site per AAG molecule [49, 287]. In humans, the 
majority of AAG is present as either 2 or 3 genetic variants [288]. Furthermore, differences in ligand 
binding properties between specific variants have been documented in the literature [289, 290]. For 
several therapeutic compounds including imipramine, propranolol, lidocaine, methadone, and 
chlorpromazine, AAG represents the major constituent modulating plasma binding [52]. In healthy 
subjects, plasma concentrations of AAG range from ≈50-130 mg/dL [285]. However, as an acute-phase 
reactant, AAG concentrations can increase 3-5 fold in response to pathologies such as Crohn’s disease, 
  98 
myocardial infarction, infection, burns, and malignancy [50, 291]. In comparison, decreased AAG 
concentrations are associated with pregnancy, oral contraceptive use, and infancy [291].  
An evaluation of the degree of change in plasma AAG concentrations associated with normal 
growth and development was published by McNamara and Alcorn [51]. Using data compiled from 
three separate publications, the authors derived a quantitative equation (i.e. linear model) describing 
the relationship between postnatal age (PNA) and plasma AAG concentrations from birth to adulthood. 
Despite providing suitable estimates for older subjects, the use of a linear model appeared to 
overestimate AAG concentrations amongst the most developmentally immature subjects (i.e. 
newborns) [51]. In addition, the aforementioned work exclusively focused on normal/healthy subjects; 
whereas, utilization of therapeutic compounds is typically focused towards diseased subjects. As AAG 
is an acute-phase reactant, it is unclear whether the equations presented by McNamara and Alcorn 
provide a suitable modality for estimating differences in AAG concentrations between pediatric and 
adult subjects with disease. 
This work will serve to quantitatively describe the ontogeny of serum AAG in normal (healthy) 
individuals as well as an additional cohort of subjects diagnosed or suspected of bacterial infection 
(infected). Pediatric fraction unbound in plasma (fu) data for compounds exhibiting preferential binding 
to AAG will be used to compare the predictive capacity of the ontogeny equation derived from this 
work to McNamara and Alcorn’s [51] previously proposed equation. 
 
5.2 Methods 
The present analysis evaluating the ontogeny of AAG in humans (from birth to adulthood) was divided 
into three corresponding subsections: (i) evaluation of AAG ontogeny in normal subjects, (ii) evaluation 
of AAG ontogeny in subjects with known or suspected infections, and (iii) comparison of the predictive 
performance of our prospectively derived ontogeny equation to a previously proposed model [51]. 
5.2.1  Ontogeny of AAG in healthy (normal) subjects 
To assess the relationship between age and plasma AAG concentrations in healthy (normal) subjects, 
the analysis utilized data compiled from the literature. Investigations quantitatively denoting the age of 
participants in addition to plasma/serum AAG concentrations expressed in terms of central tendency 
(i.e. mean or median) and spread (i.e. standard deviation, standard error of the mean, or percentiles) 
were included. Investigations reporting AAG levels among different subject groups were permitted to 
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contribute multiple data points to the analysis. Publications that expressed data graphically were 
converted to numerical values using GetData Graph Digitizer (v2.26).  
To introduce a degree of consistency between studies  conducted over various publication dates, 
protein concentrations were normalized toward certified reference material (CRM) 470 values, a widely  
circulated serum protein calibrant developed in 1993 [292], using the following process. For 
investigations conducted between 1973 to 1993 or those utilizing protein standards manufactured 
during these aforementioned years, protein standards were assumed to conform to United States 
National Reference Preparation for Serum Proteins (USNRP) lot 12-0575C values.  AAG 
concentrations were subsequently normalized towards CRM470 values using a proportional transfer 
value [293]. For investigations conducted after 1993, protein standards were assumed to conform to 
CRM470 values. As such, no adjustment was made. Studies conducted prior to 1973 were excluded 
from the analysis due to the assumed diversity in protein standards available prior to this year [294]. 
Quantitative assays utilized between studies varied and included radial immunodiffusion, 
nephelometry, turbidimetry, HPLC, and immunoelectrophoresis. Due to the inherent difficulty of 
assessing quantitative equivalence between specific assays conducted in different laboratories over 
various periods of time, an overarching assumption that AAG concentrations were equivalent between 
assay types was used. 
In human plasma, AAG concentrations are log-normally distributed [295]. Considering this 
distributional assumption, the analysis, which compiled data obtained from various investigations, 
required AAG concentrations to be expressed using log-normal parameters such as the geometric mean 
and log-normal standard error (log-normal standard deviation/√𝑛). For the majority of investigations, 
AAG concentrations were reported using an arithmetic mean and standard deviation. For these studies, 
estimates of the geometric mean (𝜇𝑔𝑒𝑜 ) and log-normal standard error (𝑆𝐸𝐿𝑁) were determined using 















      (Equation 5.2) 
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where 𝑚 is the arithmetic mean, 𝑆𝐷 is arithmetic standard deviation, and 𝑛 is the number of individuals 
examined. Two investigations [297, 298] expressed AAG concentrations in terms of percentiles (5th, 
50th, and 95th; or 2.5th, 50th and 97.5th). For these studies, the median (i.e. 50th percentile) was assumed 
to be equivalent to the geometric mean [299]. Using the assumption that log-transformation of plasma 
AAG concentrations results in a normal distribution, the log-normal standard error was estimated using 




2∗ 𝑇# ,𝑛−1 ∗ √𝑛
       (Equation 5.3) 
 
where Upper refers to the 95th or 97.5th AAG percentile, Lower refers to the 2.5th or 5th AAG percentile, 
and  𝑇# ,𝑛−1 is the one-sided critical t-value (probability 0.95 or 0.975) associated with n-1 degrees of 
freedom. One investigation [300] graphically expressed neonatal AAG concentrations using arithmetic 
means and standard errors of the mean (SEM) without denoting the number of subjects assessed at each 
time-point.  For this study, the geometric mean was estimated using equation 5.1 with an approximate 
SD value derived from additional figures from the same manuscript depicting the upper limit of normal 
for AAG values (mean +2SD). Based on the approximation that the coefficient of variation (CV=SD/m) 
of a log-normally distributed variable is equal to the log-normal standard deviation [301], an estimate 











       (Equation 5.4) 
 
Prior to evaluating AAG ontogeny, a preliminary graphical assessment was instituted to illustrate 
the of range of age-specific AAG concentrations, normalized to the CRM470 standard and expressed 
using geometric mean values, among the complied dataset (Figure 5.1). For one investigation, 
published by Philip and Hewitt [302], the researchers provided plasma AAG levels among 244 neonatal 
inpatients between birth and 7 days old. Although subjects were deemed to be ‘noninfected’ based on 
bacterial cultures and clinical determinants of infection, all were initially admitted with suspected 
sepsis. Despite this, AAG concentrations expressed by this investigation appeared to be visually 
congruent to similar aged subjects expressed by other studies (Figure 5.1). Data pertaining to this study 
was, therefore, maintained within the analysis although subjects did not meet a prototypical definition 
of healthy. Based on Figure 5.1, it was also noted that AAG concentrations contributed by Malvy at 
  101 
al.’s publication [298], which examined plasma protein concentrations within 5 different pediatric age 
groups, were notably higher than other studies depicting similar aged subjects. For example, the 
estimated 𝜇𝑔𝑒𝑜 of AAG concentrations from Malvy et al.’s publication, who examined children over 
an age range where plasma AAG levels appear to be stable (3 to 16 years) (Figure 5.1), was 131 mg/dL. 
Comparatively, the estimated 𝜇𝑔𝑒𝑜 of AAG concentrations in 9 groups of children within a similar age 
range (3-16 years) from 5 different investigations was 91.9 mg/dL [303-307].  Further stratifying 
studies based on geographic location and assay type did not address the observed difference in AAG 
concentrations documented by Malvy et al. For example, based on 3 investigations conducted in the 
same geographic location as Malvy et al.’s study (i.e. France), the 𝜇𝑔𝑒𝑜of AAG concentrations was 
91.5 mg/dL for 5 groups of children within a comparable age range [304, 306, 307].  In addition, 106 
mg/dL was the 𝜇𝑔𝑒𝑜 of AAG concentrations in 2  groups of comparably aged children observed in 1 
investigation [304] using a similar assay type (nephelometry) as employed by Malvy et al. Based on 
the aforementioned assessment, AAG concentrations obtained from Malvy et al.’s study were 
subsequently removed from the dataset. 
 To quantitatively describe the functional relationship between age and plasma AAG levels, a 
variety of models were assessed: linear, power, exponential, linear-log, and sigmoid Emax. Gestational 
ages (GA) for neonatal (preterm and term) and infant subjects’ were not a universally reported among 
all investigations. As such, PNA was utilized as the primary age descriptor within this analysis. The 
functional form of each model is denoted in Table 5.1. Parameter estimation was conducted using a 
maximum likelihood estimation (MLE) technique with minimization of the objective function value 
(the negative two log-likelihood) achieved via the fminunc algorithm in Matlab R2015a (The 
Mathworks Inc., Natick, MA). Model fits were weighted using the squared reciprocal of log-normal 
standard errors associated with each study group (1/𝑆𝐸𝐿𝑁
2). To impart a log-normal error structure, 
parameter estimation was performed using log-transformed values for observed (i.e. study 
specific 𝜇𝑔𝑒𝑜) and predicted AAG concentrations with PNA, in days, serving as the sole covariate for 
all fitted models (Table 5.1). Since predicted plasma AAG concentrations at birth (i.e. PNA = 0 days) 
under the power and sigmoid Emax model return a value of 0, the fitting algorithm, which log-
transforms predictions, fails to compute (i.e. Ln(0) = undefined). In addition, the linear-log model is 
undefined at birth. To circumvent these operational issues, the PNA for subject groups assessed at birth 
(PNA = 0) were adjusted to a PNA of 1 day. This modification was deemed defensible as the 𝜇𝑔𝑒𝑜 of 
AAG concentrations observed among subjects assessed at birth and those observed during the first day 
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of life were similar within our dataset (19.92 vs. 17.67 mg/dL, respectively). Model selection was 
performed using a combination of the Akaike Information Criterion (AIC) and a visual inspection of 
observed study data overlaid with predicted AAG concentrations to assess curve shape. 
 
Figure 5.1 Plasma AAG concentrations among publications examining healthy subjects. 
Concentrations, normalized to CRM470 values, are depicted using estimated geometric mean 
values (o) for each study group. Geometric error bars depict the log-normal SE associated with 
each study cohort. AAG values contributed by Philip and Hewitt [302] (◊) and Malvy et al. 
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Table 5.1 Ontogeny models investigated 
Model Equation1 
Linear2 ( 𝑎 ∗ 𝑨𝑮𝑬) + 𝑏 
Power2  𝑏 ∗ 𝑨𝑮𝑬𝑎 
Exponential2 𝑏 ∗ 𝑒𝑎∗𝑨𝑮𝑬 
Linear-Log2 𝑏 + [𝑎 ∗ 𝑙 𝑛(𝑨𝑮𝑬)] 






1the covariate 𝐴𝐺𝐸 was specified using either postnatal age (days) or postmenstrual age (weeks) 
2𝑎 and 𝑏 denote estimable parameters associated with the linear, power, exponential, and linear-log 
models 
3𝐴𝐴𝐺𝑚𝑎𝑥 (maximum plasma AAG concentration [mg/dL]), 𝑇𝑀50(age at 50% 𝐴𝐴𝐺𝑚𝑎𝑥[days]), and 𝑃 
(Hill coefficient) denote estimable parameters associated with the sigmoid Emax model 
 
5.2.2 Ontogeny of AAG in subjects with diagnosed or suspected of infection 
To evaluate of the relationship between age and plasma AAG concentrations in patients diagnosed 
or suspected of infection, individual subject data were compiled over three clinical trials: The 
Pharmacokinetics of Anti-Staphylococcal Antibiotics in Infants Clinical Trial (Staph Trio; NICHD-
2012-STA01, ClinicalTrials.gov NCT01728363; IND 115,396) [308], Pharmacokinetics of 
Understudied Drugs Administered to Children per Standard of Care (PTN POPS; NICHD-2011-
POP01, ClinicalTrials.gov NCT01431326; IND 113,645) [309], and Safety and Pharmacokinetics 
of Multiple-Dose Intravenous and Oral Clindamycin Pediatric Subjects With BMI ≥ 85th Percentile 
(CLIN01; NICHD-2012-CLN01, ClinicalTrials.gov NCT01744730; IND 115,396) [310]. The 
dataset consisted of a subset subjects being treated with the antibiotic clindamycin in whom plasma 
AAG concentrations were ascertained. Age was denoted as PNA; however, gestational age was 
also recorded for subjects less than 3 months old.  
A similar assessment as described in the previous section was instituted to select the most 
suitable quantitative equation (Table 5.1) to describe the relationship between plasma AAG levels 
and PNA. Parameter estimates were obtained via MLE using a log-normal error model with 
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minimization of the objective function value achieved using the previously described 
computational approach. Confidence intervals associated with estimated AAG concentrations were 
tabulated using the delta method (asymptotic theory) [301].  
An evaluation of the use of an alternative age descriptor, post-menstrual age (PMA = PNA + 
GA), was also conducted using this dataset. Parameter estimates were obtained in a similar manner 
as depicted above but using PMA, in weeks, instead of PNA. For subjects greater than 3 months of 
age, PMA was calculated assuming a GA of 40 weeks. The AIC and standard deviation of log-
normalized residuals (≈RMSE) between models utilizing PMA and PNA were utilized to assess 
the goodness of fit associated with each age descriptor. 
 
5.2.3 Prediction of pediatric fraction unbound (fu): a comparison of the AAG ontogeny 
equation derived from this study to a previously proposed model 
Estimates of pediatric fu (𝑓𝑢𝑝𝑒𝑑) were tabulated from observed adult fu (𝑓𝑢𝑎𝑑𝑢𝑙𝑡) values and the ratio 
of pediatric-to-adult plasma protein concentrations (
𝑃𝑝𝑒𝑑
𝑃𝑎𝑑𝑢𝑙𝑡
) using the following equation proposed by 















 ratios as required by equation 5.5, the derived AAG ontogeny equations, which were 
formulated in terms of absolute plasma concentrations (mg/dL), were simply divided by estimated adult 
AAG values. 
A set of experimentally determined 𝑓𝑢𝑝𝑒𝑑 values also complied by McNamara and Alcorn [51] 
were utilized to assess the predictive accuracy of estimates. The dataset consisted of 17 pairs of age-
specific fu values (pediatric and adult) for 11 xenobiotics exhibiting specific affinity towards AAG. 
Observed fu values were predominantly determined in plasma samples from healthy or control subjects. 
Correspondingly, estimates of 𝑓𝑢𝑝𝑒𝑑  were derived using observed 𝑓𝑢𝑎𝑑𝑢𝑙𝑡 values from the dataset and  
𝑃𝑝𝑒𝑑
𝑃𝑎𝑑𝑢𝑙𝑡
 ratios pertaining to the ontogeny of AAG in healthy subjects. Overall predictive performance was 
evaluated using the average-fold error (AFE) and absolute average-fold error (AAFE) as measures of 
bias and precision, respectively. The equations for both measures are given below 


















     (Equation 5.7) 
 
where 𝑜𝑏𝑠 is the observed 𝑓𝑢𝑝𝑒𝑑 value from the dataset and 𝑝𝑟𝑒𝑑 is the predicted fu value based on 
equation 5.5.  In addition, the predictive accuracy of 𝑓𝑢𝑝𝑒𝑑 estimates derived using McNamara and 
Alcorn’s [51] seminal AAG ontogeny equation was tabulated for comparison. 
 
5.3 Results 
The ontogeny of plasma AAG in healthy (control) subjects was evaluated using data from 25 separate 
studies complied from the literature [291, 295, 297, 300, 302-307, 311-325]. The analysis included 
AAG concentrations from 84 subject groups that ranged in average (postnatal) age from 0 days (i.e. 
newborns) to 79 years. Data from each subject group was weighted by observed log-normalized 
standard error values (𝑤𝑒𝑖𝑔ℎ𝑡 = 1/𝑆𝐸𝐿𝑁
2). In comparison to other models fit using PNA, the sigmoid 
Emax model was associated with the lowest AIC value (21.81) and depicted a curve shape that was 
visually congruent with observed AAG concentrations (Figure 5.2). AIC values associated with 
competing models were as follows: 149.99 (linear), 63.01 (power), 163.78 (exponential), and 37.25 
(linear-log). Table 5.2 denotes parameter estimates and associated standard errors for the sigmoid Emax 
model. The 𝐴𝐴𝐺𝑚𝑎𝑥 (89.50 mg/dL) depicts the geometric mean (or median) of plasma AAG 
concentrations in healthy adults. Comparatively, the model estimates median AAG concentrations to 
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Figure 5.2 Ontogeny of AAG among healthy subjects. Concentrations, normalized to CRM470 
values, are depicted using estimated geometric mean values (o) for each study group. Geometric 
error bars depict the log-normal SE associated with each study cohort.  Predicted AAG 
concentrations based on a sigmoid Emax model (solid line - red), as derived from this work, and 
a linear model (dashed line - blue), as proposed by McNamara and Alcorn (assuming adult 
plasma AAG concentrations ≈ 89.50 mg/dL) [51], are denoted. Observed data were compiled 
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Table 5.2 Parameter estimates (sigmoid Emax model) describing the relationship between 
postnatal age (days) and AAG (mg/dL) in healthy subjects 
 
Parameter Estimate SEa CVb 
𝐴𝐴𝐺𝑚𝑎𝑥 [mg/dL] 89.50 2.87 3.21% 
𝑇𝑀50 [days] 7.26 2.28 31.40% 
𝑃 0.481 0.0645 13.41% 
 
a Standard-Error 
b Coefficient of Variation  
 
Two-hundred and fourteen individual AAG concentrations complied over 3 separate clinical 
trials were utilized to evaluate the ontogeny of AAG in subjects diagnosed or suspected of infection. 
The dataset included 20 subjects from the CLIN01 trial, 177 from the PTN POPS trial, and 17 from the 
Staph Trio trial. Individuals ranged in PNA from 5 days to 20.5 years. As in healthy subjects, the 
sigmoid Emax model provided the best fit between PNA and AAG concentrations as determined by the 
AIC (319.24) and visual examination of curve shape (Figure 5.3A). In comparison, AIC values 
associated with the linear, power, exponential, and linear-log models were 359.87, 334.61, 360.34, and 
329.76, respectively. Parameter estimates and standard errors associated with the sigmoid Emax model 
using the covariate PNA are denoted in Table 5.3. In subjects diagnosed or suspected of infection, the 
estimated geometric mean of AAG concentrations among adults (𝐴𝐴𝐺𝑚𝑎𝑥 ; 254.71 mg/dL) was 
comparatively higher than values observed in healthy (normal) adults. This trend towards increased 
AAG concentrations was depicted throughout the entire developmental age range. For example, at 5 
days old, median AAG concentrations were estimated to be 89.41 mg/dL in infected individuals 
compared to 40.75 mg/dL in healthy subjects. On average, AAG concentrations from the Staph-Trio 
trial, which contributed data pertaining to premature born (< 30 weeks GA) neonates and infants less 
than 3 months PNA, appeared to be overestimated by the sigmoid Emax model fit using PNA (□ in 
Figure 5.3A). A similar pattern was also seen for children from the CLIN01 trial, all of whom were 
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Table 5.3 Parameter estimates (sigmoid Emax model) describing the relationship between 
postnatal age (days) and AAG (mg/dL) in subjects with confirmed or suspected infections 
 
Parameter Estimate SEa CVb 
𝐴𝐴𝐺𝑚𝑎𝑥 [mg/dL] 254.71 12.25 4.81% 
𝑇𝑀50[days] 11.53 3.11 26.97% 
𝑃 0.735 0.167 22.72% 
 
a Standard-Error  
b Coefficient of Variation  
 
 
 Figure 5.3B depicts the ontogeny of AAG derived using a sigmoid Emax model employing 
PMA as its primary covariate for subjects diagnosed or suspected of infection. The model was 
associated with an AIC value of 291.02, which was comparatively lower than the previous model fit 
using PNA. In addition, use of PMA was associated with a lower standard deviation of log-normalized 
residuals (≈RMSE) in comparison to PNA (0.4710 vs. 0.5031, respectively).  Correspondingly, PMA 
was deemed as the preferable age descriptor for defining the ontogeny of AAG within this subset of 
subjects.  Parameter estimates and standard errors for the sigmoid Emax model fit to PMA are denoted 
in Table 5.4. The estimated 𝐴𝐴𝐺𝑚𝑎𝑥 (254.37 mg/dL) was similar in value to that of the PNA model; 
however, estimates of the age at 50% 𝐴𝐴𝐺𝑚𝑎𝑥  (𝑇𝑀50) and the hill coefficient (P) were expectedly 
different between models due to the use of varying age descriptors. Additionally, use of PMA decreased 
the degree of overprediction associated with AAG estimates for premature born children from the 
Staph-Trio trial (□ in Figure 5.3B). Though, similar to the PNA model, AAG estimates for subjects 
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Figure 5.3 AAG ontogeny with respect to (A) PNA and (B) PMA in subjects diagnosed or 
suspected of infection. Median (i.e. geometric mean) AAG concentrations (solid lines) and 
associated 95% CI (dashed lines) as estimated using a sigmoid Emax model are depicted. 






Table 5.4 Parameter estimates (sigmoid Emax model) describing the relationship between 
postmenstrual age (weeks) and AAG (mg/dL) in subjects with confirmed or suspected infections 
 
Parameter Estimate SEa CVb 
𝐴𝐴𝐺𝑚𝑎𝑥 [mg/dL] 254.37 9.49 3.73% 
𝑇𝑀50 [weeks] 31.33 1.31 4.18% 
𝑃 3.97 0.714 17.98% 
 
a Standard-Error 
b Coefficient of Variation  
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A graphical comparison of model predicted AAG concentrations between healthy subjects and 
those diagnosed or suspected of infection is displayed in Figure 5.4A. The comparison employed 
models parameterized in terms of PNA as the analysis in healthy subjects did not assess ontogeny with 
regards to PMA. The span of postnatal ages depicted were limited to the age range of purportedly 
infected subjects (i.e. 5 days to 20.5 years). Normalizing AAG concentrations towards the adult levels 







 ratios in healthy subjects fell within the 95% CI of values associated with subjects 
diagnosed or suspected of infection for the assessed age range (5 days to 20.5 years). As a result, it was 
asserted that the developmental trajectory of the 
𝑃𝑝𝑒𝑑
𝑃𝑎𝑑𝑢𝑙𝑡
  ratio was not substantially different between 
healthy and infected subjects (Figure 5.4B).  
 
Figure 5.4 (A) Comparison of median (geometric mean) AAG concentrations with respect to 
PNA in healthy (dotted line) and infected subjects (Median-solid line; 95% CI –dashed line), as 
estimated by separate sigmoid Emax models. (B) Comparison of normalized estimates of AAG 
concentrations (i.e. normalized to adult AAG values) with respect to PNA in healthy (dotted 
line) and infected subjects (Median-solid line; 95% CI –dashed line). AAG estimates are 
depicted for postnatal ages ranging between 5 days and 20.5 years. 
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Overall bias associated with use of the derived AAG ontogeny model among healthy subjects, 
parameterized using PNA, at estimating 17 separate 𝑓𝑢𝑝𝑒𝑑 values was relatively low. On average, 
estimates underpredicted observed values by 3% (AFE = 0.97). The model was associated with a 
precision (AAFE) of 1.24, indicating that on average individual predictions were within 24% of 
observed values. In comparison, use of the ontogeny equation proposed by McNamara and Alcorn [51] 
for estimating 𝑓𝑢𝑝𝑒𝑑 was associated with a larger degree of underprediction (AFE = 0.74) and poorer 
precision (AAFE = 1.45). Individual predictions garnered by each respective model are displayed in 
relation to observed values in Figure 5.5. 𝑓𝑢𝑝𝑒𝑑 estimates derived from the sigmoid Emax model were 
in closer agreement to observed values in comparison to estimates derived from the linear model as 
denoted by the concordance correlation coefficient  (0.852 vs. 0.652, respectively) [326]. In addition, a 
higher coefficient of determination (R2) was associated with estimates from the sigmoid Emax model 
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Figure 5.5 Individual fuped predictions vs. Observed fuped. Lines of best fit as determined by 
linear regression are displayed for both the sigmoid Emax (red-solid) and linear models ( blue-





For estimation of AAG concentrations among subjects diagnosed or suspected of infection, the analysis 
supported use of PMA as a comparatively better age descriptor than PNA. With use of PMA, estimated 
AAG concentrations were notably less biased for the subset of premature children from the Staph-Trio 
trial (Figure 5.3). Furthermore, model parameter estimates were relatively more precise (i.e. decreased 
coefficients of variation; CV%) (Table 5.3 & 5.4). Most notably, the CV% associated with 𝑇𝑀50 was 
26.97% vs. 4.18% for models using PNA and PMA, respectively. Use of PMA as an alternative age 
descriptor for assessment of the ontogeny of AAG among healthy individuals was precluded as not all 
studies with neonatal subjects reported GA, thus preventing tabulation of PMA [311, 319]. Several 
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investigations, however, have documented lower AAG concentrations among premature newborns in 
comparison to purportedly normal term newborns [300, 302, 305]. As use of PMA provides some 
capacity to account for prematurity, it is postulated that models using this age descriptor among 
healthy/normal subjects will exhibit a better fit to AAG concentrations in comparison to PNA. 
Therefore, it is prudent that prospective studies exploring the trajectory of AAG in healthy individuals 
document GA among their youngest subjects to permit for PMA calculation.  The span of postnatal 
ages used for comparison of the ontogeny of AAG between the subject groups (healthy vs. infected) 
was restricted to 5 days to 20.5 years, the age range of purportedly infected subjects (Figure 5.4). 
Therefore, the analysis was unable to examine the acute-response of AAG associated with infection 
among extremely young children (i.e. less than 5 days PNA) or older adults (i.e. geriatric). 
As an acute-phase reactant, AAG levels increase in response to injury, inflammation, or 
infection [286]. The magnitude of increase has been related to factors such as the severity of disease 
[307] and type of infection (i.e. meningitis vs. pneumonia) [327]. Furthermore, normalization of AAG 
levels appear to follow the clinical course of infection [300]. Data utilized to evaluate the ontogeny of 
AAG in subjects diagnosed or suspected of infection did not provide sufficient information to stratify 
individuals based on infection type, severity, or time course of infection. As such, assessed subjects 
displayed a high degree of inter-subject variability in terms of AAG concentrations, thus making 
prediction of individual AAG levels precarious.  However, for the purposes of scaling PK parameters 
from adults to pediatrics, the relative difference in AAG concentrations between these two age groups 
is the measure of interest [66, 127]. The current work demonstrates that, on average, the relative 
ontogeny profile of 
𝑃𝑝𝑒𝑑
𝑃𝑎𝑑𝑢𝑙𝑡
 in infected subjects followed a similar trajectory to that observed among 
healthy subjects (Figure 5.4B).  Correspondingly, it could be asserted that scaling of fu, as determined 
according to equation 5.5, from healthy or infected adults toward pediatric subjects within the same 
respective clinical state (e.g. infected adult  infected child) could be determined using a single 
ontogeny profile for 
𝑃𝑝𝑒𝑑
𝑃𝑎𝑑𝑢𝑙𝑡
 (e.g. use of the profile pertaining to healthy subjects) . The high inter-subject 
variability observed among subjects diagnosed or suspected of infection could, indeed, result in 
individual predictions of 𝑓𝑢𝑝𝑒𝑑 that deviate from the average tendency. In terms of subsequent 
predictions of pediatric PK, this would result in individualized estimates of total compound exposure 
in plasma (i.e. AUC) that deviate from observed values. However, provided estimates of pediatric 
intrinsic clearance are sufficient, predictions of unbound plasma exposure (unbound AUC) - a metric 
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related to pharmacologic effect - should be congruent with observed data for low extraction ratio or 
orally administered high hepatic extraction ratio compounds [284]. 
 Median AAG estimates among purportedly infected, overweight and obese children from the 
CLIN01 trial (n=20) were slightly over-predicted by sigmoid Emax models incorporating PNA or 
PMA. This raises the notion of AAG concentrations differing between overweight and normal weight 
children - an observation that has been documented among ‘healthy’ adults [328]. However, as the 
dataset pertaining to infected subjects did not contain information relating to potential confounders (e.g. 
infection type, severity, and time course of infection), establishing an association between the attributes 
(i.e. obesity) of subjects from one specific trial (CLIN01) and AAG may lack external validity and was, 
therefore, was not pursued. Notably, removal of subjects from the CLIN01 trial from the analysis of 
AAG ontogeny among infected individuals did not result in a substantial change in model parameters 
(e.g. 𝐴𝐴𝐺𝑚𝑎𝑥(266.38 mg/dL), 𝑇𝑀50(32.18 weeks), and P (3.79) – sigmoid Emax model [PMA]).  
Based on an observed dataset containing 17 𝑓𝑢𝑝𝑒𝑑 values, estimates of fu derived using the 
proposed AAG ontogeny equation from healthy (control) subjects were associated with a low bias (AFE 
= 0.97) and relative accurate precision (AAFE = 1.24). Discontinuity between observed and predicted 
fu values can be related to numerous etiologies; however, an understanding of the assumptions 
associated with fu prediction in pediatrics can provide some insight. Predictions of 𝑓𝑢𝑝𝑒𝑑 were derived 
using equation 5.5, as previously depicted by McNamara and Alcorn [51]. With use of this equation, 
several assumptions are inherently presumed: 1, plasma protein binding is linear (i.e. nonsaturable 
ligand concentrations); 2, ligand-protein binding properties are the same between children and adults 
(i.e. number of binding sites per protein and affinity constants are constant with age), and 3, AAG is 
the principal protein responsible for plasma protein binding. Violation of any of these assumptions can 
result in deviation between observed and predicted values. With plasma concentrations up to 50-fold 
lower than albumin and exhibiting only a single binding site [285], AAG is frequently termed as a low 
capacity protein [52]. Resultantly, therapeutic concentrations that drugs are commonly dosed towards 
(i.e. 1 – 10 μM) may result in saturation of AAG [285]. This propensity for saturation is expected to be 
especially prominent among neonatal subjects, where concentrations of AAG are considerably lower 
than adults. One previous study exploring protein binding of lidocaine among pediatric plasma samples 
asserted that age-related differences in the binding capacity of AAG between neonates and older 
children could be responsible for the inconsistency of fu values between the groups [305]. However, 
this postulation requires further study to be corroborated. Differential protein binding properties 
between variants of AAG have been documented in the literature [289, 290]. Unfortunately, the datasets 
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utilized within this analysis did not stratify AAG into specific genetic variants; therefore, 
developmental changes in variant concentrations and their influence on protein binding estimation were 
not assessed. Furthermore, some xenobiotics may display affinity for more than one plasma protein. 
For example, the opioid antagonist naloxone displays affinity for both albumin and AAG [311]. As 
equation 5.5 only considers changes to a single protein, estimates of 𝑓𝑢𝑝𝑒𝑑 for such compounds may 
be biased.  
Compared to the ontogeny model proposed in this study, 𝑓𝑢𝑝𝑒𝑑 estimates derived from 
McNamara and Alcorn’s [51] AAG ontogeny equation were associated with a higher degree of bias 
and lower precision. On average, McNamara and Alcorn’s equation underpredicted observed fu values 
by 26% (AFE = 0.74). The authors’ utilized a linear equation to describe the ontogeny of AAG (Figure 
5.2; age is displayed on a log scale). Unfortunately, this functional form does not provide an appropriate 
depiction of AAG concentrations among the most developmentally immature subjects. For example, in 
neonates, the equation provided estimates of AAG concentrations that were well above observed data 
points. Therefore, considering that ≈80% (14/17) of fu values within the observed dataset were from 
neonatal subjects, the finding that 𝑓𝑢𝑝𝑒𝑑 estimates derived using McNamara and Alcorn’s equation 
were associated with an underprediction bias was not unexpected.  
With ever widening acceptance of the use of physiologically-based pharmacokinetic (PBPK) 
models for scaling xenobiotic exposures from adults to pediatrics [66, 329], the findings of this analysis 
can be readily integrated into common practice. PBPK models represent a bottom-up approach that 
integrates components of organism physiology with xenobiotic-specific parameters to foster a priori 
predictions of systemic as well as tissue-specific exposures [127]. Thus, within such models there exists 
an intuitive link between the quality of input parameters (i.e. physiological and xenobiotic-specific 
parameters) and the accuracy of model-predicted exposures. PBPK models typically parameterize the 
magnitude of xenobiotic-protein binding using fu. This critical parameter can exert profound influences 
towards the processes of clearance and distribution [49], thus, modulating estimates of xenobiotic 
exposure. By providing superior estimates of 𝑓𝑢𝑝𝑒𝑑, the ontogeny model derived from this work can 
be used in conjunction with PBPK modeling techniques to improve their predictive capacity for 
pediatrics. 
 The use of a sigmoid Emax model for defining the ontogeny of AAG concentrations is not 
unique to this investigation. Johnson et al. [330] previously conducted an analysis of plasma AAG 
levels using select literature sources. The authors’ found that a sigmoid Emax model suitably described 
the data. Derived parameter estimates were not considerably different from parameters reported among 
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healthy subjects from the current study. Estimates of 𝐴𝐴𝐺𝑚𝑎𝑥, 𝑇𝑀50, and P were 88.7 mg/dL, 8.89 
days, and 0.38, respectively, as reported by Johnson et al. Compared to this aforementioned publication, 
our analysis offered a more comprehensive examination of the available literature with data compiled 
over 25 separate investigations. The present study also considered a wider variety of prospective models 
and provided an evaluation of the predictive performance of the derived ontogeny equation at 
estimating fu, an important parameter utilized for PK scaling.  In addition, the assessment of AAG 
ontogeny among subjects diagnosed or suspected of infection represents a component unique to the 
current work. 
This analysis represents one of the most comprehensive examinations of published literature 
characterizing plasma AAG levels in healthy subjects from birth to adulthood. However, despite 
compiling AAG data from 25 studies conducted over a wide range of countries, the majority of data 
was assumedly directed towards a Caucasian population. For example, only one study was conducted 
in a country where the population is primarily of Asian descent (i.e. Japan) [317]. The remaining 
investigations conducted in France, Canada, the Netherlands, USA, Australia, Greece, Denmark, 
Germany, England, and Belgium, were postulated to contain a high proportion of Caucasian subjects. 
Within adults, inter-ethnic differences in AAG levels have been documented. In one study, AAG 
concentrations were denoted to be 20% higher in Caucasians compared to African Americans [331]. 
Another investigation measuring AAG concentrations in Chinese and Caucasian volunteers found 25% 
higher levels among Caucasians [332]. Considering the demographics of individuals within the 
examined studies, the analysis was incapable of investigating for the presence of inter-ethnic 
differences among healthy subjects; therefore, presented results are primarily reflective of AAG 
concentrations within a Caucasian population.  Racial demographics of individuals included in the 
analysis of AAG ontogeny among subjects diagnosed or suspected of infection was 76% White, 16% 
African American, and 8% Other. A secondary analysis was conducted based on the depicted sigmoid 
Emax model using the covariate PMA (base model) to assess whether inclusion of a binary race 
covariate (Non-White 0; White 1) could enhance model fit. However, inclusion of race in a proportional 
manner resulted in a similar AIC to the base model (291.84 vs. 291.02, respectively). As such, use of 
the covariate race was not considered to be beneficial for estimation of AAG among our sample of 
purportedly infected subjects. 
In this study, the ontogeny of AAG among healthy subjects was assessed using AAG 
concentration data averaged over multiple subjects from separate publications. Analyses of this type of 
can be influenced by the presence of an aggregation bias (ecological fallacy). This bias arises from the 
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loss of information associated with aggregating individual data, leading to distortion of the relationship 
that exists between individual subjects and the variable of interest [333]. Despite this, use of aggregated 
data within the analysis was deemed reasonable as the majority of publications failed to report 
individualized data. In addition, the ontogeny models derived from this investigation should not be 
considered to entail wider applicability towards other plasma proteins (e.g. albumin), which can follow 
alternative ontogeny patterns [51]. 
 
5.5 Conclusion 
The current investigation sought to quantitatively describe the ontogeny of AAG in both healthy 
subjects and those diagnosed or suspected of infection. A sigmoid Emax model was found to best 
describe the developmental trajectory of AAG in both groups of subjects (healthy and infected). As an 
acute-phase reactant, plasma AAG levels increase in response injury, inflammation, and infection [50]. 
Though a profound dissimilarity in median AAG concentrations between healthy and infected subjects 
was observed, the analysis depicted a similar ontogeny pattern when AAG levels were normalized 
toward adult values. Furthermore, the derived ontogeny equation demonstrated a proficient predictive 
capacity for estimation of 𝑓𝑢𝑝𝑒𝑑.  As developmental changes in plasma protein binding (i.e. fu) can 
translate into significant alterations in compound distribution and clearance, this work will aid in 
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Chapter 6: Parameterization of Small Intestinal Water Volume using 
PBPK Modelling 
 
The contents of this chapter are reflective of an original manuscript published by the Ph.D. candidate 
(Anil R Maharaj) in the European Journal of Pharmaceutical Sciences. All pertinent research analyses 
was conducted by the Ph.D. candidate. 
Maharaj A, Fotaki N, Edginton A. Parameterization of small intestinal water volume using PBPK 
modeling. European journal of pharmaceutical sciences : official journal of the European Federation 
for Pharmaceutical Sciences. 2015;67:55-64. doi:10.1016/j.ejps.2014.10.016. 
 
6.1 Introduction 
The integration of physiologically-based pharmacokinetic (PBPK) modelling into the drug 
development and regulatory review process has increased in frequency over recent years. From 2008 
to 2013, 84 Investigational New Drug/ New Drug Applications submitted to the US Food and Drug 
Administration (FDA) contained PBPK modelling techniques [22]. In addition, a recent drug 
monograph approved by the FDA utilized PBPK models to assess the clinical implications of specific 
drug-drug combinations [334].  PBPK modelling is an appealing option for users as it provides a 
rational framework for generating a priori predictions of compound disposition. Accordingly, use of 
PBPK modelling has been well documented in a variety of settings, from industry to academia, as well 
as many research areas including drug-drug interactions [335], genetic polymorphism [336], and 
investigations of altered organ function [337]. Models are mechanistic in nature, combining information 
based on organism physiology and anatomy with compound physico-chemical properties to predict the 
time-course of drug disposition. When effectively parameterized, PBPK models facilitate an 
understanding of compound pharmacokinetics by quantitatively estimating the contribution of 
absorption, distribution, metabolism and excretion.  
In general, the predictive accuracy of PBPK modelling for predicting plasma concentration-
time values following intravenous drug administration in adult humans is well-established [28].  In 
constrast, estimation of the systemic exposure following oral drug administration is comparatively less 
accurate [28]. This discrepancy in predictive performance can be linked to the complex milieu of 
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physiological and environmental factors that interact within the gastrointestinal tract to facilitate oral 
absorption.  As such, prediction of oral absorption requires a fundamental understanding of several 
processes including drug dissolution, degradation, gastric emptying, intestinal transit, drug 
diffusion/permeation, and first pass metabolism [32].  Commercially, several PBPK modelling software 
products have integrated oral absorption models into their platforms. These include the advanced 
compartmental absorption and transit model (ACAT) incorporated into GastroPlus® (Simulations Plus 
Inc., Lancaster, CA),  the advanced dissolution, absorption, and metabolism (ADAM) model 
incorporated into the Simcyp® simulator (Simcyp Ltd., Sheffield, UK), and the compartmental gastro-
intestinal model included in PK-Sim 5® (Bayer Technology Services GmbH, Leverkusen, Germany).  
Notwithstanding specific inter-model structural intricacies, all models are conceptually based on the 
compartmental absorption and transit (CAT) model, originally proposed by Yu and Amidon [35], which 
depicts the gastrointestinal tract as a series of linked compartments. 
Organism specific data required for parameterization of compartmental oral absorption models 
include gastrointestinal geometry (i.e. length, radius), gastric emptying time, intestinal transit, luminal 
pH, intestinal permeability, gastrointestinal fluid volumes, and enzyme/transporter abundance. With 
the quality of input parameters intuitively linked to model predictive accuracy, there is an 
overwhelming need to ensure that model parameters are optimally assigned.  
With regards to oral drug delivery, the small intestine is generally considered the primary site 
of drug absorption due to the presence of several surface structures (folds, villi, microvilli) which serve 
to increase the absorptive surface area several fold [34]. Since only dissolved drug is permitted to 
permeate the intestinal membrane, defining of the amount of fluid available within the small intestine 
is imperative to facilitate predictions of oral drug disposition. Among CAT models presented in the 
literature, wide variation exists in the amount of fluid allocated to the small intestine, ranging from 250 
to 600 mL [55-58]. Conversely, in vivo estimates of small intestinal fluid volume within adults denote 
a central tendency between 86-167 mL [59-61]. As PBPK models should reflect a biological basis in 
terms of structure and parameterization, this discrepancy raises concerns regarding the physiologic 
fidelity of such simulations.  In addition, use of PBPK models to extrapolate PK information towards 
unstudied populations require models to exhibit a biological resemblance. For example, procedural 
workflows for developing pediatric PBPK models capable of estimating age-specific PK alterations are 
predicated on established adult models [23, 329]. Adult models displaying appropriate agreement with 
observed data are subsequently scaled towards a pediatric population. This process leverages the 
relative abundance of adult PK data to establish confidence in model predictions prior to extrapolating 
  120 
to children. Extrapolations utilize the mechanistic framework of PBPK simulations, allowing model 
parameters to be modified using in vivo measures of anatomy, physiology, and biochemistry of the 
developmental age group of interest. Adult models incorporating parameters not consistent with known 
in vivo measures are, therefore, limited in terms of performing such extrapolations. As such, 
demonstration of a PBPK model’s physiologic applicability is a crucial step in establishing confidence 
in simulated results. 
The current investigation will serve to assess the biological relevance of the commonly utilized 
CAT model in terms of small intestinal water volume (SIWV).  Using a generic CAT model integrated 
into a whole-body PBPK model, an optimal value for SIWV will be generated using pharmacokinetic 
data sets obtained from the literature. To evaluate physiologic fidelity, model derived volume estimates 
will be compared to experimentally-based SIWV determinations. 
 
6.2 Methods 
6.2.1 CAT model structure 
A CAT model, developed in Matlab-Simulink®  (The Mathworks Inc., Natick, MA ), based on the 
works of Yu and Amidon [35] was implemented within the study to simulate oral drug absorption. 
Compared to proprietary software packages, creation of a customizable absorption model within the 
Matlab® environment was deemed necessary as it permitted for flexibility in terms of model analysis 
and parameterization. A schematic representation of the model is displayed in Figure 6.1. The small 
intestine is characterized as a series of 7 well-mixed compartments. Drug progresses aborally between 
compartments following linear transfer kinetics. Anatomically, each compartment represents an equal 
length of the small intestine with the first-half of the initial compartment pertaining to the duodenum. 
The subsequent half of the first compartment along with the second and third pertains to the jejunum, 
and the fourth to seventh compartments represent the ileum [33]. A stomach compartment was added 
to the model which functioned as a holding compartment, with no absorption occurring, before 
compound introduction into subsequent intestinal compartments.  Colon mediated drug absorption was 
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Figure 6.1 Schematic Representation of the Developed Compartmental Absorption and Transit 
(CAT) model [ks – first-order gastric emptying rate; kt – first-order intestinal transit rate; 
Amp1 – corrective factor associated with intestinal PxSA for the duodenum and jejunum; and 




Drug was permitted to exist in two states: solid and dissolved. Dissolution in the stomach and 
intestine was modelled using the following equation [56]  where, 
 
𝑅𝑑 = 𝐾𝑑𝑀𝑖 (
𝑆𝑖−𝐶𝑖
𝑆𝑖
)   (Equation 6.1) 
 
Rd is the rate of dissolution (mg/hr), Kd is the dissolution rate constant (hr-1), Mi is the time dependent 
mass (mg) of solid drug present within the compartment, Si is the compartmental solubility limit, and 
Ci is the time dependent concentration of dissolved drug within the compartment. Precipitation was 
modelled as an instantaneous process within intestinal compartments. Supersaturation of intestinal 
fluids was not considered as luminal concentrations were not permitted to exceed compartmental 
solubility limits. However, the model did permit for precipitated drug to undergo dissolution when drug 
concentrations fell below the compartmental saturation limit. 
The simulated rate of drug absorption into the portal circulation was calculated as follows, 
 
𝑅𝑎  =  ∑ 𝑃
3
𝑖=1  𝑥 𝑆𝐴𝑖 𝑥 𝐴𝑚𝑝1 𝑥 𝐶𝑖  + ∑ 𝑃
7
𝑖=4  𝑥 𝑆𝐴𝑖   𝑥 𝐴𝑚𝑝2 𝑥 𝐶𝑖   (Equation 6.2) 
 
where Ra is the rate of drug absorption (mg/hr), P is the intestinal permeability (cm/hr), and SAi is the 
geometric compartmental surface area (cm2). Amp1 and Amp2 pertain to corrective amplification factors 
associated with the permeability x surface area product (P x SA) of the upper (compartments 1 - 3) and 
lower (compartments 4 - 7) small intestine, respectively. Compartmental surface areas were derived 
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geometrically assuming a conical (flat) frustum and incorporated literature reported physiologic values 
of small intestinal radii [338] and length [339]. Permeability was set to a predefined value of 0.001 
cm/hr within all intestinal compartments. This initial parameterization was relatively arbitrary as 
compartmental P x SA values were subsequently refined through the inclusion of amplification factors 
(Amp1 and Amp2). These factors introduced additional degrees of flexibility into the CAT model, 
allowing for optimization of compartmental P x SA values based on in vivo pharmacokinetic data. Use 
of two amplification factors permitted the model to independently account for PxSA differences 
between the upper (duodenum and jejunum) and lower (ileum) small intestine.  
Gastric fluid volume was defined as 300 mL which approximates the fasted fluid volume of 
the stomach, 45 mL [61], in addition to the 200-250 mL of water co-ingested with dosages in many 
pharmacokinetic studies.  Allocation of fluid amongst the seven intestinal compartments was based on 
the relative difference in geometric volume of each compartment. Geometric volumes were calculated 
using congruent data [338, 339] as that used to estimate compartmental surface areas. Compartment 
volumes were calculated based on a conical frustum with the total geometric volume of the small 
intestine estimated to be 931 cm3. Compartments were assigned an equivalent fraction of fluid per 
geometric volume. For example, to simulate an intestinal fluid volume of 100 mL, each compartment 
would be assigned 0.107 ml (100 mL/931cm3) of fluid per cm3 of geometric volume.  Experimental 
values for pH specific compound solubility were extracted from the literature. If required, solubility 
was extrapolated from literature values using the Henderson-Hasselbalch equation [340]. CAT model 








  123 
 
Table 6.1 Compartmental Absorption and Transit (CAT) model parameters 
a - values derived from [237] 
b – values derived from  [33, 341, 342] 
c – values derived from [338, 339] 
d – value derived from [61] plus addition of 200-250 mL of fluid ingested with dosages 
e – value obtained using Henderson- Hasselbalch equation 
f – values derived from [343] 
g – values derived from [344, 345] 
 
6.2.2 Drug selection 
To effectively parameterize SIWV using PBPK model-based simulations, compound specific 
pharmacokinetic data sets following oral administration were required. In addition, compound selection 
was restricted based on several criteria. First, to provide estimates of fluid volumes reflective of the 
entire small intestine, compounds were required to display poor intestinal permeability. Poor 
permeability was defined as a fraction of absorption less than 90%, which is consistent with the 
Biopharmaceutics Classification System (BCS) [346].  To minimize the effects of dissolution within 
the model, compounds were required to either meet the FDA criterion for rapid dissolution when 


























Stomach 1.5 2.8 n/a n/a 0.001 300
d 12.98e 0.417 
Intestine-1 6.5 2.1 303.92 183.81 0.001 - 2.42
f 0.7696 
Intestine-2 6.5 2.1 281.24 157.45 0.001 - 2.42
 f 0.7696 
Intestine-3 6.5 2.1 257.11 131.61 0.001 - 2.42 f 0.7696 
Intestine-4 7.5 2.1 243.79 118.24 0.001 - 2.71
 f 2.3397 
Intestine-5 7.5 2.1 241.27 115.81 0.001 - 2.71
 f 2.3397 
Intestine-6 7.5 2.1 238.76 113.41 0.001 - 2.71 f 2.3397 
Intestine-7 7.5 2.1 236.25 111.04 0.001 - 2.71 f 2.3397 
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administered a an immediate release formulation [346] or be administered as a solution.  
Pharmacokinetic literature pertaining to candidate compounds were required to be conducted in healthy 
adults and depict time-dependent drug excretion or plasma profiles following oral absorption at a 
minimum of two different dosage levels. Parameterization of SIWV necessitated the selection of 
compounds which displayed non-proportional changes in absorption between increasing dosage 
strengths. Furthermore, the etiology of this non-linearity should be correlated to saturation of intestinal 
fluids. As such, compounds displaying non-linear clearance kinetics following intravenous 
administration or those whose absorption is largely mediated via transporter-based uptake were 
excluded.  
 
6.2.3 PBPK model parameterization 
Estimates of systemic compound disposition following oral absorption was modelled using PK-Sim 
5.2® (Bayer Technology Services, Leverkusen, Germany), a whole-body PBPK modelling platform. 
Tissue-to-plasma partition coefficients (Kp) were derived using the tissue composition based approach 
as proposed by Rodgers and Rowland [80-82]. Acyclovir and chlorothiazide were selected as candidate 
compounds based on the criteria stipulated in the previous section. Compound specific physicochemical 
properties required for model parameterization were obtained from the literature and are displayed in 
Table 6.2. Parameterization of clearance and distribution were derived using two different modalities 
depending on the availability of literature data. For acyclovir, where PK studies depicting plasma 
concentration time values following intravenous compound administration were available, clearance 
and distribution were simultaneously fit based on minimization of an objective function between 
simulated (PBPK derived) and observed data. The process of parameter optimization required a mean 
individual to be generated based on the demographics (race, age, weight, height) of the in vivo 
pharmacokinetic study [79].  Computational optimizations of clearance, in the form of intrinsic 
clearance (Clint), and distribution, in the form of lipophilicity, were conducted using the mean study 
subject while incorporating similar conditions (i.e. dose, infusion time, study duration) as those 
imposed within the in vivo investigation. Since acyclovir exhibits competing clearance processes (i.e. 
renal and hepatic), pathway specific Clint values were constrained in order to provide similar proportions 
of systemic clearance as those observed in vivo.   
For chlorothiazide, where pharmacokinetic studies following intravenous administration in 
healthy adults were not available, clearance and distribution were derived using alterative 
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methodologies. Since chlorothiazide is primarily renally excreted, clearance was tabulated using 
pharmacokinetic studies containing time-dependent rates of urinary excretion and plasma concentration 
values following extravascular (oral) drug administration in healthy adults. Alternatively, distribution 
was tabulated using literature data pertaining to intravenous compound administration in a pre-clinical 
species (i.e. rat). In this case, lipophilicity, a surrogate measure of distribution, was tabulated using a 
similar methodology as previously described for acyclovir. The lipophilicity (i.e. distribution) value 
fitted within the pre-clinical species was used for parameterization of the adult human PBPK model.  
 
Table 6.2 PBPK model parameters 
Parameter Acyclovir Chlorothiazide 
Clint (hepatic)  
(ml/min – per gram intracellular hepatic 
tissue) 
0.104732a  - 
Clint (tubular renal secretion)  
(ml/min – per gram of kidney tissue) 
0.906355a  6.11 e 
 
fGFR b 1 1 
Lipophilicity (LogP) -0.56a -0.25f 
Molecular Weight (g/mol) 225.21 295.72 
Fraction unbound (plasma) 0.846c 0.177g 
pKa (acid) 9.04d 6.7g 
pKa (base) 2.16d - 
a – values derived from model-based optimization using intravenous data from adult humans [347] 
b – proportion of free drug susceptible to passive elimination via glomerular filtration 
c – value derived from [348] 
d – values derived from [349] 
e – value was fitted to provide a systemic clearance of 4.36 ml/min/kg 
f – value derived from model-based optimization using intravenous data from rats [350] 
g – values derived from [351] 
 
6.2.4 Estimation of SIWV 
Compound specific oral pharmacokinetic data sets derived from healthy adult subjects depicting 
different dosage strengths were utilized to estimate SIWV. Integration of the developed CAT model 
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with the PK-Sim® created whole-body PBPK model provided predictions of systemic drug disposition 
(plasma concentration or fraction urinary excreted) following oral absorption. This was accomplished 
by using the rate of absorption, as quantified by the developed CAT model, as an input into the portal 
vein within the whole-body PBPK model.   
Compound data pertaining to lower dosage strengths, where permeability is postulated to be 
the rate-limiting step of absorption, were used to calculate amplification factors pertaining to the upper 
and lower small intestine. To account for the apparent impact of SIWV selection on estimation of 
intestinal PxSA, a wide range of intestinal fluid volumes were assigned within the CAT model. 
Volumes between 52.5 mL to 420 mL were allocated using increments of 10.5 mL. Amplification 
factors were optimized with respect to each SIWV to provide a minimized objective function value 
between simulated and observed time-dependent pharmacokinetic measures (i.e. ‘concentration vs. 
time’ or ‘cumulative fraction excreted vs. time’). Simulations utilized congruent conditions (i.e. dose, 
dosage form, subject demographics) to those stipulated in the observed pharmacokinetic studies. 
Derived amplification factors from the lower dosage levels were considered to reflect the difference 
between the naïve model estimate and the true in vivo PxSA value. 
 Observed pharmacokinetic data sets pertaining to higher dosage strengths, where non-
proportional changes in compound absorption were observed, were utilized to evaluate SIWV 
estimates. Based on simulations conducted at the lower dosage level, SIWV values and their 
corresponding amplification factors were incorporated into the CAT model. Models were further 
parameterized in accordance with observed study conditions (i.e. dose, dosage form, subject 
demographics) at the higher dosage level. Optimal model-based estimates of SIWV were determined 
by comparing simulated predictions of oral compound disposition to observed pharmacokinetic data 
using a predefined objective function.  
 
6.2.5 Objective function 
Parameter optimizations were conducted using MoBi® Toolbox for MATLAB® (Bayer Technology 
Services GmbH, Leverkusen, Germany/ The Mathworks Inc., Natick, MA), which permitted for 
iterative assessment of simulation results with observed data. Absolute average fold-error (AAFE) was 
selected as the objective function of choice to assess model predictive performance.  
 






|           (Equation 6.3) 
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The above objective function was utilized to compare predictions of time-dependent compound 
disposition (plasma concentration or fraction urinary excreted) to observed pharmacokinetic data sets. 
Models incorporating SIWV(s) which result in lower AAFE values were considered to possess a 
greater predictive capability.  
To minimize the potential contribution of colonic mediated absorption, all optimizations and 
assessments were conducted using observed plasma concentrations up to 8 hours following oral 
absorption of acyclovir. Urinary fraction excretion data pertaining to chlorothiazide was sampled at a 
lower intensity and, as such, assessments and optimizations were conducted up to 12 hours. 
 
6.3 Results 
Based on the restrictive inclusion criteria, which limited the range of appropriate compounds from 
which rational estimates of SIWV could be attained, acyclovir and chlorothiazide were selected.  
Briefly, acyclovir is a guanosine-based antiviral drug, whereas chlorothiazide is a diuretic [24].  
Pharmacokinetic data following oral administration of 200 and 400 mg of acyclovir in immediate 
release tablets were acquired from the literature [347]. At a dose of 200 mg, acyclovir bioavailability 
is 32%, while at 400 mg, oral bioavailability decreases to 23%. The major clearance pathways of 
acyclovir were denoted as renal clearance (fe = 0.707) and hepatic metabolism (fm = 0.293) [347]. 
Pharmacokinetic data following oral administration of chlorothiazide solutions at doses of 50, 100, and 
250 mg were obtained from the literature [352]. At a dose of 50 mg, the bioavailability of chlorothiazide 
is 56%, while at doses of 100 and 250 mg the bioavailability decreases to 47% and 33%, respectively. 
Chlorothiazide elimination was primarily attributed to renal clearance (fe = 1) [352]. 
Parameter values for acyclovir and chlorothiazide utilized by the whole-body PBPK model are 
displayed in Table 6.2. Acyclovir clearance and distribution (i.e. lipophilicity) were optimized using 
pharmacokinetic data depicting a 250 mg intravenous dose to a cohort of 24 healthy adult subjects 
[347]. For chlorothiazide, pharmacokinetic profiles following intravenous drug administration in 
healthy adult humans were unavailable. Since renal excretion contributes to the majority of 
chlorothiazide elimination, clearance was alternatively calculated using data pertaining to extravascular 
(oral) administration. Pharmacokinetic data following oral administration of 500 mg of chlorothiazide 
in cohort of 9 healthy adult males was acquired [353]. An average clearance estimate of 4.36 ml/min/kg 
was derived from time-dependent urinary excretion and plasma concentration data. Distribution (i.e. 
lipophilicity) was fitted based on pharmacokinetic profiles attained following intravenous 
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administration of chlorothiazide to Sprague-Dawley rats [350]. PBPK model-based predictions of 
acyclovir and chlorothiazide disposition following intravenous administration are depicted in Figure 
6.2.  
 
Figure 6.2 Fitted estimates of plasma concentration (log) vs. time profiles following intravenous 
administration of (A) acyclovir and (B) chlorothiazide in an adult human and rat, respectively 
(lines). Mean observed data is superimposed for reference (circles). Acyclovir, administered at a 
dose of 250 mg to a cohort of 24 healthy adult subjects [347]. Chlorothiazide, administered at a 
dose of 10 mg/kg to a cohort of 5 Sprague-Dawley rats [350]. 
 
Amplification factors for the upper (Amp1) and lower (Amp2) small intestine pertaining to 
different SIWV were derived from the CAT integrated PBPK model using the lowest dosages of 
acyclovir (200 mg) and chlorothiazide (50 mg) (Figure 6.3). Figure 6.4 displays model-based 
predictions of acyclovir and chlorothiazide disposition following oral administration at these respective 
dosages. The depicted simulations utilize a SIWV of 252 mL. For both compounds, changes in SIWV 
did not produce any visual effect on model predictions at the lower dosing level. This is the result of 
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Figure 6.3 Drug specific amplification factors for the upper (Amp1) and lower (Amp2) small 
intestine pertaining to different SIWV estimates. Values derived using the lowest dosages of (A) 
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Figure 6.4 Estimates of oral compound disposition in adult humans generated from the 
developed CAT model incorporating a SIWV of 252 mL (lines).  (A) Acyclovir plasma 
concentration (linear) vs. time estimates following a 200 mg dose. (B) Acyclovir plasma 
concentration (log) vs. time plot. (C) Chlorothiazide cumulative urinary excretion (linear) vs. 
time estimates following a 50 mg dose. (D) Chlorothiazide cumulative urinary excretion (log) vs. 






















Predictive performance of models incorporating different SIWV values, and their associated 
amplification factors (Figure 6.3), were assessed using observed data pertaining to oral administration 
at higher dosages. For acyclovir dosed at 400 mg (Figure 6.5), a CAT model parameterized with a 
SIWV of approximately 116 mL provided the best estimate of plasma concentration values, as denoted 
by the AAFE.  At a dose of 100 mg (Figure 6.6A), models incorporating SIWV values between 94.5 
mL and 136.5 mL provided optimum estimates of chlorothiazide urinary excretion.  However, at 
dosages of 250 mg, urinary excretion of chlorothiazide was most appropriately modelled using a SIWV 
A B 
C D 
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of 189 mL (Figure 6.6B).  As a comparison, in vivo estimates of small intestinal fluid volume within 




Figure 6.5 Absolute average fold error (AAFE) vs. SIWV for a 400 mg dose of acyclovir. AAFE 
values were tabulated based the discrepancy between observed [347] and predicted (model 
derived) plasma concentration vs. time values. 
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Figure 6.6 (A) Absolute average fold error (AAFE) vs. SIWV for a 100 mg dose of 
chlorothiazide. (B) AAFE vs. SIWV for a 250 mg dose of chlorothiazide. AAFE values were 
tabulated based the discrepancy between observed [352] and predicted (model-derived) 
cumulative urinary excretion vs. time values. 
 
 
*SIWV with associated P x SA values (Amp1 and Amp2) as depicted in Figure 6.3B 
 
6.4 Discussion 
By integrating the developed CAT model into the PBPK modeling framework, optimal simulation-
based estimates of SIWV were derived. Based on the described methodology, estimation of SIWV 
required a restrictive compound selection process to ensure non-linear changes in fraction absorbed, 
noted within in vivo investigations, were predominantly reflective of drug saturation of the intestinal 
fluids.  The confounding presence of Michaelis-Menten absorption kinetics were mitigated by 
exclusion of compounds that exhibited an affinity for transport mediated intestinal absorption. Studies 
investigating low permeability compounds (i.e. fraction absorbed < 90%) administered as either a 
rapidly dissolving solid formulation or in solution permitted for estimation of intestinal permeability at 
lower dosages while minimizing the effects of dissolution. Although colonic absorption may play a 
critical role in oral drug bioavailability, especially for controlled release products, this study included 
only immediate release formulations with low permeability. As a result, compared to the small intestine, 
the effects of colonic absorption was deemed to be negligible. The study utilized in vitro aqueous 
solubility values obtained from the literature to parameterize the developed CAT model. Though 
B A 
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solubility estimates derived from biorelevant media are considered to be the most physiologically 
applicable, use of aqueous values were considered appropriate due to the hydrophilic nature of the 
studied compounds (logP < 0). As such, the presence of bile acids within intestinal fluids were 
considered to have a minimal influence on compound solubility in vivo [201].  
The ability of compounds to form supersaturated solutions within intestinal fluids can largely 
influence in vivo oral absorption. Despite this, an accurate method for predicting compound specific 
supersaturation has yet to be developed. Simple molecular descriptors such as molecular weight, logP 
and pKa do not appear to allow for identification of  compounds that readily establish supersaturated 
solutions  (i.e. chasers) from those that do not (i.e. non-chasers) [354].  Furthermore, if supersaturated 
solutions are attained, estimation of the time course during which concentrations are sustained above 
the saturation solubility are not available. Slow precipitation kinetics and the resultant formation of 
supersaturated solutions can enhance drug bioavailability, especially for poorly soluble weak bases 
[355]. Within this study, drug precipitation was depicted as an instantaneous process. This assumption 
was deemed appropriate since both acyclovir and chlorothiazide were considered to possess low 
intestinal permeabilities. As such, the effects of temporal instances of supersaturation of the intestinal 
fluids were considered to be less influential with regards to drug absorption. To demonstrate this 
assertion, estimates of SIWV were derived from acyclovir data using a similar methodology as 
previously described with one alteration; precipitation was added to the CAT model using  1st order 
precipitation half-lives of 20, 10, and 5 minutes.  The results of this assessment denote models 
parameterized with SIWV values of 94.5 mL, 94.5 mL and 105 mL as the most applicable for 
simulating acyclovir oral absorption in conjunction with the aforementioned precipitation half-lives, 
respectively (Figure 6.7). Comparatively, these estimates are similar to 116 mL, the value obtained 
using the assumption of instantaneous intestinal precipitation. 
 While PBPK models can provide estimates of systemic exposure for compounds displaying 
non-linear clearance, parameterization (i.e. Vmax and Km) of these models require either intravenous 
dose escalation studies or detailed in vitro transporter/metabolic based assays. Due to limitations of 
available data within the literature, compounds exhibiting non-linear clearance in adult humans were 
excluded from the analysis. Intravenous bolus [356] and multi-dose studies [357] have demonstrated 
acyclovir clearance to be dose-independent. Though one report identifying the presence of non-linear 
clearance in rhesus monkeys (n=3) was located [358], intravenous chlorothiazide studies refuting the 
notion of dose-independent clearance were not obtained with regards to adult humans. Due to a lower 
dose per kg ratio and poor oral bioavailability, systemic plasma concentration values observed in human 
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studies [353, 359] were several fold lower than those achieved within the aforementioned primate study, 
minimizing the likelihood of observing clearance nonlinearities amongst humans. As a result, 
chlorothiazide was deemed as an acceptable candidate compound for our analysis. 
 
Figure 6.7 Absolute average fold error (AAFE) vs. SIWV for a 400 mg dose of acyclovir. 
Intestinal precipitation was modelled using a half-lives of (A) 20 minutes, (B) 10 minutes and 
(C) 5 minutes. AAFE values were tabulated based the discrepancy between observed [347] and 
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Study results indicate a SIWV of approximately 116 mL best predicted the non-linear 
absorption pattern of acyclovir between doses of 200 and 400 mg (Figure 6.5). For chlorothiazide, 
simulations indicated an approximate SIWV of 116 mL best described the non-proportionate absorption 
pattern at oral doses between 50 and 100 mg, though SIWV values between 94.5 mL and 136.5 mL 
provided similar degrees of accuracy (Figure 6.6A). In contrast, at doses of 250 mg, simulations 
indicated a SIWV of 189 mL provided the best estimates of chlorothiazide absorption (Figure 6.6B). 
This discrepancy with previous results may be explained by the pH dependent solubility of 
chlorothiazide in acidic mediums. At pH values representative of gastric media (i.e. pH = 1), 
chlorothiazide exhibits a low solubility (0.417 mg/ml) [345]. This increases the potential of gastric 
precipitation of drug from orally administered solutions, especially at higher dosages.  Assuming a 
gastric media volume of approximately 250-300 mL (basal gastric volume plus fluid administered with 
dosage), chlorothiazide doses of 50 and 100 mg in solution would drive gastric concentrations below 
the solubility limit. Conversely, at doses of 250 mg, chlorothiazide concentrations would exceed the 
gastric solubility limit and, thus, be subject to precipitation. The effects of gastric precipitation on 
overall gastrointestinal transit can be profound, leading to increased gastric retention and protracted 
absorption. Since the developed CAT model utilized within this study assumed a simple first-order 
gastric emptying rate congruent with in vivo emptying kinetics of non-caloric liquids [342], the effects 
of gastric precipitation and subsequent gastric retention were not accounted for. SIWV values derived 
using data from orally administered compounds influenced by the effects of gastric precipitation are, 
therefore, anticipated to lack appropriate specificity. Consequently, estimates of SIWV using observed 
data pertaining to administration of 250 mg of chlorothiazide in solution may be inappropriately 
assigned within the context of our model. SIWV estimates obtained from acyclovir and chlorothiazide 
doses of 400 and 100 mg, respectively, approximate an average of 116 mL. These estimates are derived 
from dosage strengths where the potential of gastric precipitation is attenuated and, as such, allow for 
effective parameterization of SIWV within the model.  
The results of our analysis are well corroborated by in vivo investigations examining small 
intestinal water content in humans. In two separate studies, Marciani et al. examined SIWV amongst 
separate cohorts of healthy adult subjects using serial MRI scans. One study quantified the average 
fasting SIWV as 86 mL (interquartile range 46–134 mL) among 16 subjects [59]. A median fasting 
SIWV of 167 mL (interquartile range 103-209 mL) was determined among 16 adults in the second 
study [60]. In a separate investigation, Schiller et al. assessed in-situ SIWV values using MRI scans 
among 12 healthy adult subjects [61]. The mean (± standard deviation) fasting SIWV was determined 
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to be 105 ± 72 mL. Within the study, intestinal fluid was not observed to be uniformly distributed 
throughout the intestine but instead contained within several discrete watery pockets. As a result, solid 
drug traversing the small bowel may not be in continuous contact with intestinal fluids. Due to the 
innate complexity of modelling the hydrodynamic movement of fluids within sequestered pockets along 
the intestine, the developed CAT model utilized a simplified approach with regards to the allocation of 
intestinal fluid. Compartmental fluid volumes were allocated using a consistent proportion of the 
geometric volume of each compartment. Despite this simplification, the results of our analysis indicate 
a SIWV of 116 mL as optimal for CAT model parameterization, a value which is consistent with in 
vivo investigations. Due to this agreement, the CAT model is considered to provide a biologically 
accurate depiction with regards to SIWV. This finding provides confidence in the potential use of such 
simulations for predicting oral drug disposition in populations where SIWV may differ (i.e. children). 
Additionally, results from the current investigation challenge the appropriateness of models 
incorporating larger SIWV (i.e. 250-600 mL) for simulating oral absorption [55-58]. 
 In terms of solubility, the BCS utilizes 250 mL as its apparent physiologically relevant volume 
for classifying compounds as high vs. low solubility. At doses between 200 and 400 mg, acyclovir falls 
within the classification of a highly soluble compound [360]. By convention, compound absorption 
should not be limited by solubility. However, study results refute this notation as oral absorption of 
acyclovir at doses of 400 mg was limited due to solubility restrictions within the intestinal fluids, as 
exemplified by the presence of non-linear absorption when compared to oral doses of 200 mg. 
 An alternative model-based assessment of gastrointestinal fluid volumes using data from four 
solubility limited compounds was conducted by Sutton [361]. The analysis found multiple 
combinations of SIWV (i.e. ranging from 65-260 mL) and drug precipitation half-lives (Tppt) provided 
appropriate fits with observed data. This result is a reflection of the compounds assessed, which 
predominantly included high permeability compounds. In such cases, the effect of precipitation on oral 
absorption is more pronounced and, therefore, requires implicit parameterization within the model. 
Since the study fit estimates of Tppt following selection of SIWV, it is unsurprising that many 
combinations of SIWV and Tppt were applicable. A SIWV of 130 mL was subsequently selected based 
on its agreement with physiologic values derived from the literature. In contrast, the current 
investigation incorporated only low permeability compounds which attenuated the confounding effects 
of intestinal precipitation on SIWV selection. In addition, our analysis utilized a quantitative 
methodology to identify an optimal SIWV for model parameterization. Physiologic values reported in 
  137 
the literature did not influence selection of SIWV but were merely used as comparative index to assess 
the biological relevance of the model. 
In a separate investigation, Sugano used an approximation of a one compartment absorption 
model to assess intestinal fluid volumes [362]. The analysis utilized fraction absorbed (Fa%) data from 
four orally administered compounds (acyclovir, chlorothiazide, lobucavir and ganciclovir). Despite 
considerable variability surrounding observed Fa% values, a mean intestinal fluid volume of 130 mL 
was ascertained.  Though this value may be valid to predict Fa% in the context of a one compartment 
model, its applicability towards multi-compartment absorption models, as utilized by many software 
platforms, is not definitive. Based on the developed CAT model, the results of our analysis converged 
to a comparable estimate of SIWV (116 mL). To maximize reproducibility, the current study employed 
a quantitative methodology to assess the appropriateness of SIWV estimates based on observed 
pharmacokinetic data. In addition, model parameters such as compartmental fluid allocation were 
clearly defined.  
 Although computationally complex in comparison to traditional compartmental models, the 
use of a whole body PBPK model to provide estimates of systemic compound exposure was deemed 
necessary. For chlorothiazide, development of a systemic compartmental model was hampered due to 
a lack of intravenous human data amongst the literature. As a result, data depicting intravenous 
administration of chlorothiazide to rodents [350] was used to refine estimates of compound distribution 
(Figure 6.2B). Refined distribution parameters were subsequently scaled to humans using PBPK 
modelling techniques. For acyclovir, plasma profiles following intravenous administration to adult 
humans were available [347], permitting for the development of traditional compartmental models. 
However, to maintain consistency with regards to the analysis of the two candidate compounds, whole-
body PBPK modelling was selected as the preferable technique.  
 The current investigation depicts a unique modality to estimate an appropriate SIWV for CAT 
model parameterization but is not without limitations. The reliance of the methodology on simplifying 
assumptions regarding gastrointestinal dissolution, transit, precipitation, and permeability are 
imperative for appropriate estimation of SIWV. Failure of compounds to conform to these 
specifications would decrease model applicability. To mitigate this potential, drug selection was 
conducted using a highly restrictive criteria. The derived SIWV represents an average value for 
parameterizing simulations for healthy adult humans. The analysis did not evaluate SIWV variability 
within the population, limiting use of our findings in facilitating appropriate population-based estimates 
of oral compound disposition. Finally, observed pharmacokinetic data sets were exclusively derived 
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from studies depicting dose administration under fasting conditions. As such, SIWV values derived 
from this investigation may preclude modeling of drug administration during fed states. 
 
6.5 Conclusion 
Using a model-based approach, we quantified an average SIWV of 116 mL using observed 
pharmacokinetic data from the literature. Compared to other model-based analyses, the methodology 
employed within the current investigation permitted for identification of SIWV independent of 
experimentally-based determinations. The estimate represents the optimal value for parameterization 
of the developed CAT model.  The ability of PBPK models to extrapolate predictions of drug exposure 
between species as well as developmental age groups is predicated on its physiologically relevant 
framework. The study establishes a correlation between in vivo SIWV estimates in adults and 
parameterization of the widely used CAT model.  Based on this finding, the use of CAT models for 
facilitating predictions of systemic drug exposure in unique and underserved research populations such 














  139 
Chapter 7: Discussion, Summary Example, Conclusion, and Future 
Directions 
Portions of this chapter are reflective of an original manuscript published by the Ph.D. candidate 
(Anil R Maharaj) in the journal CPT: Pharmacometrics & Systems Pharmacology. All pertinent 
dialogue included in this chapter was written by the Ph.D. candidate. 
Maharaj AR, Edginton AN. Physiologically based pharmacokinetic modeling and simulation in 




The collective narrative of this thesis seeks to improve the parameterization of mechanistic oral 
disposition models in pediatrics, increasing the level of confidence associated with model predictions. 
As both the structure and parameterization of PBPK models are entrenched upon the notion of 
biological fidelity, a fundamental understanding of human anatomy and physiology are essential for 
the development of informative models. Children represent a heterogeneous population in terms of 
growth and development. Owing to the disparate nature of literature examining age-related changes in 
oral absorption, parameterization of mechanistic oral disposition models within this population is quite 
challenging. The current dissertation expands our understanding of the ontogeny of key physiological 
aspects regulating oral absorption and serves to highlight differences between children and adults.  In 
particular, the thesis provided focused analyses pertaining to the ontogeny of small intestinal transit 
time (SITT), gastrointestinal (GI) solubility, and α-1-acid glycoprotein (AAG).  In addition, 
complimentary chapters defined the currently accepted modality for the development pediatric PBPK 
models as well as demonstrated the use of PBPK models as tools for identification of human 
physiological values. 
 Chapter 2 of this dissertation provided an explicit example of how structured workflows can 
be implemented to facilitate the rational development pediatric PBPK models to support clinical 
investigations. The benzodiazepine lorazepam was used as an illustrative example to demonstrate how 
each step of the proposed workflow was executed. The end result of the modeling exercise provided 
age-specific pediatric doses from birth to adulthood that approximated similar plasma exposures 
(AUC0-inf) to a 2 mg intravenous dose in adults. Similar to workflows presented by other research groups 
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[21, 23], the workflow proposed in chapter 2 also recommends the initial development, evaluation, and 
refinement of an adult PBPK model prior to extrapolation towards pediatrics. Based on this 
methodology, informative pediatric models can be developed in a fashion that leverages the relative 
wealth of adult PK information available. The importance of evaluating the adult PBPK model should 
not be understated. As demonstrated in Figure 2.2, misspecification of the adult model can translate 
into similar discrepancies within subsequently developed pediatric models. As a result, only adult 
models displaying appropriate agreement with observed PK data should be considered as candidate 
models for pediatric model development.  
One interesting finding that highlighted the intuitive nature of PBPK modeling arose when 
estimates of lorazepam CL and Vss derived via PBPK modeling were compared to estimates garnered 
using Population PK (PopPK) modeling [88] for 15 pediatric subjects in whom intensive serial 
sampling was performed. For this subset of patients, the resolution of plasma concentration-time data 
was adequate to permit for CL and Vss to be calculated via non-compartmental analysis (NCA). When 
PK estimates derived via PBPK and PopPK techniques were compared, a similar predictive capacity 
was noted between the two techniques in terms of the proportion of CL and Vss values falling within a 
1.5 fold-error (i.e. ~60% and ~80%, respectively) from observed values (i.e. NCA). This finding was 
rather remarkable as the PopPK model was built on a dataset that included the abovementioned 15 
subjects, yet its predictive capacity was similar to that of a PBPK model that was derived independently 
of any pediatric PK data. 
The research in chapter 2 demonstrated a practical example of the utility of such workflows for 
extrapolating PK information from adults to pediatrics using PBPK modeling. Within the example, 
estimates of lorazepam PK derived from the pediatric PBPK model were deemed to be relatively 
accurate in comparison to a competing PopPK model [88]. However, the research precipitates the 
question, “Does the use of a structured workflow ensure that pediatric PBPK models deliver accurate 
estimates of PK in children?” Unfortunately, the simple answer to this question is “no”. As previously 
described in the introduction, within PBPK models there exists an intuitive relationship between the 
biological relevance of its input parameters and confidence bestowed upon model predictions. What 
this means is that in order to have confidence in PBPK model predictions, model parameters should 
reflect the anatomy and physiology of the organism under study. Thus, a lack of knowledge regarding 
the ontogeny of processes regulating oral absorption will result in the development of pediatric models 
with insufficient predictive capacities. An example of this is highlighted in a recent publication that 
described the development of pediatric PBPK models for simulating the oral disposition of sotolol and 
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acetaminophen [30]. Simulations performed in older children (2-11 years) fit observed concentration-
time data well for both compounds; however, for infants (1 month – 2 years) and neonates (0 to 1 
month), the simulations tended to overestimate Cmax while underestimating tmax. The authors attributed 
this lack of fit to be the result of misspecification of gastric emptying time (GET) within infants and 
neonates. In fact, when the parameter GET was increased, post-priori, PBPK simulations displayed 
improved predictive accuracy in both age groups. In a separate study, PBPK modeling was utilized to 
simulate the oral disposition of voriconazole among children (2-11 years) [31]. The initially developed 
pediatric PBPK model displayed concentration-time values that were incongruent with observed data. 
In addition, the model predicted oral bioavailability (i.e. 60–94%) was greater than values observed 
among children (i.e. 44-66%). The authors’ postulated the poor fit was a result of a lack of incorporation 
of intestinal metabolism into the pediatric model. When intestinal first-pass was incorporated, pediatric 
simulations exhibited an improved fit with the observed data.  
 To facilitate improved PBPK model parameterization, chapters 3, 4, and 5 of this thesis 
provided focused assessments of the relationship between age and key physiological parameters (e.g. 
SITT, intestinal solubility, and AAG) responsible for modulating oral drug disposition.  Much of the 
depicted work leverages data from the current literature to provide a consensus regarding the 
developmental trajectories of these parameters. Chapter 3 examined the relationship between age and 
SITT. The analysis, which aggregated data pertaining to children and adults over 40 published 
investigations, utilized meta-regression techniques to quantitatively examine SITT as a function of age. 
Based on the results of the analysis, age was not found be a significant modulator of SITT. This finding 
deviates from previously held assertions that older children exhibit faster intestinal transit times than 
adults [97, 98]. Such assertions have been linked to previous PK investigations of sustained release 
(SR) theophylline in asthmatic children who typically display large degrees of inter-individual 
variability in systemic concentrations [99, 100].  To demonstrate that changes in SITT are unlikely to 
contribute to inconsistencies in theophylline SR disposition in children, a PBPK model-based approach 
was employed. From this assessment it was found that alterations in SITT lacked influence on the oral 
absorption of SR theophylline. Of note, discernable changes in theophylline absorption were only 
observed when total intestinal transit time (i.e. SITT and LITT) was greatly altered (i.e. ↓ 50%). These 
results, therefore, downplay decreased SITT as a primary factor contributing to PK variability of SR 
theophylline in children.  
 Chapter 4 of this thesis provided a comprehensive literature-based assessment of age-related 
changes in GI fluid composition. The physicochemical nature of GI fluids exhibits a direct relationship 
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to compound specific solubility values. Considering the importance of luminal solubility towards oral 
drug performance, determination of the relationship between age and GI fluid composition is critical to 
facilitate accurate predictions of pediatric oral absorption. The analysis, which aggregated data 
depicting GI fluid compositions from children to adults, served to quantitatively evaluate the influence 
of age on specific physicochemical and compositional properties including pH, buffering capacity, 
pepsin concentrations, osmolality, bile salt concentrations, and the presence of fat digestion products. 
The results of this chapter represent the most detailed evaluation of age-specific GI fluid compositions 
available in the current literature. Of note, the assessment depicted fasting gastric pH in neonates, with 
the exception of the first few hours after birth, to be similar to that of adults. Fasting gastric pH was 
maintained at adult levels thereafter.  This finding contrasts with a previously published review article 
that denoted fasting gastric pH in neonates to fall shortly after birth to adult levels, followed by an 
increase in pH to values between 6-7 [184]. However, the findings expressed by the review article were 
derived from tertiary sources without an evaluation of the primary literature. Comparatively, results 
reported in this dissertation incorporated a wide breath of primary literature sources and should, 
therefore, be viewed as a more comprehensive assessment.  In addition to quantitatively denoting 
developmental differences in GI fluid composition between children and adults, the chapter extended 
the applicability of this research by formulating a set of novel pediatric biorelevant media. This research 
represents one of the first reported attempts to develop biorelevant media reflective of children in the 
literature. In total, 9 different age-specific media were developed to represent the luminal fluids of the 
stomach and proximal small intestine in both fasted and fed states. Pediatric media were reflective of 
the unique physicochemical nature of GI fluids in neonates (0-1 month) and younger infants (1-12 
months). To assess the impact of developmental changes in fluid composition, solubility assessments 
were conducted for seven BCS Class II compounds in each pediatric media. Additionally, solubility 
assessments were conducted in a set of biorelevant media representative of adults [182]. The analysis 
defined relevant changes in solubility in relation to the adult media using the FDA’s in vivo 
bioequivalence criterion (i.e. 80-125%).  The absorption of BCS Class II compounds is primarily 
assumed to be limited by solubility. As such, compounds exhibiting relevant solubility changes within 
pediatric media could be at increased risk for displaying age-related alterations in oral drug absorption. 
For six of the seven compounds investigated, solubility fell outside an 80-125% range from adult values 
in at least one of the developed pediatric media. These findings infer that relevant differences in luminal 
solubility between pediatric and adult subjects could persist in vivo. This inference contrasts with a long 
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employed assumption – pediatric and adult luminal solubility values are identical - adopted by several 
research groups investigating oral drug absorption in children [38, 363]. 
Defining the relationship between age and plasma AAG concentrations was the focus of 
chapter 5. Although plasma protein binding is typically perceived to alter systemic PK parameters such 
as clearance (CL) and volume of distribution (Vss) [364, 365], it can also be culpable in influencing oral 
drug disposition. For the subset of high extraction ratio (ER) compounds, the fraction unbound in blood 
- which is proportional to the fraction unbound in plasma - exhibits an inverse relationship to hepatic 
bioavailability (i.e. first-pass) [366]. Thus, increases in the degree of protein binding (i.e. ↓ fu,p) will 
result in higher hepatic availability; whereas, decreases in the degree of protein binding (i.e. ↑ fu,p) will 
result in the opposite.  Within the chapter, the ontogeny of plasma AAG was quantitatively defined in 
healthy subjects, using a literature-based dataset, and subjects suspected of infection (i.e. sick subjects), 
using data aggregated over 3 clinical trials. Compared to other models, the sigmoid Emax model 
provided the best approximation of the ontogeny of AAG along the entire developmental age range for 
both subject groups. When utilized to estimate fu,p values in children, the derived Emax equation (from 
healthy subjects) exhibited a lower degree of bias and higher precision in comparison to a previously 
proposed approach [51]. Within PBPK models, fu,p represents a key parameter with ramifications 
towards several processes such as hepatic first-pass (for high ER drugs), CL (low ER drugs), and Vss 
(for all compounds that distribute outside the plasma space). Thus, by providing more accurate 
estimates of pediatric fu,p, use of the derived AAG ontogeny equation will serve to reduce uncertainty 
associated with pediatric PK predictions. In addition, the analysis of AAG ontogeny within infected 
subjects denotes one of the first attempts to quantitatively model plasma AAG levels from neonates to 
adults in this subject group. This is quite pertinent as drug administration in pediatrics is principally 
focused towards sick patients. 
Chapter 6 demonstrated an alternative use of PBPK modeling to serve as a framework for 
generating estimates of human physiology.  Plasma-concentration time data depicting oral 
administration of acyclovir and chlorothiazide in adults were utilized to generate model-based estimates 
of SIWV. The results of this modeling exercise defined a value of ~116 mL as the optimal SIWV for 
CAT model parameterization in adults. In comparison, CAT models implemented by other research 
groups have utilized a wide range of SIWV values (250-600 mL) to facilitate predictions of oral 
compound absorption [55-58]. In terms of in vivo estimates of SIWV, the results of one representative 
investigation from the literature, which examined SIWV among 12 healthy adult subjects using MRI 
scans, depicted an average volume of 105 mL [61] . This value was closely approximated by the model-
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derived value reported in chapter 6, thus confirming the biological fidelity of the depicted CAT model 
with regards to SIWV parameterization. The work also explicitly denoted how the parameter SIWV 
can be distributed throughout the multiple compartments of the CAT model, an important consideration 
in the use of such models for simulating oral drug absorption. Within the depicted CAT model, water 
volumes were allocated using a consistent proportion of the geometric volume of each compartment 
with the sum of all compartments equaling the total SIWV (~116 mL). This represents an overt 
simplification of in vivo conditions, where small intestinal water is not uniformly distributed throughout 
the intestine but instead contained within several discrete watery pockets [61]. Nevertheless, the 
depicted parameterization scheme was deemed as appropriate based on the congruent relationship 
between model-based and in vivo derived estimates of SIWV. Additionally, the implemented 
simplification was considered as preferable as it circumvented the innate complexity associated with 
modeling the hydrodynamic movement of fluids within sequestered pockets along the intestine.   
Despite focusing on the parameterization of SIWV within an adult model, the depicted research 
in chapter 6 encompasses implications towards pediatric model development.  Based on the dialogue 
of chapter 2, the importance of adult model development and evaluation prior to extrapolation to 
pediatrics was highlighted. An essential component in establishing confidence in PBPK models focuses 
on evaluating the model’s biological relevance in terms of structure and parameterization [39].  The 
reliability of adult models incorporating parameters not consistent with known in vivo measures is 
considered questionable in terms of performing extrapolations towards pediatrics. The research in 
chapter 6 confirms the biological fidelity of the CAT model with regards to SIWV, thus instilling 
confidence in the prospective use of such models for estimation oral drug disposition in pediatrics. The 
depicted methodology exploits the mechanistic and physiologic framework of PBPK models to 
facilitate predictions of human physiology using compound specific PK datasets. This demonstrates an 
alternative use of PBPK modeling that could be of potential benefit in children. Children are considered 
as a vulnerable population and, as such, may be prohibited from participating in clinical investigations 
that lack direct benefit towards individual study subjects [367]. As such, invasive assessment 
techniques that have been employed in adults to quantitatively define aspects of human physiology may 
be precluded in children, making appropriate parameterization of pediatric PBPK models difficult. 
Provided the recorded measure (i.e. plasma-concentration time data) is sensitive to the parameter of 
interest, the methodology presented in chapter 6 could be applied to estimate a variety of anatomical 
and physiological parameters. In children, the described methodology could be employed to increase 
our understanding of pediatric physiology in cases where in vivo determinations are prohibited.   
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Quantitative assessments of pediatric physiology, as depicted in this dissertation, will aid in the 
development of informative pediatric PBPK models with improved capacities for estimating oral 
compound disposition in children. The findings of a recent publication assessing the age-dependency 
of gastric emptying (GET) time can also serve to support pediatric model parameterization. In the 
investigation by Bonner et al. [179], a nonlinear mixed-effects based approached was employed to 
assess the influence of age on GET using data from 49 studies denoting gastric transit in children, 
including neonates, and adults. The analysis found meal type (e.g. aqueous, breast milk, formula, semi-
solid, and solid) to be a significant covariate of GET; however, age was not. Through use of the final 
nonlinear mixed-effects model derived from the analysis, GET can be quantitatively defined for 
pediatric PBPK model parameterization. 
Although the research presented in this dissertation strives to increase the knowledge base of 
pediatric physiological attributes that regulate the oral drug disposition, there is still a need for 
additional investigations to fully elucidate the age-dependency of the oral absorption process. 
Knowledge gaps particularly endemic in children with regards to GI anatomy and physiology have been 
denoted in a 2012 publication by the Pediatric Biopharmaceutics Classification System (P-BCS) 
Working Group [186]. The group was assembled to assess whether a similar classification system as 
utilized in adults (i.e. BCS) could be developed for children. Of note, the P-BCS Working Group 
recognized that significant knowledge gaps with regards to pediatric GI physiology, including intestinal 
permeability and ontogeny of drug transporters, needs to be addressed prior to establishing a pediatric 
focused BCS [186]. With regards to the development of informative pediatric PBPK models, these 
same knowledge gaps are also of relevance. 
  Intestinal permeability is a measure of the mucosal membrane’s inherent resistance to 
movement of substances across the epithelium. As a surrogate measure, the absorption and subsequent 
rapid urine excretion of non-metabolizable sugars such as lactulose, mannitol, and L-rhamnose, can be 
used to provide relative estimates of intestinal barrier function. Mannitol and L-rhamnose are 
monosaccharaides that can transverse the intestinal membrane via the transcellular pathway; whereas, 
lactulose permeates across the intestinal membrane through the tight junctions in-between the 
enterocytes (paracellular) [368].  Based on such tests, it has been noted that intestinal permeability is 
enhanced during the first few days after birth due to an increased capacity for paracellular transport. 
With initiation of enteral feeds, permeability rapidly declines as transport via the paracellular route 
becomes attenuated [369-371].  Mature levels of intestinal permeability are normally attained during 
the first weeks of life [372]. These findings can be viewed as qualitative indicators of intestinal 
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permeability; however, they do not provide a capacity to quantitatively discern how the permeability 
of specific compounds will change with age. Therefore, data derived from the abovementioned tests 
are of little value for parameterizing PBPK models that are focused on simulating the disposition of 
specific compounds. In adults, in vivo estimates of drug specific intestinal permeability have been 
determined through the use of intestinal perfusion techniques. These techniques serve to provide 
regional specific (i.e. jejunum) estimates of compound permeability [122]. Ideally, to examine the age-
dependency of permeability, such tests should be employed in developmentally unique cohorts of 
children (e.g. neonates, infants, toddlers, etc.). However, considering the status of children as a 
vulnerable population and the invasiveness of this technique, studies among pediatrics would likely be 
prohibited. PBPK modeling may offer an alternative modality for quantitatively defining intestinal 
permeability in children. As depicted in chapter 6, the biologically relevant structure and 
parameterization of PBPK models can be exploited to define optimal values for parameters pertaining 
to human physiology. For compounds whose oral disposition is sensitive to intestinal permeability, in 
vivo PK measures (e.g. plasma concentration-time data) can be used to facilitate model-based estimates 
of permeability. To fully evaluate the influence of age on intestinal permeability using this approach, 
compound-specific PK datasets depicting oral drug administration in children from different 
development stages as well as adults would be required. In addition, a robust analysis would entail 
inclusion of a wide range of compounds that vary in terms of physiochemical properties (e.g. logP, 
molecular weight, pKa). This would permit for an analysis to evaluate whether potentially observed 
age-specific differences in intestinal permeability are related to specific aspects of compound physico-
chemistry. 
The presence of transporters along the gut wall can significantly influence compound 
absorption. Absorptive transporters mainly function to transport their substrates from the 
gastrointestinal lumen into the intracellular space of the enterocytes. Examples of absorptive transporter 
families located along the intestine include oligopeptide transporters (PEPT), organic anion-
transporting polypeptides (OATP), monocarboxylate transporters (MCT), and organic cation 
transporters (OCT) [373]. ATP-binding cassette (ABC) transporters are efflux proteins that prevent 
intracellular accumulation of their substrates by transporting them either apically (back into the 
intestinal lumen) or basolaterally (into the bloodstream). Examples include P-glycoprotein (P-gp) 
(transcoded by the MDR1 gene), multi-drug resistance-associated protein 2 (MDR2), and breast cancer 
resistance protein (BCRP) [373]. Several currently marketed drugs known to be substrates of P-gp 
include digoxin, tamoxifen, tacrolimus, and nifedipine  [374]. Literature reports regarding the ontogeny 
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of intestinal drug transporters are in relative short supply.  Of the few studies published, most have 
focused on P-gp. Fakhoury et al. [375] observed highly variable levels of P-gp mRNA from duodenal 
biopsies taken from children of varying ages. No relationship between age and mRNA expression was 
established. Unlike the previous study, Miki et al. [376] observed a trend towards higher MDR1 (gene 
responsible for encoding P-gp) mRNA levels with increasing age. Small intestinal samples from fetuses 
and neonates had lower mRNA expression levels than older children/adults though these differences 
were not significant. Therefore, in order to increase confidence in estimates of oral drug disposition 
garnered from pediatric PBPK models, additional investigations defining the ontogeny of P-gp as well 
as other intestinal transporters are needed. 
 
7.2 Summary Example 
This section will demonstrate how specific elements of this thesis can be employed to facilitate the 
development of pediatric PBPK models for prediction of oral drug absorption. PBPK models were 
developed for two BCS class II compounds: carbamazepine (antiepileptic) and griseofulvin 
(antifungal). These compounds were selected based on the results from chapter 4, where both exhibited 
relevant age-dependent alterations in GI solubility. The objective of this modeling exercise was to use 
PBPK modeling to discern whether these age-related changes in GI solubility would translate into 
alterations in oral drug absorption between children and adults.  
 PK-Sim 6.3® (Bayer Technology Services GmbH, Leverkusen, Germany) was utilized to 
develop all prospectively described PBPK models for both compounds. To generate age-specific 
predictions of oral carbamazepine absorption, pediatric PBPK models were developed based on the 
workflow presented in chapter 2 with one exception. As PK data (e.g. plasma concentration-time 
profiles) depicting the disposition of carbamazepine following IV administration in adult humans was 
unavailable, an initial PBPK model was developed based on IV data from a preclinical species (i.e. 
rhesus monkey) [377]. This was similar to the approach employed in chapter 6 for chlorothiazide. 
Carbamazepine fraction unbound in plasma (fu,p) among rhesus monkeys was parameterized as 0.32 
[378]. For all models, tissue-to-plasma partition coefficients were predicted in silico using the tissue-
composition based approach proposed by Rodgers and Rowland [80-82].  Concentration-time data 
describing IV administration from the abovementioned preclinical investigation was utilized in 
conjunction with a preclinical species (i.e. rhesus monkey) PBPK model to derive an estimate of in vivo 
lipophilicity for carbamazepine. This value was subsequently used for parameterization of all 
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prospective PBPK models (e.g. children and adult). Estimates of intestinal permeability were derived 
from PK-Sim’s proprietary algorithm, which tabulates permeability based on compound specific 
physicochemical properties. Drug dissolution within all oral absorption models was described using a 
Noyes-Whitney based approach, as depicted by equation 6.1. Models utilized the assumption that 
hepatic metabolism represented the primary process regulating carbamazepine clearance [379].  Adult 
biorelevant solubility values pertaining to the appropriate feeding state, as derived in chapter 4, were 
employed to parameterize GI solubility within the initially developed adult PBPK models (Table 7.1). 
SIWV was defined using a congruent method as stated in chapter 6, which assumes a constant 
proportion of geometric volume of each small intestinal compartment to be comprised of water (e.g. 
0.107 mL of fluid per cm3 of geometric volume). A fu,p  of 0.24 was used for parameterization of adult 
simulations [380]. PK data depicting oral administration of a carbamazepine suspension to a cohort of 
healthy adult subjects under fasting conditions was utilized to parameterize the in vivo dissolution rate 
constant (Kd) and hepatic intrinsic clearance (Clint) [381] within the model. Following qualification of 
the adult PBPK model within the fasted state, an additional simulation was instituted to estimate adult 
oral disposition under fed-state conditions. The effect of feeding on carbamazepine bioavailability (i.e. 
no change in AUC0-inf) as described by the simulation was similar to the findings of an in vivo 
investigation examining the influence of enteral feed administration on carbamazepine PK [382]. This 
fed-state simulation in adults was conducted to provide a like-for-like comparison with prospectively 
developed pediatric models for which drug administration was exclusively simulated in the fed-state. 
As children, especially those within the youngest age groups, are typically fed on a more consistent 
basis than adults during waking hours, it was inferred that fed-state simulations in children would 
provide the most appropriate reflection of pediatric oral disposition. Once the adult model was finalized, 
pediatric model development, as depicted in chapter 2, commenced. SITT was parameterized similarly 
for all age-groups. Pediatric simulations utilized the same Kd value as previously derived for adults. 
Age-specific models were developed to provide estimates of fraction absorbed (Fa) vs. time in 
developmentally distinct subjects: neonate (5 days), infant (3 months), child (3 years), and adult (30 
years). As described above, all simulations were reflective of drug administration within the fed-state; 
age-specific GI solubility values used within each model are stated in Table 7.1.   Doses ascribed in 
each simulation were representative of age-specific initial dosing recommendations for primary 
treatment of epilepsy [24]. Daily doses were divided to represent the typical dosing frequency of a 
carbamazepine suspension, which is recommended to be administered at least three times a day.  
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Table 7.1 Carbamazepine biorelevant solubility values utilized for PBPK model 
parameterization  





















a - Solubility in simulated fed-state gastric media representative of neonates fed cow’s milk-based formula 
(Pnc-FeSSGF) 




 Development of pediatric and adult PBPK models for predicting griseofulvin oral absorption 
followed a similar trajectory as presented above. However, in this case, data depicting IV administration 
of griseofulvin in adults was available [383]. Adult simulations incorporated a fu,p  of 0.16 [384]. 
Estimates of in vivo lipophilicity and hepatic Clint, the primary clearance pathway of griseofulvin [385], 
were generated using concentration-time data describing IV administration to humans [383] in 
conjunction with an adult PBPK model. The optimized lipophilicity value was employed in all 
forthcoming models (e.g. pediatric and adult); whereas, the optimized hepatic Clint value served to 
exclusively parameterize subsequently developed adult oral absorption models. Adult PK data 
describing oral administration of a micronized griseofulvin suspension under fasting conditions was 
employed to estimate the in vivo dissolution rate constant (Kd) for micronized griseofulvin [386]. 
Biorelevant solubility values used for adult model parameterization are presented in Table 7.2. Similar 
to above, a fed-state adult model was developed following qualification of the fasted-state model. The 
results of the fed-state simulation depicted an 80% increase in AUC0-inf compared to the fasted-state, a 
finding that correlates well with in vivo data (i.e. 70-120% increase in griseofulvin absorption with co-
administration of a meal) [387]. Pediatric models were subsequently developed to simulate fed-state 
administration only. Simulations of Fa vs. time were developed for subjects pertaining to the same age-
groups as depicted above. Age-specific GI solubility values used within each model are presented in 
Table 7.2.  Simulated doses were based on age-specific recommendations for the treatment of tinea 
capitis [24, 388]. 
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Table 7.2 Griseofulvin biorelevant solubility values utilized for PBPK model parameterization  





















a -  Solubility in simulated fed-state gastric media representative of neonates fed cow’s milk-based formula 
(Pnc-FeSSGF) 
b - Solubility in simulated fed-state intestinal media representative of neonates fed cow’s milk-based formula 
(Pnc-FeSSIF) 
 
 PBPK model derived predictions of oral absorption of a carbamazepine suspension under fed 
conditions is presented for different age groups in Figure 7.1. Despite changes in gastric solubility 
(~75% of adult values), intestinal solubility, and administration of higher mg/kg doses, both the rate 
and extent of carbamazepine absorption were largely unchanged in the neonate and infant in 
comparison to the adult. The child (3 years) simulation, which was parameterized using the same GI 
solubility values as the adult but incorporated a higher mg/kg dose, also predicted a similar absorption 
pattern to the adult simulation. Furthermore, model predictions indicated that all age groups would 
achieve complete absorption (i.e. Fa = 1). In contrast, PBPK model simulations depicting oral 
administration of a micronized griseofulvin suspension under fed conditions (Figure 7.2) displayed 
developmental differences in absorption. All pediatric subjects (e.g. neonate, infant, and child), 
displayed slower rates of absorption in comparison to the adult subject. The extent of absorption in the 
neonate and infant, who were administered slightly higher weight normalized doses than the adult (i.e. 
10 mg/kg vs. 7.35 mg/kg, repectively), was approximately 0.77. In comparison the extent of absorption 
in the adult model was marginally higher at 0.85. In accordance with pediatric dosing 
recommendations, the child model was simulated using a dose of 25 mg/kg, which is 3.5x higher than 
the weight normalized dose commonly prescribed to adults (~7 mg/kg). Simulations from the child 
model predicted a lower extent of absorption at 0.67.  
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Figure 7.2 Griseofulvin suspension (micronized) simulated fraction absorbed in different age 




The results of this simulation-based exercise found divergent developmental patterns of 
absorption for the two BCS class II compounds assessed. For carbamazepine, changes in gastric 
solubility, intestinal solubility, and administration of different weight normalized doses, failed to induce 
any discernable changes towards the rate or extent of oral drug absorption. Yet for griseofulvin, changes 
in the same aforementioned parameters, albeit to different degrees, induced age-specific changes in oral 
drug performance. The etiology of this discrepancy between the two compounds can be rationalized 
through an assessment of dose-to-solubility (D/S) ratios. Considering a therapeutic dose of 
carbamazepine (e.g. 200 mg) and a solubility value pertaining to adult fasted-state intestinal media 
(0.236 mg/mL), as recommend by the proponents of the Developability Classification System [389], a 
D/S ratio of 847 can be calculated. For griseofulvin, a similar ratio calculated based on a dose of 500 
mg and a biorelevant fasted-state intestinal solubility of 0.015 mg/mL would be ~33000. The magnitude 
of this value provides an indication of the influence that solubility exerts towards modulating oral 
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compound absorption. BCS class II compounds with higher D/S ratios are more likely to display 
solubility limited absorption [389]. In addition, such compounds would be most susceptible to exhibit 
changes in oral drug absorption due to developmental changes in solubility. However, in order to fully 
elucidate the impacts of age on oral drug absorption, consideration of GI permeability, transit, and 
dissolution should also accompany assessments of age-specific GI solubility. To discern why changes 
in intestinal solubility failed to propagate changes towards oral carbamazepine absorption in pediatric 
subjects, an understanding of the mechanistic equation employed within PBPK models to describe 
intestinal absorption can provide some insight. Equation 7.1 presents the factors influencing the rate of 
intestinal absorption within CAT model compartments, 
 
𝑅𝑎𝑡𝑒 (𝑚𝑔/ℎ𝑟) = 𝑃𝑒𝑓𝑓 ∙ 𝑆𝐴 ∙ 𝐶  (Equation 7.1) 
 
where Peff represents the intestinal permeability (cm/hr), SA is the intestinal surface area (cm2), and C 
is the luminal concentration of drug within intestinal fluids. For all age-groups, PBPK derived 
simulations denoted luminal concentrations of carbamazepine in the small intestine, the principal site 
of oral xenobiotic absorption, to fall below the solubility limit. Considering differences in 
anthropometry between children and adults, it can be inferred that total intestinal SA in children is 
smaller than that of adults. However, as children were administered larger mg/kg doses, luminal 
solubility values within the small intestine were higher - yet still below the solubility limit - in 
comparison to the reference adult subject. Based on equation 7.1, which depicts a compensatory 
relationship between SA and luminal concentrations, minimal disruptions in the rate of oral 
carbamazepine absorption would be expected in children. As a result, simulations depicted similar 
absorption profiles (rate and extent) between pediatrics and adults. This finding is supported by a recent 
publication depicting the use of PBPK modeling to explore the age-dependency of fluconazole 
absorption [38]. The analysis denoted a similarity with regards to the absorption profiles (Fa vs. time) 
of fluconazole in both children and adults. The article asserted a similar etiology as depicted above to 
explain the lack of age-dependent differences in fluconazole absorption. 
 Dissimilar to carbamazepine, simulations conducted for griseofulvin indicated the presence of 
age-specific differences in oral drug absorption. The greater influence of solubility towards modulating 
oral griseofulvin absorption is conveyed by its high D/S ratio. Based on its mechanistic design, PBPK 
models, which include parameters for both dose and luminal solubility, can intrinsically account for the 
impact of specific interrelationships between parameters (e.g. high D/S ratio). Simulations exhibited 
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luminal concentrations of griseofulvin within the small intestine to be in a state of saturation (i.e. at the 
solubility limit) for all age groups. Therefore, increased weight-normalized dosages administered to 
children did not result in higher luminal concentrations. As such, the complimentary relationship 
described above, where increases in luminal concentrations compensate for decreases in intestinal SA 
in children, does not exist for griseofulvin. Consequently, age-related changes in intestinal solubility 
will result in dissimilar oral drug absorption profiles between children and adults. In addition, since 
drug absorption is already at its upper limit, further increases in the administered dose, as depicted by 
the simulation pertaining to the child, will result in decreases in Fa. These examples serve to 
demonstrate the unique capacity of PBPK models to integrate multiple sources of information regarding 
the age-dependency of human physiology. Within PBPK models, mechanistic equations are employed 
to quantitatively describe the inter-relationship between model parameters and drug PK. In this regard, 
PBPK modeling offers a rational approach to discern the effects of changes to a single parameter as 
well as changes to several parameters on overall drug PK. By incorporating age-specific parameters 
associated with luminal solubility, intestinal SA, SITT, and intestinal water volume, the derived 
pediatric PBPK models in this section were able to provide quantitative estimates of the rate and extent 
of oral absorption specific to each compound. Simulations depicted that despite a similar BCS 
classification (i.e. class II), age-related differences in oral absorption would be expected for griseofulvin 
but not carbamazepine. However, the results presented in this section should be viewed with caution 
since in vivo data among pediatric subjects was not available to corroborate them. 
 
7.3 Conclusion 
With legislation in both North American and Europe mandating pediatric drug development research, 
interest in the use of modeling and simulation has increased. Dissimilar to empirically derived modeling 
techniques (e.g. PopPK), PBPK models offer the unique capacity to generate informative predictions 
of compound PK in unstudied subpopulations. This attribute is based on their mechanistic design and 
strategic division of parameters into those that are drug and system-specific. Based on an understanding 
that parameters pertaining to drug physico-chemistry (i.e. drug-specific) are fixed and those that pertain 
to anatomy and physiology (i.e. system-specific) can be altered to reflect the age group of interest (e.g. 
neonate, infant), a priori assessments of drug PK in children can be generated. Within PBPK models, 
the confidence bestowed upon such estimates are intuitively linked to the quality of input parameters. 
This entails that system-specific parameters should appropriately quantify the underlying anatomy and 
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physiology of the subject group being modeled. In comparison to adults, there is relative paucity of 
investigations quantitatively defining key aspects pediatric physiology that influence drug PK, making 
the parameterization of pediatric PBPK models difficult.  Such knowledge gaps particularly persist 
towards physiological processes governing oral compound disposition in children. As a result, 
predictions garnered from pediatric PBPK models simulating oral drug absorption may be of 
questionable reliability. The collective narrative of this thesis sought to improve the parameterization 
of mechanistic oral disposition models in children. The dissertation offered quantitative assessments 
pertaining to the ontogeny of small intestinal transit time (SITT), intestinal solubility, and α-1-acid 
glycoprotein. The results of these analyses both challenged and affirmed long held assumptions 
regarding pediatric GI physiology as well as improved the accuracy of estimates of pediatric protein 
binding (i.e. fu,p) - a parameter with implications towards hepatic first-pass. Although, this dissertation 
served to improve the parameterization of PBPK models tasked with simulating oral drug disposition 
in children, more research is still required to address additional knowledge gaps associated with 
pediatric GI physiology. For example, quantitative research devoted to assessing intestinal permeability 
in children and defining the ontogeny of intestinal transporters is lacking. With future advancements in 
model development there is the potential for PBPK models to shift from being used as a compliment to 
clinical PK studies to a partial replacement. For example, PBPK models may be used to decrease the 
number of clinical trials required in children by functioning as the primary exploratory investigation of 
drug PK.  This could potentially eliminate the need for exploratory PK studies in children and permit 
clinical investigations to function on a confirmatory basis. The capacity of PBPK modeling to support 
the pediatric drug development process while reducing the burden imposed on study subjects makes it 
an invaluable tool for improving medication safety and efficacy in children. 
 
7.4 Future Directions 
The research portrayed within this thesis represents an initial attempt to consolidate diverse sets of 
literature sources to provide specific estimates of pediatric physiology that modulate oral drug 
disposition. With the eventual goal of developing a comprehensive oral absorption model in children, 
such research should be continually updated to reflect the current literature. In addition, a quantitative 
understanding of the ontogeny of GI permeability and expression of intestinal transporters needs to be 
ascertained prior to the development of such a model. 
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To ensure pediatric PBPK models are developed based on a current state of knowledge, the 
analyses contained within this thesis should be continually updated to include prospectively conducted 
research examining pediatric physiology. This process is most pertinent to analyses where 
physiological information in developmentally immature age groups were sparsely reported. For 
example, the analysis of small intestinal transit time as a function of age contained data reflective of 52 
subject groups of various ages; however, only 2 of these groups pertained to subjects under the age of 
2 years. The analysis was therefore compelled to draw conclusions regarding intestinal transit among 
younger cohorts of subjects using a limited sample. With the inclusion of prospective data from 
investigations within neonates and infants, reported findings may be amendable to change. This 
highlights the need for continued revaluation of such research based on the contemporary literature. 
To facilitate the effective parameterization of an in silico oral disposition model in children, 
expansion of the research presented in this thesis to include assessments of the age-dependency of GI 
permeability and intestinal transporters is required. For intestinal permeability, an analysis would 
normally require in vivo determinations conducted in different developmental age-groups (i.e. neonate, 
infants, children, and adults) using wide array of compounds that vary in terms physicochemistry. 
However, owing to the myriad of logistic and ethical issues associated with conducting pediatric 
research, such studies may be prohibited. As an alternative approach, model-based techniques can be 
employed to provide estimates human intestinal permeability [390]. This process has been depicted in 
chapter 6 with regards to small intestinal water volume in adults but can be suitably redesigned to 
provide estimates of GI physiology in children. With regards to intestinal transporters, ongoing research 
is still required to define both their localization and expression in an age-dependent manner. Most work 
to date has focussed on the ontogeny of P-glycoprotein [375, 376]. However, several other transporters 
that can influence oral drug disposition remain unaccounted for (e.g. OCT, OATP, PEPT1, BCRP). In 
addition, investigations exploring transporter expression/localization should coincide with either the 
development of new quantitative assays or the adoption of international assay standards in order to 
reduce inter-laboratory variability associated with transporter protein quantification. This will permit 
for the integration of data from different research groups, allowing for comprehensive assessments of 
transporter ontogeny to be conducted. 
With an increased legislative demand for pediatric focussed research, the development of a 
comprehensive and functional in silico model capable of providing accurate predictions of pediatric 
oral absorption is of great interest. However, in order to achieve this goal, ongoing research tasked with 
deciphering the unique physiology of pediatrics is still required. 
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Appendix A 
Appendix A Table 1 – Lactulose H2 Breath Tests – 2nd Order Meta-Regression Model 
 




k=14 QM (df=2)= 0.5693 (p = 0.7523) I2 = 92.74% R2 = 0.00% 
 






     
















     
Between study 
variance (τ2) 
265.7347 133.4775 - - - 
Tau (τ) 16.3014 - - - - 
      
      
Summary 
Statistics 
k=14 QM (df=3)= 2.2215 (p = 0.5277) I2 = 92.62% R2 = 0.00% 
 






     






-0.0115    
1.4616  
0.1072 
0.0090       
0.4846 
0.2388 






0.0062               
 
Random Effects 
     
Between study 
variance (τ2) 
250.4728 132.6760 - - - 
Tau (τ) 15.8263 - - - - 
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Appendix A Figure 1 - OCTT as a function of age for investigations employing lactulose H2 
breath testing in normal subjects free of GI disease (open circles). The diameter of each circle is 
proportional to the 1/(Variancei)1/2. Estimates of OCTT based on meta-regression models with 
age as a (A) 2nd order polynomial and (B) 3rd order polynomial regressor have been 
superimposed for reference (mean – solid line; 95% CI – dotted lines). 
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Appendix A Table 3 - Scintigraphy and Other Techniques – 2nd Order Meta-Regression Model 
Summary 
Statistics 
k= 38 QM (df=3)= 19.1390 (p = 0.0003) I2 = 84.69% R2 = 38.15% 
 






     
Intercept (B0) 209.1456    8.7541 <0.0001   191.9879 226.3032 
Measurement Method 
(B1) 
63.3489 14.5391 <0.0001    34.8527 91.8451 
Age (B2) 
Age2 (B3) 
0.5571    
-0.0140 










     
Between study 
variance (τ2) 
1193.9761 383.0047 - - - 
Tau (τ) 34.5540 - - - - 
      
      
 
Appendix A Table 4 - Scintigraphy and Other Techniques – 3rd Order Meta-Regression Model 
Summary 
Statistics 
k=38 QM (df=4)= 18.5941 (p = 0.0009) I2 = 85.16% R2 = 35.88% 
 






     
Intercept (B0) 209.1322 8.8842 <0.0001   191.7194 226.5450 
Measurement Method 
(B1) 
62.8645 15.1339 <0.0001    33.2027 92.5264 
Age (B2) 0.6653 0.9135 0.4664 -1.1252 2.4558 
Age2 (B3) -0.0112 0.0307 0.7150 -0.0714 0.0489 
Age3 (B4) -0.0002 0.0013 0.8829 -0.0028 0.0024 
 
Random Effects 
     
Between study 
variance (τ2) 
1237.7908 399.9655 - - - 
Tau (τ) 35.1823 - - - - 
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Appendix A Figure 2 - SITT or OCTT as a function of age for investigations employing 
scintigraphy (black circles) and other measurement techniques (open circles) in normal subjects 
free of GI disease. The diameter of each circle is proportional to the 1/(Variancei)1/2. Estimates 
of mean intestinal transit time based on meta-regression models with age as a (A) 2nd order 
polynomial and (B) 3rd order polynomial regressor have been separately superimposed for 
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Appendix A Table 5 - Capsule Endoscopy Studies – 2nd Order Meta-Regression Model 
 
 









k=16 QM (df=2)= 12.1807 (p = 0.0023) I2 = 91.64% R2 = 46.87% 
 






     
Intercept (B0) 230.2096   21.5577   <0.0001   187.9573   272.4618   





0.0369      
0.0379 
0.0435        
-1.5830 
0.0022     
-0.0455 
0.1466     
 
Random Effects 
     
Between study 
variance (τ2) 
825.9859 416.7517 - - - 
Tau (τ) 28.7400 - - - - 
      
Summary 
Statistics 
k=16 QM (df=3)= 21.6888  (p < 0.0001) I2 = 87.87% R2 = 66.18% 
 






     
Intercept (B0) 210.9497   20.1139   <0.0001   171.5273   250.3721   
Age (B1) 1.8768    1.0820    0.0828    -0.2440     3.9976     
Age2 (B2) 0.0924    0.0325    0.0045     0.0286     0.1562    
Age3 (B3) -0.0041    0.0015   0.0085    -0.0071    -0.0010 
 
Random Effects 
     
Between study 
variance (τ2) 
525.6570 295.9862 - - - 
Tau (τ) 22.9272 - - - - 
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Appendix A Figure 3 - SITT as a function of age for investigations employing capsule 
endoscopy (open circles). The diameter of each circle is proportional to the 1/ (Variancei)1/2. 
Estimates of SITT based on meta-regression models with age as a (A) 2nd order polynomial and 
(B) 3rd order polynomial regressor have been superimposed for reference  (mean – solid line; 
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Appendix A Table 7 - Scintigraphy and Other Techniques – 1st Order (Linear) Meta-
Regression Model with Interaction Terms 
 
Appendix A Table 8 - Scintigraphy and Other Techniques – 2nd Order Meta-Regression Model 
with Interaction Terms 
Summary 
Statistics 
k= 38 QM (df=5)= 18.8281 (p = 0.0021) I2 = 85.13% R2 = 34.49% 
 






     
Intercept (B0) 209.5920 9.1776 <0.0001   191.6043 227.5797 
Measurement Method 
(B1) 
55.4072 21.5381 0.0101 13.1933 97.6211 
Age (B2) 0.3505 0.7896 0.6572 -1.1971 1.8981 
Age2 (B3) -0.0144 0.0290 0.6207 -0.0713 0.0425 
Age*Measurement 
Method (B4) 
0.5113 1.0988 0.6417 -1.6422 2.6649 
Age2*Measurement 
Method (B5) 
0.0336 0.0670 0.6157 -0.0977 0.1650 
 
Random Effects 
     
Between study 
variance (τ2) 
1264.6466 416.3814 - - - 
Tau (τ) 35.5619 - - - - 
      
      
Summary 
Statistics 
k=38 QM (df=3)= 19.5837 (p = 0.0002) I2 = 84.48% R2 = 38.85% 
 






     
Intercept (B0) 207.4751    7.9619 <0.0001   191.8700 223.0802 
Measurement Method 
(B1) 
62.3044 14.1997 <0.0001    34.4735 90.1354 
Age (B2) 0.1117 0.6107 0.8549 -1.0854 1.3087 
Age*Measurement 
Method (B3) 
0.7562 0.9599 0.4309 -1.1253 2.6376 
 
Random Effects 
     
Between study 
variance (τ2) 
1180.4401 380.7146 - - - 
Tau (τ) 34.3575 - - - - 
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Appendix A Table 9 - Scintigraphy and Other Techniques – 3rd Order Meta-Regression Model 
with Interaction Terms 
Summary 
Statistics 
k=38 QM (df=7)= 25.2448 (p = 0.0007) I2 = 82.97% R2 = 42.44% 
 






     
Intercept (B0) 209.3306 8.7403 <0.0001   192.2000 226.4612 
Measurement Method 
(B1) 
68.6123 21.3590 0.0013 26.7495 110.4752 
Age (B2) 0.6738 1.2194 0.5806 -1.7162 3.0637 
Age2 (B3) -0.0078 0.0335 0.8162 -0.0735 0.0579 
Age3 (B4) -0.0005 0.0014 0.7322 -0.0033 0.0023 
Age*Measurement 
Method (B5) 
-4.6744 2.7732 0.0919 -10.1098 0.7611 
Age2*Measurement 
Method (B6) 
-0.0474 0.0755 0.5301 -0.1954 0.1006 
Age3*Measurement 
Method (B7) 
0.0123 0.0060 0.0391 0.0006 0.0240 
 
Random Effects 
     
Between study 
variance (τ2) 
1111.1671 389.1959 - - - 
Tau (τ) 33.3342 - - - - 
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Appendix A Figure 4 - SITT or OCTT as a function of age for investigations employing 
scintigraphy (black circles) and other measurement techniques (open circles) in normal subjects 
free of GI disease. The diameter of each circle is proportional to the 1/(Variancei)1/2. Mean 
estimates of SITT based on a meta-regression model with age as a linear regressor and an 
interaction term (measurement method * age) have been separately superimposed for studies 
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Appendix A Figure 5 - SITT or OCTT as a function of age for investigations employing 
scintigraphy (black circles) and other measurement techniques (open circles) in normal subjects 
free of GI disease. The diameter of each circle is proportional to the 1/(Variancei)1/2. Mean 
estimates of SITT based on a meta-regression model with age as a 2nd order regressor and 
interaction terms between each order of age and measurement method have been separately 
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Appendix A Figure 6 - SITT or OCTT as a function of age for investigations employing 
scintigraphy (black circles) and other measurement techniques (open circles) in normal subjects 
free of GI disease. The diameter of each circle is proportional to the 1/(Variancei)1/2. Mean 
estimates of SITT based on a meta-regression model with age as a 3rd order regressor and 
interaction terms between each order of age and measurement method have been separately 
superimposed for studies utilizing scintigraphy (solid line) and other measurement techniques 
(dotted line). 
 
 
